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Abstract 
 
Background and aims 
Intrathecal drug delivery (IDD) is a last resort treatment for the management of severe 
chronic pain due to its invasive nature, high initial cost, concerns about long-term opioid use 
and possible complications related to the procedure. Although it has been available since 
1981 some of the possible complications of this treatment have only recently been observed 
and are not fully understood. Additionally the current available literature exploring the long-
term effectiveness and cost effectiveness of IDD is limited. The aims of this study were to 
explore some of the least investigated complications, long-term effectiveness and cost 
effectiveness of IDD. 
 
Methods 
The methodology used included both retrospective and prospective data collection to 
investigate intrathecal morphine dose escalation, granuloma formation, hormonal effects, 
bone mineral density (BMD), long-term effectiveness and cost effectiveness of IDD. 
 
Results 
A model was developed that allows the prediction of the intrathecal opioid dose at year six of 
therapy based on year two dose and the duration of pain prior to initiation of intrathecal 
therapy. An association between opioid concentration and formation of intrathecal 
granulomas was confirmed for the first time in humans and a tool to assist recognition of 
asymptomatic granulomas was identified. It was observed that hypogonadism is prevalent in 
this population and free testosterone is a more reliable method to diagnose this condition. 
An association between low BMD and hypogonadism as a result of IDD was reported for the 
first time. Effectiveness of IDD was verified following a mean of 13.5 years of therapy. A new 
concept with implications for cost analyses was identified. 
 
Conclusion 
This study presents a thorough analysis of IDD therapy. Despite potential side effects, this 
therapy can be effective over periods longer than 10 years in appropriately selected 
patients. The cost effectiveness of IDD systems was confirmed based on real patients’ data. 
Most side effects can be prevented with attentive follow-ups. 
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SECTION 1. Background to the study 
 
Pain is one of the most universal sensations in the sense that, with the rare exception of 
individuals with congenital insensitivity to pain, at some point every person will experience 
some type of physical pain during the course of their lives. Pain is an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage or described in 
terms of such damage (International Association for the Study of Pain 1979). This definition 
is regarded as the most approximate to the experience of pain since it takes into account 
both emotional and sensory dimensions. 
 
The widespread use of morphine and over-the-counter availability of opium and alcohol 
based compounds that people used to self-medicate in the 1870s led to concerns by the 
physicians about the morphine habit (Meldrum 2003). The conflict between the physician’s 
desire to relieve the patient’s pain and fear of inducing addiction still persists nowadays and 
can influence the selection of therapies that include opioids. 
 
One of the possible modes of opioid administration is through intrathecal drug delivery 
(IDD). An IDD system consists of an implanted pump which delivers medication directly into 
the cerebrospinal fluid through a catheter. Patients that may benefit from this therapy include 
cancer pain patients and patients with intractable chronic non-malignant pain. Patients with 
chronic non-cancer pain have the potential for long-term survival and therefore adequate 
pain control is paramount to this population. 
 
This thesis explores different outcomes of intrathecal drug delivery for the management of 
chronic non-malignant pain. Potential pharmacological complications derived from this 
therapy are explored. Investigations of long-term outcomes and cost effectiveness of this 
treatment are also undertaken. This will contribute to the understanding of this treatment in 
the context of chronic non-malignant pain for which many patients require pain management 
throughout the rest of their lives. 
 
 
1.1.1 Structure of the thesis 
This thesis is divided into five different chapters (Figure 1.1.1). Chapter 1 provides the 
background to the thesis. Besides the current structure of the thesis, section 1 presents the 
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aim and objectives of this research. Moreover, the collaboration established, ethical 
considerations and approval for the studies performed are clarified. Section 2 includes a 
brief history of pain with a focus on events/concepts/authors that contributed to the current 
understanding of pain. The physiology and different types of pain are described as well as 
the basic mechanisms of opioids. Section 2 also comprises the prevalence of chronic pain in 
Europe and the United Kingdom to provide an idea of the magnitude of the chronic pain 
problem. Furthermore, treatments usually undertaken for chronic pain are described with a 
focus on intrathecal drug delivery. Chapter 1, section 3 provides a literature review of IDD 
systems for chronic non-malignant pain, focusing on the possible complications/side effects 
and effectiveness of this therapy. Following the literature review (I), Chapter 1, section 4 
presents the results of a pilot study that helped to determine which complications/side 
effects would be of interest to include in this thesis based on its occurrence, literature 
available and feasibility (II). 
 
The subsequent chapters consist of the research undertaken to investigate the different 
complications/side effects identified in the pilot study. These were divided into increase in 
opioid dose (Chapter 2, section 1), granuloma formation (Chapter 2, section 2) and 
hormonal effects (Chapter 2, section 4). The study of the intrathecal opioid dose increase 
over a period of six years assumes particular importance as the escalation level can impact 
on subsequent side effects/complications resultant from this therapy. Similar to most 
medications, a high intrathecal opioid dose is synonymous with an increase in the probability 
of a side effect to occur such as the formation of intrathecal inflammatory masses (III). This 
possibility was investigated in Chapter 2, section 2 where the association between yearly 
opioid dose increases with the development of granulomas was examined. The formation of 
granulomas is one of the most perilous complications of IDD. When not detected and treated 
appropriately it can cause functional paraplegia. An additional study of granuloma 
development was performed to try to further the understanding of this side effect (IV). 
Endocrine complications such as hypogonadotropic hypogonadism are a risk factor for 
decreased bone mineral density with potential to cause osteoporosis. Therefore, the 
prevalence of low bone mineral density was also investigated in this population (V). 
 
The occurrence of side effects/complications can influence both effectiveness and cost 
effectiveness of a treatment (VI). Chronic pain patients require effective long-term 
treatments to manage their pain. In Chapter 3, a prospective, longitudinal study with a mean 
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follow-up of 13 years is presented. In this study, benefits of IDD, despite potential 
complications are explored to evaluate if chronic non-malignant pain patients benefit from 
long-term pain relief when undertaking IDD therapy. 
 
 
 
The long-term effectiveness and complications can affect the cost effectiveness of a 
therapy. IDD therapy is initially very expensive; therefore a cost effectiveness study was also 
carried out (VII). Currently, the cost effectiveness of a treatment is always taken into 
consideration when deciding which therapy to administer. In an UK national audit of centres 
where IDD was presented, the respondents indicated that they would perform more implants 
if funding were available (Williams and Grady 2008). Chapter 4 refers to a study 
investigating the cost effectiveness of IDD and the identification of a concept which may also 
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influence cost effectiveness evaluations of other therapies where there is a waiting time 
between the decision and commencement of treatment. Moreover the literature review also 
revealed the paucity of IDD studies concerning the long-term effectiveness and cost 
effectiveness of this therapy (VIII). Finally, Chapter 5 highlights the main findings resultant 
from this work (IX), clinical implications and possible directions for future studies. 
 
 
1.1.2 Aim of the study 
The aim of this study was to assess intrathecal drug delivery when employed in the 
management of chronic non-malignant pain patients. 
 
 
1.1.3 Objectives of the study 
The primary objectives of this study were to investigate the cost effectiveness and the long-
term effects of intrathecal drug delivery systems (IDDS). 
 
The secondary purposes were to explore the development of opioid tolerance, potential 
consequences of hormonal side effects and possible motives for the formation of 
granulomatous masses. 
 
 
1.1.4 Collaboration 
This research was a collaborative project between the Faculty of Health, Birmingham City 
University, Birmingham and the Pain Management Department, Russells Hall Hospital 
(RHH), Dudley. The subjects who took part in this study were recruited from the Pain 
Management Department at Russells Hall Hospital. 
 
 
1.1.5 Ethical approval 
Research ethics committees were first established in 1964 at the 18th World Medical 
Assembly, thereafter known as the Declaration of Helsinki (DoH). The initial purpose of the 
DoH was to avoid atrocities like the ones verified during World War II, when prisoners of the 
Nazis were used for experimentation, as well as to prevent pharmaceutical companies and 
research organizations from exploitation of poor populations by using them for testing new 
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treatments from which they would never benefit (Christie 2000; Giordano 2010). Since its 
inception, the DoH became the most widely accepted guidance on medical research 
involving human participants (Christie 2000). Six amendments to the DoH have been made 
in the intervening years to maintain relevance to contemporary medical practice with the 
latest adopted during the 59th World Medical Assembly in Seoul, South Korea in 2008 
(World Medical Association 2008). The main objective of the DoH is to provide an ethical 
framework to safeguard those voluntarily participating in medical research. 
 
The DoH is a document in constant evolution and under continuous scrutiny. It has recently 
been claimed that some of the DoH statements are of dubious interpretation (Giordano 
2010). To avoid erroneous interpretation and to ensure that clinical research investigations 
are carried out in accordance with the DoH, Research Ethics Committees (REC) were 
created to ethically review every potential research project involving human participants. 
 
Informed consent and ethical approval was not required for the majority of chapters included 
in this thesis according to the Russells Hall Hospital institutional guidelines and the National 
Research Ethics Service (2006) (Table 1.1.1). 
 
The data included in Chapter 2 sections 1, 2 and 3 was collected retrospectively. A 
prospective design was used to carry out Chapter 2, sections 4 and 5. The data comprised 
blood tests and dual energy X-ray absorptiometry (DEXA) scans. Ethical approval was not 
required to perform this piece of research as it is routine practice at RHH to collect blood 
samples periodically from IDD patients. After analyzing the blood samples results only the 
patients diagnosed with hypogonadism were requested to have a DEXA scan. The 
diagnosis of hypogonadism is one of the indications to carry out a DEXA scan, thus the 
reason not to pursue ethical approval for this examination. 
 
The data collected for the cost effectiveness analysis (Chapter 4) was retrospective in 
nature. However, the general practitioner (GP) notes were thought to be relevant for 
inclusion in the study. For that reason, informed consent was obtained from all participants 
to examine their GP notes in addition to the hospital records throughout the study period. 
Data collected from GP notes was not included in the study. Rationale for this decision is 
included in Chapter 4. 
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Ethical approval was sought to accomplish Chapter 3. Taking into account the DoH (World 
Medical Association 2008), a research protocol (appendix 1), patient information sheet 
(appendix 2) and patient consent form (appendix 3) were developed to apply for University 
sponsorship (appendix 4) and REC approval (appendix 5) prior to the commencement of 
recruitment. 
 
 
 
The UK ethical approval submission form is quite broad and detailed, however, it does take 
into consideration the majority of issues that can arise when conducting a patient based 
research and is therefore a useful and informative exercise. RECs were created primarily to 
protect patients from hazardous research, but they encompass a secondary responsibility to 
foster superior research (Masterton and Shah 2007). 
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The research ethics committee attended consisted of a combination of clinicians and 
academics from a range of specialties as well as lay members. Several questions regarding 
study design, recruitment process, protection of participants, patient information sheets and 
consent form were made during the meeting by different members of the board. After 
deliberation by the committee, the research project received a favourable opinion on the 
condition that a few adjustments were made. Following a review of the alterations the study 
was approved. Ethical approval was granted by Birmingham, East, North and Solihull 
Research Ethics Committee (REC reference: 08/H1206/184; appendix 5) and informed 
consent was obtained from all participants. 
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SECTION 2. Pain: an introduction 
 
1.2.1 History of pain 
The term “pain” derives from the Latin word poena meaning a penalty or punishment. 
Despite being experienced by almost everyone, the concept of pain has undergone several 
modifications throughout the ages and still today has not the same status in every society 
(Rey 1998). Ancient cultures believed that pain was related to evil, magic or to a punishment 
from the Gods. In Greek mythology Poine (or Poena) was the goddess of punishment. Pain 
has been attributed philosophical, political and religious meanings; these defined the 
suffering of individuals for much of human history and often complicated its treatment 
(Meldrum 2003). The Christians inherited many ideas from the Greeks and Jews, for whom 
disease and pain were punishment, inflicted for breaking divine law (Caton 1985). It is likely 
that Christ’s Incarnation and His sufferings on the cross may have been responsible for 
other connotations, and the perception among Christians of pain as a form of divine 
retribution or a sign of having been chosen, which could have encouraged an attitude of 
stoic indifference towards pain (Caton 1985; Rey 1998). For many centuries in most of 
Western culture, people would try to hide their pain and, when unbearable, they would seek 
priests and the church to try to find some comfort. The dogma of pain as a test of faith was 
the predominant belief throughout the Middle Ages hence not much progress in the 
treatment of pain was made throughout this period. It was considered inevitable that men, 
women and children would suffer physical pain; what mattered to the good life was the 
meaning rather than the fact of pain (Meldrum 2003). However, pain during surgery was 
perceived differently even throughout this period and attempts were made to supply the 
most relief possible throughout surgical procedures. Plant derivatives such as alcohol, 
cannabis, mandrake and opium have been used for surgical analgesia for around 2500 
years (Hamilton and Baskett 2000). 
 
While the church dominated Western thought, medicine continued to develop in the Arabic 
world through the Middle Ages (Jaros 1991). This development was influenced by the 
translations of classical Greek and Roman works brought by Greek scholars who had fled to 
Persia when the Greek Academy was brought to an end because its teachings were 
considered pagan by an increasingly Christian world (Jaros 1991). An elaborate theory of 
pain was created by Avicenna, an Arabic physician, who believed that the body consisted of 
four temperaments (heat, cold, dryness and moistness) and each organ or limb had an ideal 
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balance for that organ (Jaros 1991). According to the same physician, there were 15 
different types of pain (throbbing, tension, tearing, stabbing, relaxing, pricking, itching, 
irritant, incisive, heavy, fatigue, dull, corrosive, compressing and boring) and the type of pain 
would be the result of specific changes in the combination of temperaments. 
 
A significant change of mood in Europe was observed during the 1600s, with a movement 
from the Age of Faith to the Age of Reason and people seeking to control the environment 
leaving their pessimism and passivity behind (Caton 1985). In 1664 René Descartes 
described a pain pathway (Descartes 1664). According to his example of fire as painful 
stimulus, if the fire is close to the foot, small particles of that fire (A) can activate a section of 
the skin (B) connected by a thread to the brain (F). This would work as a warning system, 
described as pulling a string attached to a bell at the other end, leading to a movement of 
the head and eyes towards where the stimulus was being received and moving the foot 
away from the fire (Figure 1.2.1). In other words, a fixed and dedicated pain pathway links 
the site were a peripheral noxious stimulus occurs to the brain, where the perception of pain 
takes place (Costigan and Woolf 2002). 
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Despite several criticisms, Descartes’ stimulus-response model, now known as specificity 
theory, was predominant for approximately three centuries until Ronald Melzack and Patrick 
Wall proposed the concept of the gate control theory (GCT) of pain (Melzack and Wall 
1965). 
 
In the early 19th century a gradual change of attitude regarding pain relief started to take 
place. This was due to the emphasis of utilitarian philosophy on reducing pain for the 
greatest number of people combined with the new philosophy of individual rights and the 
Romantic poets’ rethinking of pain and resolve in the importance of the individual experience 
(Morris 1998). Several factors contributed to this change of attitude and the implementation 
of this school of thought such as the American, French and German Revolutions, the 
Napoleonic wars, major new developments in physics, geology, biology and chemistry, the 
Western migration and Queen Victoria’s coronation in 1837 (Caton 1985). The progress 
verified during this era lead to an increase in prosperity as well as facilitation of migrations, 
travelling, and debate of ideas and concepts which created an atmosphere favourable to the 
advance in several scientific disciplines. This cultural change was required for the 
development of anaesthesia (Calatayud and González 2003). During this period, modern 
medicine as well as anaesthesia was born. This era is also noticeable for the discovery of 
morphine and its analgesic properties. In 1805, Friedrich Sertürner isolated morphine from 
opium, which made parenteral administration possible; after the development of the 
hypodermic needle and syringe in the 1850s, morphine started to be administered 
subcutaneously as an analgesic and its use became widespread (Hamilton and Baskett 
2000). The development of a syringe with a hollow needle in 1855 by Alexander Wood made 
frequent subcutaneous administration so convenient that it might have inadvertently 
contributed to the overuse of morphine (Howard-Jones 1947). 
 
The relief of physical pain started to be seen as a positive good and a few experimenters 
recognised the possibilities of sedative gases, especially ether (Meldrum 2003). On October 
16, 1846, William T. G. Morton publicly demonstrated the anaesthetic properties of ether, 
with news of his work promptly spreading and ether starting to be used as an anaesthetic in 
most of the world within five months (Caton 1985). After Morton’s’ demonstration, several 
others claimed to have used ether for the same purpose, therefore, credit for the discovery 
of anaesthesia has been given to various individuals including William T. G. Morton, Horace 
Wells, Charles A. Jackson, Gardner Q. Colton and Crawford Long (Stoelting and Miller 
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2007). The introduction of surgical anaesthesia was one of the greatest breakthroughs of 
modern medicine and although considered a blessing by most of the patients, not all 
physicians were immediately enthusiastic about this concept due to ethical debates about 
operating on an unconscious patient, the possibility of retarding the healing process and 
religious writers considering anaesthesia a violation of God’s law (Meldrum 2003). 
 
Spinal anaesthesia for surgery was first introduced on August 16th, 1898. When faced with a 
patient who had suffered severe adverse effects from previous general anaesthesia, August 
Bier decided to try spinal anaesthesia by “cocainization of the spinal cord”, using 15 mg of 
cocaine injected intrathecally before performing a resection of a tuberculous ankle joint (Wulf 
1998). To test the efficacy of the analgesia, Bier and his assistant also attempted spinal 
injections of cocaine on each other, developing severe headaches, a number of cuts, 
bruises and burns (Hamilton and Baskett 2000). Prior to this date, only local anaesthetic 
procedures such as topical anaesthesia of the eye and infiltration anaesthesia had been 
employed; spinal anaesthesia was the first major regional anaesthetic technique to be 
introduced into broad clinical practice (Wulf 1998). 
 
The observation of severe side effects after administration of cocaine derivatives in 
combination with the introduction of general anaesthesia caused a restriction of spinal 
anaesthesia to only those who could not withstand general anaesthesia (Brock, Bell and 
Davison 1936). The status of the spinal anaesthesia technique suffered an additional set-
back on October 13, 1947, when Albert Woolley and Cecil Roe became paraplegic on the 
same day after receiving spinal anaesthesia for minor surgery at the same hospital, 
administered by the same anaesthetist, Dr Malcolm Graham (Maltby, Hutter and Clayton 
2000). The patients sued their anaesthetist for alleged negligence. Initially it was thought 
that the origin of the paralyses was related to cracks in the ampoules which were invisible to 
the eye but which had caused a leak of phenol, a sterilizing agent and therefore the 
plaintiffs’ claims against both the hospital and Dr Graham failed (Cope 1954). The case was 
reassessed after new information was obtained which indicated that the most likely source 
of contamination was the water in which the syringes and needles were boiled, and the 
contaminating agent was an acid used to descale the water-boiling sterilizer (Hutter 1990). 
Despite the fact that there were other reports of neurological complications, the Woolley and 
Roe case made spinal anaesthesia unpopular, especially in the UK (Hutter 1990). Due to 
the uncertainty over the cause of the paralyses and fear of producing permanent 
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neurological damage, the practice of spinal anaesthesia in the UK was deterred for 20-25 
years (Morgan 1995). The discovery, in 1973, of opioid receptors in the brain (Pert and 
Snyder 1973) and in 1977 in the spinal cord (Snyder 1977) led to the reintroduction of spinal 
opioid injections for clinical use. 
 
In 1946 following on from observations made by George J. Guthrie and Guillaume 
Dupuytren, Harry K. Beecher challenged the belief, common at the time of a direct relation 
between the extent of the wound and the severity of pain reported. While working as a 
doctor during World War II, Beecher asked severely wounded soldiers (penetrating cerebral 
wounds, penetrating wounds of the thorax, extensive soft-tissue injury, compound fractures 
of long bone, penetrating abdominal wounds) who were able to speak if they were in pain, 
the severity of pain (slight pain, moderate pain, or bad pain) and if they wanted something to 
relieve the pain; to his surprise, only 23.7% reported their pain as bad and 73% of the 
soldiers said no to narcotics for pain relief (Beecher 1946). After returning to the 
Massachusetts General Hospital and asking the same questions to civilians with surgical 
wounds, 83% said yes to narcotics for pain relief (Beecher 1956). One of the possible 
explanations Beecher advanced for these findings was the association made by the 
participants with the pain they were suffering. For the soldiers, the injury meant the war was 
over for them and they would soon return home, while for the civilians, the surgery could be 
seen as the beginning of an undesired event. The same author described pain as an 
experience subject to modification by many factors, and these factors served to be more 
important than the extent or degree of the wound. Beecher questioned the use of morphine 
without inquiring the patient about the need for it and also noted that many times the 
morphine doses given did not correspond adequately to the severity of pain (Beecher 1946). 
A holistic approach for the management of pain which focused on the individual patient was 
proposed by Cicely Saunders, who also portrayed “total pain” as a clinical phenomenon that 
compounded physical and mental distress with social, spiritual and emotional concerns 
(Meldrum 2003). This approach is still in line with today’s understanding of pain. 
 
In 1955, after analyzing the therapeutic effectiveness of placebos in treating subjective 
responses, Beecher recognised the importance of placebos and its potential application in 
research studies (Beecher 1955). The same author describes the importance of a control 
group, the double-blind technique as well as the value of randomisation. Following this 
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article randomised double-blinded control studies were recognised as one of the most 
valuable methodologies when investigating the effects of a medicine or treatment. 
 
Ensuing on the work of Willem Noordenbos, William Livingston, Ivan Pavlov as well as the 
authors previously mentioned, Ronald Melzack and Patrick Wall wrote a paper focusing on 
somesthesis (sensory systems in the skin) and discussed the limitations of the specificity 
theory, presenting some of the concepts of what was to become the gate control theory of 
pain, such as physiological specialization (Melzack and Wall 1962). This article evoked 
some interest but had little impact among the scientific community. Melzack and Wall used 
the concepts from that article as the basis for a theory focusing specifically on pain 
mechanisms. The gate control theory was published in 1965 and since then has become a 
seminal work (Melzack and Wall 1965). Contrary to the direct stimulus-response relationship 
model described by Descartes, the gate control theory describes pain as a complex 
interaction of sensory and cognitive processes (Figure 1.2.2). These processes include past 
experience, attention, expectation and the situation in which the injury occurs (Melzack and 
Wall 1965). This explains why pain can be perceived differently in similar injuries. 
 
 
The pain experience as described by the GCT is the result of an interaction between three 
spinal cord systems after transmission of nerve impulses induced by stimulation of the skin: 
the substantia gelatinosa (SG) cells in the dorsal horn, the dorsal-column fibres that project 
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towards the brain, and the first central transmission (T) cells in each dorsal horn (Melzack 
and Wall 1965). The authors proposed that the SG (consists of small, densely packed cells 
extending the length of the spinal cord) functions as the gate control system, which is 
modulated by activity from the large (L) and small (S) fibres that influence the activation by 
the T cells of neural mechanisms comprising the action system responsible for response 
and perception. The action system is activated when the output of the spinal cord 
transmission (T) cells exceeds a critical level (Melzack 1996). An increase in activity in L 
fibres will inhibit the transmission of stimulus (closes the gate); S fibres activity facilitates the 
transmission (opens the gate) (Melzack 1996). The positive and negative effects of the large 
and small fibre inputs tend to counteract each other but if stimulation is prolonged the large 
fibres begin to adapt, causing an increase in small fibre activity, which results in the gate 
opening further and the output of the T cells to rise; however, if the large fibre activity is 
raised by vibration or scratching (which can overcome the tendency of the large fibres to 
adapt), the output of the cells decreases (Melzack and Wall 1965). The gate control system 
is also influenced by descending efferent fibres from the brain. The gate can also be closed 
or opened according to the information descending from the central nervous system. Pain 
response and perception are influenced by psychological factors such as prior experiences, 
attention and emotions which can open or close the gate. The presence or absence of pain 
is therefore determined by the balance between the sensory and central inputs to the gate 
control system (Melzack and Wall 1965). 
 
The GCT theory had a huge scientific and clinical impact, causing an explosion in research 
on the physiology and pharmacology of the dorsal horns and descending control systems; 
psychological factors, previously regarded as reactions to pain, started to be seen as an 
integral part of pain processing; cutting nerves and pathways were gradually replaced by 
modulation techniques while electrical stimulation of the large afferent fibres started to be 
used for treating several painful conditions (Bonica 1991; Melzack 1996). 
 
Painful conditions where sensory inputs are absent do not fit with the GCT, such as pain in 
paraplegics and phantom limb pain. Although peripheral and spinal processes are an 
important part of pain, the data on phantom pain indicated a need to go beyond the foramen 
magnum and into the brain (Melzack 1996). After analyzing the phantom limb phenomena, 
Melzack developed a new conceptual model, the neuromatrix (Melzack 1999). According to 
this theory, the body is felt as a unity and the brain mechanism that underlies the experience 
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comprises a unified system acting as a whole and producing a neurosignature pattern of the 
whole body (Melzack 1999). This model proposes that the neurosignature for pain 
experience is determined by the synaptic architecture of the neuromatrix, which is produced 
by genetic and sensory influences; moreover, the neurosignature pattern is also modulated 
by sensory inputs and cognitive events such as psychological stress (Melzack 1999). The 
same author suggests that the development of chronic pain syndromes may be determined 
or predisposed by genetic influences on synaptic architecture. Besides detecting and 
analyzing inputs, the brain generates perceptual experience even when no external inputs 
occur (Melzack 1996). Functional imaging studies during a noxious stimulus demonstrated 
the involvement of different regions of the brain assumed to process the affective, sensory, 
cognitive, motor, inhibitory and autonomic responses, confirming the existence of a 
neuromatrix (Derbyshire 2000). The output of the neuromatrix can be adjusted by different 
treatments to change the inputs and influences on the neuromatrix (Loeser and Melzack 
1999). 
 
The neuromatrix theory of pain does not invalidate the GCT but complements it. While the 
GCT clarifies why physical, acute pain can be perceived differently, the neuromatrix reveals 
an additional role of the brain in our pain perception and helps to explain phantom limb pain 
as well as chronic pain. The gate control theory of pain assumes particular importance for 
the development of the therapy explored in this thesis. The GCT lead to a rapid increase in 
research, more importantly to this work, into the physiology and pharmacology of the dorsal 
horns which resulted in the discovery of opioid receptors in the brain (Pert and Snyder 1973) 
and in the spinal cord (Snyder 1977). Ultimately, this path culminated in 1981 with the first 
morphine reservoir implanted in a human (Onofrio, Yaksh and Arnold 1981). 
 
Alongside the theories of pain, the creation and foundation by John Bonica of the 
International Association for the Study of Pain (IASP) in 1973 and the journal Pain in 1975 
had a significant impact on pain research, therapy and its dissemination. 
 
To complement the described pain models, the following segment of this thesis provides a 
description of the physiology of pain. 
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1.2.2 Physiology of pain 
The main purpose of pain is to alert the body to potential damage (nociception). When injury 
occurs, peripheral nociceptors are activated and the signal is conducted via afferent nerve 
fibres to the dorsal horn and the brain. The process of perception and response to pain can 
be divided into four different stages: transduction, transmission, modulation, and perception 
(Hawthorn and Redmond 1998; Cepeda, Cousins and Carr 2007) (Figure 1.2.3). 
 
 
 
Transduction 
Transduction consists of the conversion of a stimuli (mechanical, thermal or chemical) with 
the potential to cause damage into nerve impulses by nociceptors (unspecialised, 
unmyelinated, free nerve endings), also known as first order neurons. The nociceptors are 
located in any external (e.g. skin) or internal (e.g. muscle) area of the body with potential to 
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sense pain. The nerve cell bodies are localized either in the trigeminal ganglia (specific for 
the trigeminal nerve in the face) or in the dorsal root ganglia (rest of the body) (Woolf and 
Ma 2007). The nociceptors transmit the stimuli information via sensory/afferent/nerve fibres 
to the central nervous system (CNS). There are two types of nerve fibres responsible for the 
transmission of noxious stimuli to the CNS: C fibres which are unmyelinated, with small 
diameter (0.25 to 1.5 µm) and conduct the information slowly (1 to 2.5 m/s rate); and A-delta 
(Aδ) fibres with larger diameter (1 to 5 µm), myelinated nerves that conduct the information 
faster (6 to 30 m/s) (Melzack and Wall 1988). Approximately 60 to 70% of all the sensory 
afferents are C fibres (Melzack and Wall 1988). The C fibres respond to mechanical, thermal 
and chemical stimuli, while the Aδ fibres respond to mechanical and thermal stimuli (Patel 
2010). The fast-conducting Aδ fibres are responsible for a sensation of sharp, fast pain, 
while the slower C fibres produce the sensation of delayed, dull pain (Patel 2010). The pain 
from the Aδ fibres (first pain) lasts only for the length of the acute painful stimulus and the 
threshold for this pain is uniform from person to person; pain from C fibres (second pain) is 
more diffuse and persistent, lasting beyond the termination of an acute painful stimulus 
(Cross 1994). Tolerance to this second pain is variable from person to person because it is 
associated with the affective-motivational aspects of pain (Cross 1994). 
 
The nociceptors are activated when stimulation occurs beyond a certain individual threshold. 
The thermal receptors respond to extremes of temperatures (heat or cold); mechanical 
receptors respond to pressure such as squeezing, crushing or as a consequence of tissue 
inflammation or oedema; chemical receptors can be stimulated by both external (sting of a 
wasp or nettle) and internal chemicals (Hawthorn and Redmond 1998). When the tissue is 
cut or burned, or a cell ruptured by excessive pressure, chemicals such as 5-hydroxy-
tryptamine (5-HT or serotonin), histamine, potassium ions (K+) or acetylcholine are released; 
damage can also lead to synthetisation of other inflammatory mediators, such as bradykinin 
or cytokines (Hawthorn and Redmond 1998). 
 
 
Transmission 
Following transduction, the stimuli information is conducted by the afferent nerves to the 
dorsal root ganglia and enters the spinal cord through the dorsal horn (Hawthorn and 
Redmond 1998). Once in the spinal cord, these fibres ascend one or two segments in the 
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dorsolateral tract of Lissauer, before entering the grey matter and terminating in laminae I, II 
or V (Cross 1994; Hawthorn and Redmond 1998) (Figure 1.2.4). 
 
 
 
Lamina I receives inputs mainly from the skin and muscle nociceptors through both Aδ and 
some C fibres; lamina II, also known as substantia gelatinosa contains neurones that make 
local connections; and lamina V receives inputs from Aδ and C fibres, but also from 
interneurones in laminae I and II. C fibres innervate mainly the cells in the substantia 
gelatinosa layer of the spinal cord (Patel 2010). In the dorsal horn laminae, the afferent 
fibres synapse with second order neurons. The nociceptors release the excitatory 
neurotransmitters substance P and glutamate which bind respectively to neurokinin 1 (NK1) 
and N-methyl-D-aspartate (NMDA) receptors, causing an influx of calcium and activation of 
the calcium-dependent enzyme protein kinase C (PKC) in the second order neurons 
(Cepeda, Cousins and Carr 2007). These neurons have their cell bodies in the dorsal horn 
and their axon terminations in the thalamus (Cross 1994). They ascend from the spinal cord 
to the thalamus via the anterolateral spinothalamic pathway. There are two different types of 
second order neurons: those that respond to both nociceptive and non-nociceptive A-beta 
(Aβ) afferents are termed wide dynamic range (WDR) neurons; and those that respond 
exclusively to noxious stimuli are termed nociceptive-specific neurons (Besson and Chaouch 
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1987). WDR neurons are involved in the affective-motivational component of pain, while the 
nociceptive-specific neurons are involved in the sensory-discriminative aspects of pain 
(Cross 1994). Although the WDR neurons respond to both nociceptive and non-nociceptive 
inputs, they usually do not signal pain in response to stimulus at a non-nociceptive level. It is 
at this moment (transmission) that influences can be exerted and the message modified by 
other information, a process known as modulation. 
 
 
Modulation 
The GCT theory, also known as segmental modulation and described in the section 1.2.1 of 
this thesis, explains one of the mechanisms that can modify pain transmission (Melzack and 
Wall 1965). Although many advances have been verified, the GCT theory remains valid in its 
essence (Patel 2010). 
 
Information can be transmitted from supraspinal levels (brain) to the spinal cord and these 
descending inhibitory nerves can control (modulate) the ascent of nociceptive information to 
the brain. As the nociceptive afferents enter the spinal cord via the dorsal horn, they form 
synapses with other nerve endings. Some of these nerve endings are from neurons whose 
cell bodies are in the brain and whose axons form a descending pathway (Hawthorn and 
Redmond 1998). These descending pathways have the potential to modify functions at the 
spinal level and can originate in the cortex, the thalamus and the brain stem (Cross 1994). 
The descending pathways carry signals from the aforementioned higher brain centres 
through the periaqueductal grey matter and the brain stem back to the dorsal horn 
(Hawthorn and Redmond 1998). The main transmitters of the descending inhibitory system 
are serotonin, noradrenaline and endogenous opioids (Cepeda, Cousins and Carr 2007; 
Patel 2010). The release of these transmitters inhibits the nociceptors that produce 
excitatory mediators such as substance P and glutamate, therefore preventing them from 
binding respectively to the NK1 and NMDA receptors in the dorsal horn (Cepeda, Cousins 
and Carr 2007). 
 
Due to the importance of serotonin and noradrenaline in pain modulation, selective serotonin 
reuptake inhibitors such as fluoxetine hydrochloride (Prozac) and tricyclic antidepressants 
such as amitriptyline were found to have analgesic properties and started to be used for the 
treatment of chronic pain (McQuay and Moore 1997). 
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Opioid receptors were first discovered in the brain (Pert and Snyder 1973) and afterwards in 
the spinal cord (Snyder 1977). Within the spinal cord, opiate receptors are localized in an 
area corresponding to the substantia gelatinosa, which is a first site for the integration of 
sensory information in the CNS (Snyder 1977). Since the discovery of opioid receptors in the 
brain, the existence of endogenous opioids was hypothesized and started to be investigated. 
Two enkephalin peptides were the first endogenous opioids to be isolated from the brain 
(Hughes et al., 1975). There are three groups of opioid peptides (enkephalins, endorphins, 
and dynorphins) that bind to the opioid receptors and are referred to as endogenous opioids 
(Atcheson and Lambert 1994). Exogenous opioids mimic the action of endogenous opioids. 
The mechanism of action of opioids is described in segment 4 of this section. 
 
 
Perception 
In the ascending pain pathway, once the WDR or the nociceptive-specific neurons reach the 
thalamus (where they terminate), they activate third order neurons. These originate in the 
thalamus and project to the cortex (Cross 1994). Neurons from the lateral thalamic nuclei 
project to the somatosensory cortex and allow the conscious localisation and 
characterisation of painful stimuli; neurons from the intralaminar and medial nuclear areas 
project to the anterior cingulate gyrus and are thought to be involved in the perception of 
suffering and the emotional reaction to pain (Cross 1994). 
 
Another stage that could be included in this description of pain is interpretation. As the IASP 
definition states, pain is a sensory and emotional experience, and therefore, individual and 
personal. Even if evoked by identical forms of tissue damage, pain may differ significantly 
because of variations in factors such as social background and personal experience, 
including individual memories, beliefs and emotional state (Morris 1998). 
 
 
1.2.3 Classification of pain 
The classification of pain may take into consideration aspects such as duration, aetiology, 
intensity or type of injured tissue. Pain associated with tissue damage, inflammation, or a 
disease process expected to resolve with time, regardless of the pain intensity, is referred to 
as acute pain (Turk and Melzack 2001). Acute pain is characterized by a short duration, 
typically after an injury, surgery or disease and usually disappears during the healing 
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process. Acute pain can be regarded as a transitional period between coping with the injury 
and preparing for recovery (Melzack and Wall 1988). A few types of acute pain, such as 
post-herpetic neuralgia (nerve damage caused by herpes zoster) can frequently give rise to 
chronic pain (Merskey 2007). 
 
The chronic pain syndrome is the consequence of a variety of pathological and 
psychological mechanisms that at any stage may have included tissue or nerve damage, in 
which symptoms have failed to resolve with healing or repair (Grady and Severn 1997). It is 
not the duration of pain that distinguishes acute from chronic, but the incapacity of the body 
to restore its physiological functions to normal homeostatic levels (Loeser and Melzack 
1999). Chronic pain persists long after pain can serve any useful function and is no longer a 
simple symptom of injury or disease but a medical problem in its own right that requires 
urgent attention (Melzack and Wall 1988). The injury may exceed the capacity of the body to 
heal for several reasons, such as the loss of the body part, the extensiveness of the trauma 
and subsequent scarring, or the involvement of the nervous system in the injury as it can be 
damaged in such a way as to be unable to restore itself to a normal state (Loeser and 
Melzack 1999). When chronic pain is not treated effectively it is likely that stress, 
environmental and affective factors may be superimposed on the original injury and 
contribute to the intensity and persistence of the pain (Loeser and Melzack 1999). 
 
Besides duration, pain can also be characterised according to diagnosis. A correct diagnosis 
is seen as the avenue to suitable treatment (Merskey 2007). Pain can be described as 
nociceptive, neuropathic or mixed. 
 
Nociceptive pain is the result of tissue damage and can be either somatic or visceral. It 
results from the activation of the nociceptors by noxious mechanical, thermal or chemical 
stimuli (Costigan, Scholz and Woolf 2009) (Figure 1.2.5). Somatic pain refers to stimuli 
received in parts of the body such as skin, bones, or muscle while visceral pain is caused by 
the activation of nociceptors in the internal organs (viscera). Somatic pain sensations in the 
skin (superficial somatic) are sharp and well localised. Somatic pain in deeper areas such as 
muscle (deep somatic) can be harder to localise because it is frequently diffuse or spread 
over a large area. Visceral pain is caused by distension, spasm or contraction, twisting, 
ischemia, chemical irritation or inflammation (Hawthorn and Redmond 1998). It can be 
extremely difficult to pinpoint and can also be referred pain (the sensation of pain is 
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perceived in one part of the body and the pathology is in a different area). Examples of 
visceral pain include bladder pain, endometriosis pain or irritable bowel syndrome pain. 
 
 
 
Neuropathic pain has been defined as pain arising as a direct consequence of a lesion or a 
disease affecting the somatosensory system (Treede et al., 2008). Neuropathic pain results 
from lesions to the peripheral (PNS) or central nervous system (Costigan, Scholz and Woolf 
2009) (Figure 1.2.6). Peripheral neuropathic pain can be caused by mechanical trauma, 
metabolic diseases, neurotoxic chemicals, infection or tumour invasion involving numerous 
physiological changes within both the PNS and CNS (Dworkin et al., 2003; Woolf and 
Mannion 1999). Central neuropathic pain is generally the result of spinal cord injury or 
multiple sclerosis (Ducreux et al., 2006). 
 
Disruptions of the normal sensory mechanisms may lead to different phenomena such as 
the occurrence of pain without a clear stimulus or in the presence of a non-nociceptive 
stimulus, also known as sensitisation (Woolf 1991). An example of sensitisation is allodynia 
where a non-noxius stimulus activates nociceptive pathways producing pain. In the 
presence of allodynia, when the non-nociceptive Aβ fibres synapse at the dorsal horn they 
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can cause the neurone to respond as if they were nociceptive fibres, and pain would be 
perceived even in response to light touch or other non-nociceptive stimuli (Hawthorn and 
Redmond 1998). Another disruption of the sensory mechanism is related with the 
continuous stimulation of C fibres which can lead to a “wind-up” reaction where the second 
order WDR neurons response increases progressively leading to an enhancement of the 
pain. This concept is important because, if a painful stimulus is present for a long time, it will 
become increasingly more painful and may cause changes to the nociceptive pathway and 
potentially leading to hyperalgesia (Hawthorn and Redmond 1998). 
 
Pain can also have a mixed aetiology. Failed back surgery syndrome (FBSS) pain is a 
mixed type of pain (nociceptive and neuropathic). Patients with this condition experience 
constant pain following unsuccessful back or spine surgery. The nociceptive pain in FBSS 
can result from disc or bone injury, reaction to hardware or graft harvesting, or reactive 
spasm; the neuropathic pain in this condition can be due to nerve injury prior to or during 
surgery, chronic compression, scar tissue formation or arachnoiditis (inflammation of the 
arachnoid membrane that surrounds and protects the nerves of the CNS) (Prager 2002). 
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1.2.4 Basic mechanisms of opioids 
Opioids are a type of drug with the potential to provide pain relief by binding to and blocking 
receptors found in the brain and spinal cord. Opioids exert their effect by attachment to 
opioid receptors, a group of G protein-coupled receptors (GPCRs), which are the largest 
family of cell-surface molecules involved in signal transmission and more than 50% of the 
current available pharmacological agents target these receptors (Marinissen and Gutkind 
2001). 
 
There are three major opioid receptors subtypes: mu (µ), delta (δ) and kappa (κ) (Dickenson 
and Kieffer 2006); and the endogenous opioids act as agonists at these receptors. 
Endorphins and enkephalins have affinity with the µ receptor, enkephalins bind to the δ 
receptor and dynorphins bind to the κ receptor (Dickenson and Kieffer 2006; Lambert 1995). 
More recently, a receptor with similar structure to opioid receptors has been discovered and 
termed opioid-receptor-like 1 (ORL1) (Mollereau et al., 1994). These receptors are located in 
the dorsal horn of the spinal cord and midbrain and brain stem sites, and bind to the 
endogenous peptide nociceptin/orphanin FQ and not to conventional opioids. The effects of 
the ORL1 receptor agonists on pain modulation are still controversial and not fully 
understood as it seems to have differential functions based on spinal or supraspinal activity. 
When administered in supraspinal sites, nociceptin produces hyperalgesia, whereas spinal 
administration has an inhibitory effect and produces analgesia (Darland, Heinricher and 
Grandy 1998; Dickenson and Kieffer 2006; Taylor and Dickenson 1998). 
 
The understanding of opioid pharmacology has advanced considerably since the µ, δ and κ 
receptors were cloned and sequenced successfully (Chen et al., 1993; Evans et al., 1992; 
Kieffer et al., 1992; Yasuda et al., 1993). The main mechanism of both endogenous and 
exogenous opioids seems to be related to the coupling of opioid receptors to calcium (Ca2+) 
and potassium (K+) channels. Opioid receptor activation opens the K+ channels or closes the 
Ca2+ channels, leading to a decrease of neuronal excitability and therefore producing 
analgesia (Dickenson and Kieffer 2006). 
 
Throughout the spinal cord, the distribution and contribution of µ, δ and κ receptors to the 
total opioid binding is estimated at 70%, 24% and 6% respectively (Besse et al., 1990; 
Dickenson 1991), mostly (>70%) at a presynaptic location on the central terminals of both C 
and Aδ fibres (Dickenson and Kieffer 2006). This suggests that the main mechanism of 
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spinal opioid analgesia of both endogenous and exogenous opioids is via activation of 
presynaptic opioid receptors, which act to selectively decrease transmitter release from 
nociceptive afferents and therefore nociceptive transmission (Ossipov et al., 1995). The 
activation of postsynaptic opioid receptors has a similar effect on the second-order neurons. 
The postsynaptic opioid receptors activation causes a reduction in the response to the 
inputs from the first-order nociceptive neurons. 
 
The different types of receptors have been suggested to regulate distinct pain stimuli 
(Dickenson and Kieffer 2006). Investigations with knockout mice reported that µ receptors 
influenced responses to mechanical, chemical and supraspinal thermal nociception; κ 
receptors modified spinally mediated nociception and chemical visceral pain; δ receptors 
influenced mechanical nociception and inflammatory pain (Martin et al., 2003). The same 
study suggested that although the specific contribution of each opioid receptor was subtle, 
the opioid system as a whole produces a significant inhibitory effect on physiological pain. 
 
Morphine mimics the action of the β-Endorphin endogenous opioid and has a high affinity 
with the µ opioid receptor. The µ ligands are the most potent opioids, possibly because µ 
opioid receptors are present in larger number in the spinal cord (Dickenson and Kieffer 
2006). Morphine acts via the µ receptor to activate potassium channels and to block calcium 
currents, reducing membrane excitability and transmitter release (Pasternak 2001). This was 
confirmed in µ knockout mice (mice with deoxyribonucleic acid sequence engineered to lack 
the µ opioid receptor) in which morphine did not produce analgesia (Matthes et al., 1996). 
There are however, several processes that can follow agonist-induced receptor activation 
such as phosphorylation or downregulation of the opioid receptor with potential to cause 
tolerance, dependence or withdrawal (these processes are explained in more detail in 
Chapter 2, section 1). With the exception of constipation, tolerance to opioid related side 
effects such as respiratory depression, nausea and sedation may also occur, however, this 
tolerance is favourable because it contributes to the effective use of the drugs and allows 
dose titration (Portenoy and Savage 1997). 
 
Animal studies have demonstrated that intrathecal morphine administration was more 
effective than systemic administration in producing inhibitions of electrical, mechanical and 
chemical stimuli of spinal nerve ligated rats (Suzuki, Chapman and Dickenson 1999). The 
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same study also reported marked side effects, such as respiratory depression in the 
systemic route of delivery. 
 
Because intrathecal drug administration delivers the medication directly into the intrathecal 
space it bypasses the blood brain barrier. Opioid analgesics applied closer to their sites of 
action should provide better analgesic efficacy without the adverse effects that accompany 
systemic administration of these composites (Figure 1.2.7). Spinally applied opioids act on 
the substantia gelatinosa of the dorsal horn causing both pre-synaptic and post-synaptic 
inhibition of primary afferent transmission (Cousins and Mather 1984). The analgesic effect 
of morphine when administered at the spinal level was first demonstrated in 1976 in animal 
studies (Yaksh and Rudy 1976). Prior to this investigation it was believed that narcotic 
analgesia was mediated by the action of a drug on a supraspinal level. The clinical 
application of these discoveries was demonstrated when spinally administered opioids were 
used to manage cancer pain successfully (Wang, Nauss and Thomas 1979). 
 
 
 
1.2.5 Prevalence of chronic pain in Europe and United Kingdom 
Chronic pain is a highly prevalent condition, with an impact on an individual’s health, 
healthcare services, society and one for which successful treatment outcomes are difficult to 
achieve (Smith, Macfarlane and Torrance 2007). A systematic review of the prevalence of 
chronic pain in the general population reported a range of 10.1% to 55.2% after evaluation 
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of 13 articles (Harstall and Ospina 2003). In Europe, one in five adults (19%) suffer from 
chronic pain and more than a third of European households have at least one pain sufferer 
(chronic or acute) (Breivik et al., 2006). For this survey of 15 European countries and Israel, 
chronic pain was defined as pain lasting more than six months, experiencing pain during the 
last month, several times during the last week, and the reported last experience of pain 
having an intensity of five or more on a numeric rating scale (NRS) ranging from one (no 
pain) to 10 (worst pain imaginable). Prevalence of chronic pain in the United Kingdom 
corresponded to 13% which accounts for approximately 3.8 million of the UK population, 
with a third of these people suffering chronic pain constantly and 32% of these participants 
reporting severe pain (eight to 10 on the NRS) (Breivik et al., 2006). There were differences 
between the European countries studied with chronic pain incidence ranging from 12% 
(Spain) to 30% (Norway) and severe pain ranging from 18% (Netherlands) to 50% (Israel). 
Possible reasons advanced for this variance include differences in the perception of pain 
and pain treatment, age stratification of the population and lifestyle (Breivik et al., 2006). As 
the lifespan rises, it is likely that chronic pain will have a higher impact upon quality of life as 
increases in persistent pain have been observed in the elderly (Elliott et al., 1999). Chronic 
pain among adults of advanced age is a common problem which affects 50% of the elderly 
living in a community setting (Helme and Gibson 2001) and more than 80% of nursing home 
residents (Ferrell 1995). 
 
Despite the differences among European countries (e.g. health care systems, treatment 
approach and development and technology), the UK Chief Medical Officer, Sir Liam 
Donaldson, has documented that chronic pain is a major health care problem in Europe that 
needs to be taken more seriously and action to alleviate this condition undertaken 
(Donaldson 2009). 
 
 
1.2.6 Chronic pain treatments 
Intrathecal drug delivery systems are a last resort treatment to treat severe chronic non-
malignant pain due to their invasive nature, high initial cost, concerns about long-term opioid 
use, and the possible complications related to the procedure. It is considered that the use of 
IDD should only be considered at the end of a long treatment continuum after all possible 
alternative therapies have been tried and failed due to inadequate pain relief or intolerable 
adverse effects (Chambers and MacSullivan 1994; Krames 1996; Krames and Olson 1997). 
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There are also reports in the literature of situations where the patients requested pump 
removal because their primary care physicians refused to continue treatment with what they 
considered addictive drugs (Winkelmüller and Winkelmüller 1996). A treatment continuum 
for the management of chronic non-cancer pain has been suggested (Table 1.2.1). 
 
Treatment strategies for the management of chronic pain start with the lowest risk, least 
invasive and less costly intervention and then progress if a treatment is not effective. The 
first attempts to manage chronic pain consist of conservative treatment options. These 
include exercise programs, relaxation, over-the-counter medications (e.g. ibuprofen), 
adjunctive medications (e.g. anti-depressants), physical rehabilitation and cognitive 
behavioural therapies. Cognitive and behavioural treatments can be used to change the 
effect of the pain on an individual’s life. If these treatments do not provide sufficient pain 
relief, more aggressive therapies such as nerve blocks (injection of a local anaesthetic or 
steroid applied directly to the nerve causing the pain) and oral opioids are attempted. 
 
 
 
Oral opioids 
Following good treatment results observed in cancer patients, oral opioid therapies started 
to be prescribed to patients with chronic non-malignant pain if the cause of the pain could 
not be treated and/or when other treatment methods did not produce satisfactory results 
(Portenoy and Foley 1986; Zenz, Strumpf and Tryba 1992). Opioid treatment should be 
considered for both nociceptive and neuropathic pain conditions (Breivik 2005). No evidence 
exists to support the suggestion that non-malignant pain or different types of pain such as 
neuropathic pain are inherently unresponsive to opioid medication (Portenoy 1996). The 
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long-term use of opiods in chronic non-malignant pain is only justified if other drugs and 
methods with less risk of side effects have been tried and failed; the pain relief obtained with 
the opioid is significant and sustained; and the improvement in quality of life is sufficient to 
tolerate side effects and the risks of long-term adverse events of opioid therapy (Breivik 
2005). 
 
The World Health Organization (WHO) (1996) recommends a three step approach for the 
use of analgesics to provide pain relief (Figure 1.2.8). Non-opioids should be the 
administered for mild pain (step 1), followed by mild opioids if the pain continues or is 
moderate (step 2), and if the pain persists or is severe, strong opioids should be provided 
and the dose adjusted until pain relief is observed (step 3). Although commonly used, the 
systemic adverse effects of the medication administered via intravenous and oral routes 
often limit their use. Oral opioid therapy side effects may result in deterioration of the overall 
functional capabilities of the patients (Portenoy and Foley 1986). 
 
 
 
Intrathecal Drug Delivery Systems 
An intrathecal drug delivery system consists of a pump (Figure 1.2.9) implanted into an 
abdominal subcutaneous pocket which delivers medication directly into the cerebrospinal 
fluid through a catheter inserted into the intrathecal space of the spine and tunnelled under 
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the skin. Intrathecal spinal analgesia has become a recognized treatment for chronic non-
malignant pain since the first reservoir was implanted in 1981 (Onofrio, Yaksh and Arnold 
1981). Fully implantable devices have a lower infection rate when compared with external 
drug pumps (Sjöberg et al., 1992). 
 
Oral administration was previously considered the optimal method of chronic opioid 
administration, however, emerging evidence demonstrates that intrathecal opioid delivery 
has a therapeutic advantage when comparing to alternative modalities (Mueller-Schwefe, 
Hassenbusch and Reig 1999). The use of opioids via IDD allows for a selective 
concentration to reach an important site of pain transmission, the spinal cord dorsal horn 
(Grady and Raphael 2008). Opioid administration into the intrathecal space achieves its 
effects at lower doses than using the oral or epidural route (North et al., 1991). The oral 
opioid dose conversion to an intrathecal dose is approximately 300:1 (Lamer 1994; Levy 
1997), while the conversion ratio between epidural and intrathecal has been suggested to be 
24:1 (Nordberg et al., 1984). The drug is highly localized, so its analgesic efficacy is 
maximized at lower doses (Coombs et al., 1983); and therefore, only a small amount of the 
drug reaches the circulatory system and is systemically absorbed (Winkelmüller and 
Winkelmüller 1996). Generally this leads to a decrease in the side effects, which also 
facilitates the provision of greater analgesia (Prager 2002). 
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The cerebrospinal fluid has limited capacity to distribute intrathecally administered morphine 
away from the catheter tip (Bernards 2006; Flack, Anderson and Bernards 2011). This 
results in a greater delivery of the medication into the spinal cord. Besides having 
implications to the efficacy of the intrathecal therapy, this also means that only very small 
amounts of the medication would reach the supraspinal regions (Figure 1.2.10). Both brain 
and spinal cord are important sites of analgesia but they have a differing spectrum of non-
analgesic effects with more derived from the brain (Grady and Raphael 2008). 
 
 
 
An intrathecal pump can have a programmable or constant flow rate and there are also 
variations concerning the volume of the reservoir. The selection will depend on what is 
considered to be more advantageous to the patients’ pain relief. With fixed rate pumps, 
changes in the delivery dose are only possible with a different concentration of the 
medication (Wallace and Yaksh 2000). Programmable pumps allow greater flexibility for 
Page | 33 
dosing changes and also allow for changes in the timing of medication delivery. This feature 
is particularly relevant for patients whose pain changes during the course of a day. 
Programmable pumps are also implanted when dose titration and regulation is anticipated 
(Prager 2002). The pump is refilled periodically via subcutaneous port injections. The 
frequency of refills depends on the flow rate of medication delivery that the patient requires. 
Patients with higher doses require more frequent refills. 
 
The intrathecal medication administered to a chronic non-malignant patient is often low and 
drug delivery can be monitored with precision, therefore decreasing the risk of addiction. 
 
 
IDDS Procedure 
Due to the invasive nature, high initial cost, concerns about long-term opioid use and the 
possible complications derived from the procedure, IDD is only considered after more 
conventional treatments have failed. Generally, patient selection criteria for IDD includes 
inadequate pain relief with more conservative therapies, absence of surgically correctable 
lesions, pain responsive to oral, epidural or intrathecal opioids, 50% or greater pain relief 
during IDD trial, and no significant psychological / behavioural contraindications (Doleys et 
al., 1998). 
 
At RHH Pain Management Department, a multidisciplinary assessment involving a pain 
consultant, a psychologist and a physiotherapist is undertaken to assess the different facets 
of pain and to determine patient suitability for IDDS. A biopsychosocial history is performed 
where factors such as pain topography, duration of pain, pain intensity, coping strategies, 
social support, history of anxiety and/or depression, previous treatments, and drug and/or 
alcohol abuse are taken into consideration. Before proceeding to surgery, a temporary 
inpatient trial of intrathecal medication takes place, lasting between two to five days to 
determine if the patient would obtain pain relief via intrathecal drug delivery. The trial 
consists of a single blinded placebo controlled administration of morphine. Patients are 
given different doses of morphine or saline, which they would be unaware of because they 
would not be informed and their drug chart would not be accessible to them. Placebo 
administration is randomly administered according to the preference of the physician in one 
or two of the days during the trial period. NRS pain intensity measurements are taken 
throughout duration of the trial, ranging from zero (no pain) to 10 (worst pain possible). 
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As recommended, if at least 50% pain reduction is achieved without intolerable side effects 
to medication and dose used during the trial, the patient should be considered a suitable 
candidate for IDD (Anderson and Burchiel 1999; Deer et al., 1999). In some countries, the 
implantation of the IDD system occurs immediately following a successful trial. In the United 
Kingdom, if the procedure is performed in a National Health Service (NHS) hospital, usually 
there is a waiting time between trial and full implantation because of the time required to 
obtain funding from the patient’s Primary Care Trust (PCT). 
 
After implantation of the IDD device, the patients attend the hospital to refill the pump. At this 
time, adjustments are made to the medication if needed. The time between pump refills 
depends on the intrathecal dose the patient is being administered and can range from one 
month (patients receiving high intrathecal doses) to three or four months (patients on low 
intrathecal doses). Between follow-ups, a helpline managed by pain management nurses is 
available for urgent situations. The patient can also request an appointment if the pain is not 
under control or if there are suspicions of malfunctions. 
 
The following section presents a review of the literature focusing on complications and 
effectiveness of intrathecal drug delivery. 
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SECTION 3. Intrathecal drug delivery for chronic non-malignant pain: a review 
 
1.3.1 Introduction 
Prior to the start of the literature review, the author of this thesis was aware of the lack of 
randomised controlled trials (RCTs) investigating the efficacy of intrathecal drug delivery 
therapy for the management of chronic non-malignant pain. In contrast, several systematic 
literature reviews on this topic are currently available (Williams, Louw and Towlerton 2000; 
Turner, Sears and Loeser 2007; Patel et al., 2009; Noble et al., 2010; Hayek et al., 2011) 
(Table 1.3.1). A systematic review of multiple well-designed RCTs is considered the highest 
level of evidence for the efficacy of a pain treatment, followed by a well-designed RCT of 
adequate size as the next best level of evidence (McQuay et al., 1997). The best available 
long-term evidence for IDD is currently from open-label, uncontrolled, time-series studies 
(Noble et al., 2010). 
 
Systematic reviews of observational studies, by assembling the results and assessing the 
methodological quality of the articles included in a review, represent as well a high level of 
clinical evidence. Different criteria can be employed to analyse the quality of evidence and 
grade of recommendation when performing a systematic review. The quality assessment 
tools employed in the reviewed systematic reviews are described. Some of the reviews 
evaluated both cancer and non-cancer studies but for the purpose of this thesis the results 
presented refer to non-cancer pain studies only. 
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1.3.2 Results 
Williams, Louw and Towlerton (2000) 
This review aimed to investigate the effectiveness, side effects and cost effectiveness of 
intrathecal pump systems for patients with chronic pain. The databases searched included 
MEDLINE and PubMed, however, PubMed contains all the MEDLINE citations, and 
therefore it is not clear why the authors mentioned the use of both databases and not only 
PubMed. The initial literature search resulted in 5764 studies that mentioned the use of 
opioids. Further reading revealed that 49 studies assessed efficacy of IDD for chronic pain; 
11 of these were non-cancer pain studies. Although included in the review, the Anderson 
and Burchiel (1999) study was considered by the authors to be a cancer pain study when in 
fact all the patients had chronic non-cancer pain. The number of patients enrolled in these 
studies was 656. Quality assessment was performed using a modified version of the York 
model (Table 1.3.2), but no studies were excluded from the review based on this 
assessment tool score. Included in the seven studies that scored the highest (14 points out 
of 16 possible) were four non-cancer pain studies (Anderson and Burchiel 1999; 
Hassenbusch et al., 1995; Tutak and Doleys 1997; Winkelmüller and Winkelmüller 1996). 
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Morphine dose escalation was observed. For the studies that provided accurate initial and 
final dose information, the average dose increase per week ranged from 0.9% to 7% for 
non-cancer pain patients and from 11% to 160% for cancer pain patients. 
 
This was the only review that also aimed to assess the cost-effectiveness of intrathecal 
pumps. The author’s conclusion regarding this outcome was that there was little evidence on 
the comparative costs of intrathecal pump systems with conventional therapies. Based on 
cost-modelling studies, it was suggested that intrathecal drug delivery may be cost-effective 
at varying times after initiation of therapy, depending on individual patient circumstances. 
 
The authors concluded that the main risks associated with intrathecal pumps are 
pharmacological side effects of the drugs used and mechanical complications associated 
with the system used. Regarding effectiveness, it was concluded that the use of intrathecal 
therapy seems beneficial but definite conclusions can only be drawn with the emergence of 
clearer and more standardised information. 
 
 
Turner, Sears and Loeser (2007) 
The authors performed a systematic literature review of IDD effectiveness and 
complications. This review was limited to programmable pumps because the authors 
considered that at the time the search was performed, the majority of implanted intrathecal 
pumps for chronic non-malignant pain were programmable. Literature search strategies 
were provided for all the bibliographic databases used (PubMed, Science Citation Index 
Expanded, Cochrane Central Register of Controlled Trials, EMBASE, Current Contents 
Connect, Global Health, and International Pharmaceutical Abstracts). Search sensitivity was 
verified by ensuring that almost all articles identified via hand search of reference lists were 
identified via one or more of the structured database searches. Hand search of reference 
lists was also carried out. Quality assessment was carried out with the American Academy 
of Neurology (AAN) evidence classification (Moxley et al., 2005) (Table 1.3.3). The same 
group also developed a system for translation of the evidence into recommendations (Table 
1.3.4), however, it was not clear if the authors used this tool. 
Page | 43 
 
 
Besides the inclusion criteria specified in Table 1.3.1, there were specific methodological 
characteristics the papers should have. Additional inclusion criteria for the effectiveness 
review was that the study should be Class I to III or a Class IV study with independent 
observer-completed or patient-completed standardised measures of pain or functioning 
obtained both before IDD implantation (or ziconotide initiation) and at planned, regular 
follow-ups; data from patient baseline descriptive and outcome measures reported for all 
study participants who underwent IDD implantation (or ziconotide initiation) during the study 
period; and original data reported on pain or functioning before IDD implantation and for ≥ 
75% of implanted patients at a follow-up ≥ 6 months. Articles that failed the inclusion criteria 
for the effectiveness review could still be used for the complications review if the article 
reported original data on complications for ≥ 6 months after pump implantation for ≥ 80% of 
patients that received a pump during the study period. The rationale for minimum 
proportions of patients and duration of therapy were not clarified. Two authors used a 
structured form to screen each article for the inclusion and exclusion criteria and 
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discrepancies were resolved by discussion; however, it was not clarified if there were any 
discrepancies. Following screening of abstracts, 78 articles were reviewed for possible 
inclusion in either the effectiveness or complications review. Fifty-two of the articles were 
excluded from both reviews with 26 remaining. For the effectiveness review, 20 more 
articles were excluded from the review; 14 for not meeting the study methodology criteria 
and 6 because they did not report pre-IDD data on pain or functioning; six articles were 
included. For the complications review, 16 articles were excluded because they did not 
report original data on complications for ≥ 6 months after pump implantation for ≥ 80% of the 
study participants who received a pump; 10 articles met the inclusion criteria. 
 
 
 
Improvements in pain intensity were observed in all six studies included in the effectiveness 
review. There was, however, a high attrition rate in the two studies reporting pain intensity 
ratings at a follow-up time longer than six months. Patients reporting ≥ 50% reduction in pain 
ranged from 38% to 56% at six months and 30% at 24 months or 44% at last follow-up with 
a mean of 29 ± 12 months. All the studies included in the effectiveness review were Class IV 
observational according to AAN levels of evidence (Moxley et al., 2005). Besides the 
pharmacological side effects in Table 1.3.1, other side effects mentioned, but for which no 
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prevalence were reported, included asthma, insomnia, dry mouth, nightmares, myoclonic 
jerk/spasm, dizziness, loss of appetite, diarrhoea, and headache. 
 
Although the authors indicated the use of the AAN levels of evidence, no reference is made 
to what their recommendation regarding IDD therapy would be based on the results of their 
systematic review and quality appraisal of the available evidence. 
 
 
Patel et al. (2009) 
The aim of this study was to determine the efficacy, safety, and complications associated 
with the use of intrathecal drug delivery systems for long-term management of chronic non-
cancer pain. 
 
Some of the search terminology was described but the search strategy used was not 
included in the review. The studies were evaluated for the inclusion and exclusion criteria by 
two physicians and disagreements resolved by a third physician. The same method was 
employed for quality assessment of the studies. If a conflict of interest was present (e.g. an 
author reviewing his own study), the involved authors did not assess the study. There was 
no indication in the review if disagreements or conflict of interests occurred during the review 
process. 
 
Quality assessment of the articles was performed using the levels of evidence from the 
United States Preventive Services Task Force (USPSTF), supported by the Agency for 
Health Care Research and Quality (AHRQ) criteria for observational studies that translates 
into quality of evidence levels (Harris et al., 2001) (Table 1.3.5), the Cochrane 
Musculoskeletal Review Group criteria for randomised trials as described by Koes et al. 
(1995) (Table 1.3.6) and recommendation for therapy based on Guyatt et al. (2006) grading 
of recommendations and quality of evidence (Table 1.3.7). The reason why the authors 
mentioned the Cochrane criteria for randomised controlled trials is unclear because no 
RCTs met the inclusion criteria and, therefore, no RCTs were assessed for methodological 
quality. Only the studies scoring at least 50 out of 100 on weighted scoring criteria were 
included in the analysis. 
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Following review of titles, abstracts and manuscripts based on inclusion and exclusion 
criteria, 15 observational studies were considered for inclusion in the review. There were, 
however, two manuscripts that were not reviewed because according to the authors, the full 
manuscripts were not available. After methodological quality assessment only four studies 
were included in the review. There were three studies for which no reason was provided to 
exclude from the review. 
 
This systematic review concluded that intrathecal infusion systems used for management of 
chronic intractable pain provide positive long-term outcomes. The grade of recommendation 
was 1C/strong based on Guyatt et al. (2006) grading recommendations. 
 
 
Noble et al. (2010) 
The aim of this systematic review was to summarize the evidence pertaining to the safety 
and efficacy of long-term opioid therapy for chronic non-malignant pain. This review also 
included studies where the opioids administered were oral or transdermal but the results 
were presented separately. This Cochrane review is also an update and the full report of a 
previous opioid therapy systematic review (Noble et al., 2008) by the same group. The 
authors declare that the differences in the studies that met the inclusion criteria did not 
impact significantly on the conclusions of the previous review. 
 
This was the only systematic review without language restrictions. Hand search of reference 
lists and review of grey literature was carried out. The authors mention that although grey 
literature was reviewed, only outcomes data from published, peer-reviewed literature was 
analysed. 
 
Two independent reviewers screened abstracts against the inclusion criteria and assessed 
the quality of the possible relevant studies using a 10-item methodological quality 
assessment instrument developed by the ECRI Institute (Table 1.3.8). Discrepancies were 
resolved by consensus, although it was not mentioned if this occurred with any of the 
studies. 
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This was also the only systematic review to perform a meta-analysis when at least two 
studies of the same mode of administration addressed an outcome of interest. Ten 
intrathecal therapy studies met the inclusion criteria. All of these were open-label, single-arm 
time series. For two of these studies, it was unclear whether they were prospectively 
designed. The quality of evidence was considered low primarily due to failure to describe 
patient recruitment methods; failure to compare the characteristics of patients who 
completed the study with patients who did not in studies with attrition; high prevalence of use 
of adjuvant therapies and use of a funding source with a potential conflict of interest in the 
outcome. All the patients enrolled in intrathecal therapy studies reported severe pain at 
baseline due to nociceptive, neuropathic, or mixed pain. Only one intrathecal opioid patient 
appeared to present an opioid abuse and/or addiction behaviour in the form of drug-seeking 
behaviour, indicating a rate of 0.43% (1/228). 
 
The most common reasons for withdrawal of a study were adverse events and insufficient 
pain relief. For each mode of administration, the studies reported that adverse events/effects 
diminished over time and the majority of these were minor. The withdrawal rates due to 
adverse events at follow-up means of 20 and 29 months were lower in intrathecal studies 
with a proportion of 8.9% (95% CI: 4.0% to 18.6%) when compared with the other modes of 
administration. For oral administration, the overall (weak and strong opioids) withdrawal 
rates for a follow-up range of six to 24 months were 22.9% (95% CI: 15.3% to 32.8%). For 
transdermal opioids the withdrawal rates for a follow-up range of six to 48 months were 
12.1% (95% CI: 4.9% to 27%). 
 
The withdrawal rates due to insufficient pain relief at a follow-up range of seven to 24 
months for oral opioids were 10.3% (95% CI: 7.6% to 13.9%); for transdermal opioids at a 
follow-up range of 12 to 48 months were 5.8% (95% CI: 4.2% to 7.9%); and for intrathecal 
opioids at a follow-up range of six to 29 months were 7.6% (95% CI: 3.7% to 14.8%). 
 
The proportion of patients who had at least 50% pain reduction using oral opioids was 
44.3% (95% CI: 33.3% to 55.9%); for transdermal opioids was 38.2% (95% CI: 33.1% to 
43.5%), however, this was the result of a single study. Under the protocol developed, the 
results of a single study cannot be used to form-evidence based conclusions. The proportion 
of patients undertaking intrathecal opioids that achieved at least 50% pain reduction was 
44.5% (95% CI: 27.2% to 63.2%). 
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No conclusions could be drawn regarding the effects on quality of life and function for 
intrathecal patients due to inconsistent or inconclusive findings. No studies were identified 
for the function outcome for oral or transdermal opioids and for the quality of life outcomes 
they were inconclusive for both oral and transdermal opioids. 
 
The authors concluded that the evidence regarding the effectiveness of long-term opioid 
therapy is currently too sparse to draw firm conclusions. 
 
 
Hayek et al. (2011) 
The aim of this systematic review was to evaluate and update the available evidence for the 
efficacy and safety of intrathecal infusions used in long-term management (> 6 months) of 
cancer and non-cancer pain. The inclusion and exclusion criteria states that non-cancer pain 
studies with less than 12 months follow-up and cancer pain studies with less than three 
months follow-up would not be included in the review. The search was carried out by two 
unblinded reviewers. Quality assessment was carried out using the same tools as in the 
Patel et al. (2009) systematic review. 
 
Discrepancies in the analysis were evaluated by a third reviewer who, working with the other 
reviewers, reached a consensus. Studies scoring below 50 of 100 in the quality assessment 
were excluded from the review. The search was limited to English language studies. The 
keywords used for the search were provided. The authors also indicated that the reviewers 
did not evaluate their own articles (conflict of interests) but there is no clarification as to how 
this situation was resolved. 
 
The search resulted in the inclusion of 20 studies. The majority (15) involved non-cancer 
pain patients’ observational studies and from the five cancer studies, four were 
observational studies and one was a randomised controlled trial involving only cancer pain 
patients. With the exception of three non-cancer studies, complications derived from the 
therapy were reported. All of the studies included reported positive outcomes including pain 
relief measured with a VAS or NRS. 
 
This systematic review used both USPSTF and Guyatt et al. (2006) quality of evidence 
criteria. Based on Guyatt et al. (2006) criteria the authors suggest moderate 
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recommendation of IDD for both cancer and non-cancer pain management. However, this 
level of recommendation is absent from Guyatt et al. (2006) grade of recommendation / 
description. 
 
 
1.3.3 Conclusion 
All of the evaluated systematic literature reviews aimed to investigate the effectiveness of 
IDD for the management of chronic pain. It is interesting to notice that no study was included 
in all the reviews (Table 1.3.9). This occurred most likely due to the inclusion and exclusion 
criteria chosen as well as the assessment tool used to measure the methodological quality 
of the studies. However, both the Patel et al. (2009) and the Hayek et al. (2011) reviews had 
similar inclusion and exclusion criteria, the same quality assessment tools, methodology and 
two of the authors participated in both reviews. Seven additional studies published until the 
end of 2007 were included in the Hayek et al. (2011) review but not in the Patel et al. (2009) 
review. One difference in the inclusion criteria was the minimum number of participants 
included, 25 for the Patel et al. (2009) review and 24 for the Hayek et al. (2011) review. 
There was only one study with 24 participants and therefore meeting the exclusion criteria 
for the Patel et al. (2009) review. The Patel et al. (2009) review used an additional 
bibliographic database (National Institutes of Health Clinical Trials Registry) that was not 
used in the Hayek et al. (2011) review. Therefore, the reasons for the discrepancy in the 
number of included articles in these reviews are not clear. 
 
The conclusions for the effectiveness of intrathecal drug delivery for the management of 
chronic non-malignant pain were similar for all the systematic reviews assessed. None of the 
systematic reviews identified randomised controlled trials for non-cancer pain. All of the 
reviews recognize the paucity of good quality long-term effectiveness papers for IDD 
therapy, especially non-cancer pain. Overall, the use of IDD for chronic non-malignant pain 
patients seems beneficial, but the current available literature is too sparse to draw definite 
conclusions regarding its effectiveness. 
 
Following the review of intrathecal drug delivery for chronic non-malignant pain, a pilot study 
is presented. The side effects/complications of this therapy were investigated. The pilot 
study was carried out at Russells Hall Hospital Pain Management Department. 
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SECTION 4. Pilot study of intrathecal drug delivery complications/side effects 
 
This section was published as three separate abstracts in Regional Anesthesia and Pain 
Medicine 2008;33(5):e20/e201/e202 (Appendix 6, 7, 8). Appendix 8 was also selected for 
oral presentation at the Neuromodulation Society of United Kingdom and Ireland Joint 
Scientific Meeting with British Stereotactic and Functional Neurosurgery Group 2007. 
Appendix 6 was selected for oral presentation at the 27th Annual European Society of 
Regional Anaesthesia Congress 2008. These publications have been reformatted to fit with 
the overall PhD thesis. 
 
 
1.4.1 Background 
In order to determine which complications would be of interest to study, a pilot study was 
performed at Russells Hall Hospital, Pain Management Department to investigate which 
complications/side effects are more prevalent at this centre. This department is one of the 
largest UK centres for intrathecal drug therapies. IDD systems were introduced at this centre 
as a treatment for chronic pain in the late 1980s, and since then, its staff have acquired a 
vast knowledge and experience regarding this therapy. 
 
Opioid dose increase and hormonal effects were investigated alongside the investigation of 
complications/side effects as they can be underreported. Opioid dose increase can be 
regarded as a normal consequence of long-term therapy and sexual dysfunction as a result 
of hormonal imbalance not always is reported by the patient to the consultant. 
 
 
1.4.2 Methods 
Complications/side effects 
A longitudinal retrospective case notes review of 62 consecutive patients receiving 
continuous intrathecal analgesics by implanted reservoir administration was carried out. 
Patients’ case notes were screened from date of implant to August 2008. Data collected 
included duration of pain prior to implant, age at the time of IDD system implantation and 
duration of IDD therapy. Complications reported were recorded and categorized for the 
purpose of analysis. 
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Opioid dose increase 
A longitudinal retrospective review of the doses of 47 patients receiving intrathecal morphine 
or diamorphine was performed through examination of the patients’ case notes from date of 
implant to August 2008. The intrathecal dose since implant date was computed for 
consecutive years. The data presented comprises the intrathecal opioid doses up to year 10. 
Less than 10 patients included in the study had been undertaking IDD therapy for longer 
than 10 years. 
 
 
Hormonal effects 
The hormone levels of seven males who had been receiving long-term (> 4 years) and low-
dose (< 2.5 mg/day) intrathecal morphine therapy were reviewed. The hormones 
investigated included testosterone, luteinizing hormone (LH), follicle stimulating hormone 
(FSH) and sex hormone binding globulin (SHBG). The reference levels used for these 
hormones were: testosterone (male 20 to 49 years: 9.1 - 55.2 nmol/L; > 49 years: 6.3 - 26.6 
nmol/L); LH (2.2 – 13.3 IU/L); FSH (1 - 7 IU/L) and SHBG (13 - 71 nmol/L). Morphine dose 
and duration of IDD therapy were also recorded. 
 
 
Data analysis 
The mean and standard deviation were calculated for the variables age, duration of pain 
prior to implant, duration of therapy, intrathecal dose and hormones studied. Proportions 
were calculated to examine the prevalence of the complications identified. Events per 
patient year were calculated using the formula: ((number of events ÷ number of patients) ÷ 
average follow up). Statistical tests were performed using the Statistical Package for the 
Social Sciences (SPSS) software (version 12.0, SPSS Inc., Chicago, IL, USA). 
 
 
1.4.3 Results 
Complications/side effects 
The mean age of the patients investigated was 59 ± 9 years (range: 38-77). The average 
duration of IDD therapy was 6.7 ± 4 years (range: 1-16). Prior to implantation of an 
intrathecal pump, the mean duration of painful symptoms was 14 ± 10 years (range: 2-38). 
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At the moment of this retrospective analysis, 53.3% of the patients had not reported any 
symptomatic complications/side effects. More than one adverse event was identified for 13 
patients (20.9%) while 16 individuals (25.8%) had one single complication throughout the 
course of IDD treatment. Table 1.4.1 details the number of patients who had an adverse 
event during the course of IDD therapy. 
 
 
 
With the exception of life threatening overdose which is more likely to occur due to leakage 
or human error during pump refill, the other pharmacological side effects observed are 
common in long-term intrathecal therapy (Chaney 1995) (Table 1.4.2). 
 
 
Page | 57 
Infections usually occurred subsequent to implant, revision surgery or replacement of the 
pump. Three patients were diagnosed with intrathecal catheter tip granulomas, 
corresponding to 0.007 events per patient year. Complications related to the equipment or 
technical difficulties were the commonest adverse events identified with an occurrence rate 
of 0.055 events per patient year. Adverse events requiring discontinuation of IDD device, 
revision surgery or explantation of the IDD system accounted for 27.4% of the situations. 
 
 
Opioid dose increase 
The mean age of the patients was 60 ± 9 years (range 38-77) with an average duration of 
treatment of 6 ± 3 years (range 1-10). The mean opioid dose of these patients throughout 
the years was 2.66 ± 2.39 mg/day (range 0.3-14.2). There was a gradual increase in opioid 
dose with time to reach 5.23 mg/day (range 0.75-14.2) at 10 years (Fig. 1.4.1). 
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The graph illustrates that opioid dose increases with time, however, the increase is modest. 
Some patients did not demonstrate any tolerance and only one patient (#19 in the graph) 
very rapidly showed dose escalation, reaching an intrathecal opioid dose > 10 mg/day within 
four years of IDD therapy. 
 
 
Hormonal effects 
The mean age of the patients evaluated was 55 ± 7 years (range 45-66). The mean 
morphine dose was 1.5 ± 0.7 mg/day (range 0.35-2.3) and the mean duration of treatment 
was 7.2 years (range 4-15). Serum testosterone concentrations were below the lower limit of 
the reference range for age in three patients and borderline low in three other patients. 
Serum LH levels were low (< 2.2 IU/L) in five patients and FSH levels were within the 
reference range (1-7 IU/L) in all seven patients (Table 1.4.3). 
 
 
 
Based on serum testosterone and LH levels, five of the seven patients were considered to 
have hypogonadotropic hypogonadism. 
 
 
1.4.4 Limitations 
This pilot study allowed determination of the prevalence of complications/side effects at this 
centre. However, possible causes of the identified complications/side effects were not 
explored. 
 
The opioid dose increase study was based on a single dose per patient per year. A more 
robust investigation could be performed with the dose per year based on the average of all 
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the refills throughout each year. Moreover, a complete data set would allow further analyses 
which were not possible with this sample. 
 
The aim of the hormonal effects investigation was to verify if hypogonadotropic 
hypogonadism, also known as secondary hypogonadism could occur even at small doses. 
This study included a limited number of participants and did not investigate if the occurrence 
of hypogonadotropic hypogonadism could have more repercussions in the patients other 
than the potential loss of libido. 
 
 
1.4.5 Need for this study 
The pilot study enabled identification of which complications are more prevalent at this 
centre for IDD therapy administration. Taking into consideration the incidence and 
magnitude of the adverse events categorized, research feasibility and available literature; it 
was considered that an investigation of intrathecal opioid dose increase, intrathecal 
granuloma formation, and hormonal effects could potentially provide new knowledge in this 
area. 
 
Intrathecal opioid dose increase was investigated because the possibility of tolerance 
development is a commonly used reason to withhold the use of opioid treatment until an 
undeniable need (Portenoy 1994). The opioid dose increase observed in the pilot study was 
modest; therefore it was considered that a more robust analysis as described above could 
shed some light into the dose escalation problematic. 
 
The majority of possible pharmacological side effects resolve with time, often without the 
need of additional medication (e.g. nausea, urinary retention). Intrathecal granulomas have 
the potential to cause paralysis if not identified in its early development. Moreover, the 
conservative method to manage this adverse event, involves the decrease, change or 
cessation of the opioid administration impacting on a patients’ pain relief. Therefore, and 
since the current available literature on this topic is limited, an investigation of this IDD side 
effect would be of value. 
 
The possible effect of IDD on the endocrine system is one of the least noted and 
investigated IDD side effects and consequently undertreated (Doleys et al., 1998; Reddy et 
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al., 2010). This usually occurs because the patients may attribute the signs and symptoms 
of hypogonadism to the chronic pain and its related conditions. Moreover, hormonal 
imbalance can cause further complications not directly related with the IDD therapy. 
 
Additionally, due to the potential dimension of some of these adverse events and possible 
implications to the treatment and condition of the patients undertaking this therapy, the long-
term benefits and the cost effectiveness of IDD were also considered to be of interest to 
investigate. The long-term effectiveness and cost effectiveness of IDD therapy have also 
been considered by the described systematic reviews as areas where current knowledge is 
limited. 
 
The following chapters will focus on the mentioned pharmacological complications as a 
result of intrathecal drug delivery therapy. 
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SECTION 1. Intrathecal opioid dose increase throughout the years 
 
2.1.1 Abstract 
Background and aims 
The fear of the development of dependence, tolerance or addiction as a consequence of 
opioid medication contributes regularly to the stigmatisation and withholding of intrathecal 
opioid delivery therapy for chronic pain of non-malignant origin. Tolerance is defined as a 
phenomenon in which exposure to a drug results in a decrease of an effect or the 
requirement of a higher dose to maintain an effect. However, often the need of opioid dose 
escalation is the result of deterioration of a patient’s condition. The aim of this study was to 
describe the intrathecal opioid dose throughout the years in chronic non-malignant pain 
patients and to develop an intrathecal opioid dose predictive model. 
 
Methods 
A longitudinal retrospective assessment of medical records was performed and pump refill 
notes were screened from date of implant to November 2010 for 31 patients undertaking 
continuous intrathecal opioid delivery for the management of chronic non-malignant pain. All 
the participants included had a minimum of six years of IDD therapy when the data was 
collected. Changes in opioid dose were investigated and controlled for gender, age, duration 
of pain prior to IDDS, topography of pain, type of pain, IDD system replacements and 
administration of intrathecal adjuvant medication. 
 
Results 
Significant increases in the intrathecal morphine dose were verified between follow-up at 
one year and all subsequent observations, F (2.075, 62.238) = 13.858, p < 0.001. From year 
three onwards, no significant differences were observed with the following assessments, F 
(3, 90) = 2.516, p = 0.63, indicating stability of the morphine dose. A model that accounts for 
76% of the variability of morphine doses at year six based on year two assessment was 
developed. 
 
Conclusion 
A model accounting for 76% of the variability of the opioid dose at year six based on the 
dose of year two combined with duration of pain prior to initiation of intrathecal therapy was 
developed. This model has the potential to assist the physician in the identification of a need 
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for an alternative treatment strategy. Since many of the pump replacements are performed 
prior to year six, it can also assist in the informed decision of the benefits and risks of the 
maintenance of this therapy. 
 
 
2.1.2 Introduction 
Nomenclature of concepts 
The concepts of addiction and dependence are often associated with tolerance. Therefore, it 
is important to clarify the differences between these terminologies. To describe a physically 
dependent patient as an addict may lead to stigmatization and potentially cause distress and 
risk of under-treatment (Portenoy 1991). 
 
Dependence can be divided into physical and psychological. An individual is physically 
dependent on a substance when an abstinence syndrome or withdrawal occurs after sudden 
dose reduction, cessation of therapy or administration of an antagonist drug (Jaffe 1985). 
The phenomenology of physical dependence has been widely researched and described in 
animals (Gellert and Holtzman 1978; Martin et al., 1974; Redmond and Krystal 1984) and 
humans (Heishman et al., 1989a; Heishman et al., 1989b; Judson, Himmelberger and 
Goldstein 1980). Physical dependence is likely to commence with the initial administration of 
an opioid drug and its development should be assumed if the opioids are administered on a 
regular basis for pain relief (Collett 1998; Portenoy and Savage 1997). When there is a need 
to cease the opioid therapy, the current practice for pain management patients, is to reduce 
the opioid dose slowly, therefore reducing the likelihood of withdrawal symptoms. An abrupt 
stop of opioids or the administration of opioid antagonists is very likely to cause withdrawal 
(Kanner and Foley 1981). 
 
Psychological dependence can be considered as a component of the addiction concept 
because it implies the craving of a substance for its psychological effects (Portenoy 1994). 
Addiction is characterized by the compulsive use of a substance (despite harm), drug 
seeking behaviours and a high tendency to relapse following withdrawal (Jaffe 1985; Rinaldi 
et al., 1988). In the clinical setting, addiction is also associated with noncompliance with 
suggested opioid changes (Raphael et al., 2010). Fear that opioid treatment may lead to 
addiction or abuse is one of the great medical concerns and at the same time a potential 
barrier to administration of this therapy (Noble et al., 2008). However, opioid addiction is 
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more common outside a pain clinical setting. In a recent systematic review, the observed 
signs of opioid addiction in pain management patients corresponded to seven cases in 
4,884 participants, indicating a low rate of opioid addiction development (0.14%) (Noble et 
al., 2010). The same author considers that the low rates of addiction should only be 
generalized to patients without a history of addictive/abusive behaviours. Despite situations 
where extremely high doses of intrathecal opioids were administered, only one IDDS study 
has reported a possible development of opioid addiction in the form of drug seeking 
behaviour (Anderson and Burchiel 1999). 
 
Tolerance refers to a phenomenon in which exposure to a drug results in a decrease of an 
effect or the requirement of a higher dose to maintain an effect (Jaffe 1985). Tolerance to 
opioids is characterized by a shortened duration and decreased intensity of the effects 
caused by depression of the central nervous system such as analgesia, euphoria or 
sedation (Jaffe 1985). The type of tolerance can be divided into innate or acquired (O’Brien 
1995). Innate tolerance is genetically determined and refers to sensitivity or lack of 
sensitivity to a drug which can be observed during the first administration. Acquired 
tolerance can be divided into pharmacokinetic, pharmacodynamic and learned tolerance. 
Pharmacokinetic tolerance refers to modifications in the metabolism or distribution of the 
drug following repeated drug administrations which result in reduced concentrations in the 
blood and at the sites of drug action. Pharmacodynamic tolerance refers to adaptive 
changes which take place within the systems affected by the drug, such as changes ensuing 
drug administration in receptor density or receptor sensitivity, so that response to a given 
concentration of the drug is reduced. Learned or associative tolerance refers to a reduction 
of the effects of a drug as a result of learned compensatory mechanisms, for example 
through operant conditioning. 
 
 
Physiological mechanisms and potential contributors to opioid tolerance 
G protein-coupled receptors (GPCRs) are the largest family of cell-surface molecules 
involved in signal transmission and more than 50% of the current available pharmacological 
agents target these receptors (Marinissen and Gutkind 2001). Opioids exert their effect by 
attachment to a group of GPCRs (Figure 2.1.1). The GPCRs encompass seven 
transmembrane helices. These receptors are activated by extracellular stimulus which is 
then decoded into intracellular signals causing an activation of a guanine nucleotide-binding 
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protein (G protein). The G proteins are signal transducers that communicate signals from a 
diverse selection of sensory and chemical stimuli, such as light, odour, taste hormones, 
neurotransmitters, chemokines, autocrine and paracrine factors (Ferguson 2001; Neves, 
Ram and Iyengar 2002). The effect of the G protein is dependent on the type of binding 
agonist. The GPCRs respond to a multiplicity of extracellular stimuli, and activate a variety of 
intracellular signalling pathways (Kroeze, Sheffler and Roth 2003). After the agonist binds to 
the receptor, a structural arrangement in the receptor occurs. The signalling pathways that 
are activated will depend on the type of G protein to which the receptor is attached 
(Marinissen and Gutkind 2001; Neves, Ram and Iyengar 2002). The functional activity of 
GPCRs extends beyond the traditional model of receptor → G protein → effector (Ferguson 
2001). Most biological responses that are mediated by GPCRs are not dependent on a 
single biochemical route, but result from the integration of the functional activity of an 
intricate network of intracellular signalling pathways (Marinissen and Gutkind 2001). 
 
GPCRs can be grouped into five different families: glutamate, rhodopsin, adhesion, 
frizzled/taste 2 and secretin (Fredriksson et al., 2003). The glutamate family has a 
physiological role in a variety of central nervous system functions including pain modulation 
and also interacts with the opioid system (Fundytus 2001). Glutamate receptors have been 
found to be present in the brain, spinal cord and periphery in animals and humans (Fundytus 
2001). 
 
 
The activity of GPCRs is characterized by a coordinated balance between molecular 
mechanisms controlling receptor signalling, desensitisation and resensitisation (Ferguson 
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2001). Receptor desensitisation (or tolerance) indicates the decline of GPCRs 
responsiveness to an agonist with time and it is an important physiological “feedback” 
mechanism that protects against both acute and chronic receptor overstimulation (Ferguson 
2001). Nevertheless, receptor desensitisation can also significantly limit the therapeutic 
benefits of many receptor agonists (Ferguson 2001). 
 
A combination of events contributes to the desensitisation of GPCRs: the uncoupling of the 
receptor from its G protein as a result of receptor phosphorylation, the internalisation 
(sequestration) of plasma membrane associated receptors, and the downregulation of the 
total cellular complement of receptors as a consequence of reduced messenger ribonucleic 
acid (mRNA) and protein synthesis (Ferguson et al., 1996). Second messenger-dependent 
protein kinases, G protein-coupled receptors kinases and arrestins are the three families of 
regulatory molecules known to contribute to the GPCR desensitization process (Ferguson 
2001). Receptor phosphorylation is the fastest way of GPCR desensitisation, achieved 
within seconds to minutes of agonist stimulation by second messenger activated protein 
kinases (cAMP-dependent protein kinase (PKA) and protein kinase C (PKC)) and G protein-
coupled receptors kinases (GRKs) that specifically phosphorylate agonist-activated GPCRs 
(Ferguson et al., 1996; Premont, Inglese and Lefkowitz 1995). Although receptor 
internalisation potentially contributes to desensitisation as a result of loss of plasma 
membrane associated receptors, it is thought to be primarily associated with receptor 
resensitisation (Ferguson et al., 1996). 
 
One of the main contributors to the development of tolerance in both spinal and supraspinal 
systems appears to be the β-arrestin-2 mediated mechanism of desensitisation (Bohn, 
Lefkowitz and Caron 2002). The β-arrestin-2 is a G protein-coupled receptor-regulating 
protein which regulates the µ opioid receptors. Mice lacking β-arrestin-2 did not develop 
tolerance to acute or chronic morphine administration, but still developed morphine 
dependence (Bohn et al., 2000). In the absence of the β-arrestin-2 mechanism, the 
contributions of a PKC dependent regulatory system become apparent (Bohn, Lefkowitz and 
Caron 2002). These authors suggested that the spinal antinociceptive actions of morphine 
are regulated by β-arrestin-2 and PKC-dependent pathways, and within the spinal system 
both of these regulatory mechanisms contribute to the µ opioid receptors regulation. 
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N-methyl-D-aspartate (NMDA) is an agonist that mimics the action of glutamate at the 
NMDA receptor. Glutamates are the neurotransmitters that usually bind to the NMDA 
receptors. Dorsal horn neurons that process pain information have both µ-opioid and NMDA 
receptors (Price et al., 2000). These neurons are at the origin of ascending pain pathways. 
NMDA receptors consist of four transmembrane helices that are linked to an ion channel 
permeable to calcium (Ca2+), sodium (Na+) and potassium (K+) (Fundytus 2001; MacDermott 
et al., 1986; Mayer et al., 1987). The mechanism related to morphine tolerance has been 
suggested to involve the NMDA receptor (Bilsky et al., 1996; Mayer, Mao and Price 1995). 
NMDA receptors mediate slow excitatory postsynaptic potentials, and activation of these 
receptors stimulates PKC activation (Fundytus 2001; Mao, Price and Mayer 1995). There is 
evidence indicating a role for PKC in pain; the inhibition of this protein reduces hyperalgesia 
and allodynia associated with nerve injury (Mao et al., 1992; Mayer, Mao and Price 1995) 
and mechanical hyperalgesia associated with thermal injury (Yashpal et al., 1995). PKC has 
been shown to be involved in several types of acute and chronic pain as well as tolerance 
and dependence, particularly through phosphorylation of the NMDA receptor or the G 
protein coupled to opioid receptors, therefore desensitising these receptors leading to a 
reduction of the efficacy of opioid agonist analgesics (Fundytus 2001). The effects on opioid 
receptors assume particular importance for certain types of intractable chronic pain where 
opioid therapy can be less effective, such as neuropathic pain (Fundytus 2001). 
 
Morphine delivered into the intrathecal space of morphine-tolerant rats induced the release 
of glutamate and aspartate (an excitatory amino acid such as glutamate) in the spinal cord 
producing a loss of the morphine analgesic effect (Wen et al., 2004). The same effect was 
observed in the cerebral spinal fluid of terminal cancer pain patients undertaking long-term 
intrathecal morphine delivery for pain relief (Wong et al., 2002). The administration of an 
NMDA antagonist in combination with morphine in rats blocked the release of morphine 
induced excitatory amino acids and attenuated morphine tolerance development (Lin et al., 
2005; Wen et al., 2004). The findings of these studies seem to indicate an association 
between the release of excitatory amino acids and the development of morphine tolerance. 
It has been suggested that the administration of amitriptyline as an adjuvant medication may 
help to prevent the development of morphine tolerance by reducing the release of morphine 
induced excitatory amino acids (Tai et al., 2006; Tai et al., 2007). 
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Animal studies have demonstrated opioid tolerance to be pharmacodynamic, time and dose 
dependent, receptor specific and reversible if the agonist is removed (Sosnowski and Yaksh 
1990; Stevens and Yaksh 1992). A comparison of morphine self-administration in rats with 
adjuvant-induced arthritis and pain-free rats was performed to evaluate the development of 
tolerance in a model of chronic pain (Lyness et al., 1989). The morphine dose in the arthritic 
rats remained stable for 29 days, while an escalation in the dose of the pain-free rats was 
observed. The addition of an anti-inflammatory to the arthritic rats initially led to a reduction 
in the morphine intake, but with the reduction of the adjuvant-induced arthritis, these rats 
increased their opioid intake. The authors suggested that this may be related to the positive 
reinforcement properties of the opioid. The initial positive reinforcement for the arthritic rats 
was analgesia, hence the dose stability. As the pain disappears, the arthritic rats may look 
for other positive reinforcements such as euphoria, or to prevent withdrawal symptoms. The 
authors inferred that the presence of pain may have a significant influence on the 
development of tolerance in animals. The development of tolerance to anti-nociceptive 
opioid drug effects within a small time frame described in animal studies does not seem to 
occur in humans. 
 
The predominant pharmacodynamic tolerance described in animal studies should not be 
considered as the cause for loss of analgesia in humans unless there is no evidence for 
pharmacokinetic or learned tolerance (Portenoy 1994). Unlike the animal models of 
tolerance, human pain is more complex and there are several factors that may lead to a 
decrease in the analgesic effect of a drug. Psychological processes such as anxiety, 
depression, mood and cognition influence pain perception and may lead to a worsening of 
pain (Berna et al., 2010; Portenoy 1994; Turk and Okifuji 2002; Vlaeyen and Linton 2000). A 
contributor for an increase in pain perception is also the progression of a condition or its 
associated factors, such as an increase of activity in central or peripheral nociceptive 
pathways (Portenoy 1994). 
 
 
Importance of this study 
Patients with chronic non-malignant pain have the potential for long-term survival and 
therefore adequate pain control is paramount to this population. The investigation of opioid 
dose escalation assumes particular importance because the possibility of tolerance 
development is a commonly used reason to withhold the use of opioid treatment until an 
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undeniable need (Portenoy 1994). The opioid dose via intrathecal route is often low when 
administered to a chronic non-malignant pain patient and drug delivery can be monitored 
with precision, therefore decreasing the risk of addiction. The oral opioid dose conversion to 
an intrathecal dose is approximately 300:1 (Lamer 1994; Levy 1997), while the conversion 
ratio between epidural and intrathecal has been suggested to be 24:1 (Nordberg et al., 
1984). 
 
The primary purpose of this study was to describe the results of a long-term, longitudinal 
assessment of the intrathecal opioid dose of a cohort of patients undertaking IDD therapy for 
the management of chronic pain of non-malignant origin. A secondary objective was the 
development of an intrathecal opioid dose predictive model. 
 
 
2.1.3 Methods 
Participants 
Thirty one patients undertaking continuous intrathecal opioid delivery by implanted reservoir 
administration for chronic non-malignant pain at Russells Hall Hospital Pain Management 
Department were included in the study. The sample consisted of 19 females (61.3%) and 12 
males (38.7%) with an average age at the time of IDD system implantation of 48 ± 1.5 years 
(range: 30-63). The average duration of pain prior to IDD was 12 ± 1.4 years (range: 2-35). 
Participants who had undertaken IDD therapy for at least six years when the data was 
collected were included in this study. 
 
The pain syndrome the majority of the participants (74.2%) experienced was nociceptive, 
and included degenerative spine disease, post spinal fractures or cervical dysplasia. Three 
patients (9.7%) had neuropathic pain as the result of complex regional pain syndrome type II 
and five patients (16.1%) suffered from mixed nociceptive-neuropathic pain including failed 
back surgery syndrome caused by multiple spinal operations. For the purpose of 
comparison, the pain topography was divided into low back and other. For most participants, 
the topography of pain was the lower back (48.4%), while in the other group the pain was 
localized in the abdominal area, knee or back pain radiating to one or both legs. In all cases, 
the catheter was inserted in the lumbar area and positioned in the thoracic area, most 
commonly T10. 
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Data collection 
A longitudinal retrospective assessment of medical records was performed and pump refill 
notes were screened from date of implant to November 2010. Intrathecal drugs administered 
and intrathecal opioid dose (mg/day) were recorded (Table 2.1.1). To try to attain optimal 
pain relief, some patients had additional drugs besides morphine added to the intrathecal 
medication, such as bupivacaine (87.1%), clonidine (35.5%) and baclofen (19.4%). The type 
of pain of the patients (12.9%) that were not administered adjuvant intrathecal medication 
was nociceptive. Yearly opioid dose averages were computed for each patient from the time 
of implant until last refill between June and November 2010. 
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Data analysis 
Repeated-measures ANOVA were performed to investigate changes in opioid dose 
throughout the treatment period. Repeated-measures ANOVA examine all members of a 
sample measured at several time points. Assumption of sphericity was verified through 
Mauchly’s test. This test, through analysis of sphericity (homogeneity of the variances of the 
differences between data from the same participant) is used to validate the result of the 
repeated-measures ANOVA analysis of variance (Field 2005). If the assumption of sphericity 
were violated, the degrees of freedom associated with the analysis needed to be corrected. 
Degrees of freedom were corrected using Greenhouse-Geisser estimate of sphericity, when 
the variances of the differences between levels were significantly different. The 
Greenhouse-Geisser correction is an estimate of distance from sphericity and it is used to 
investigate if the data meets the assumption of sphericity (Field 2005). Opioid dose changes 
were controlled for gender, age, duration of pain prior to IDDS, topography of pain, type of 
pain, IDD system replacements and administration of intrathecal adjuvant medication. This 
allows verification if other variables have a significant impact in the variable of interest, 
which for this study is the opioid dose. 
 
Stepwise multiple regression analyses were used to evaluate the significance of the 
variables above mentioned in a model predicting the intrathecal morphine dose at year six 
based on the dose at year two. Stepwise multiple regression evaluates whether variables 
entered in a model strengthen the model or should be removed, based on correlation with 
the outcome variable (Field 2005). Shapiro-Wilk test was carried out to investigate if the 
unstandardized residuals data was normally distributed, therefore examining the validity of 
the model derived from the multiple linear regression. The Shapiro-Wilk test verifies if the 
distribution of scores is significantly different from a normal distribution. In this situation, it 
was employed to investigate the distribution of the residuals, which represent the difference 
between the value a model predicts and the value observed in the data on which the model 
is based (Field 2005). 
 
Since the variable type of pain was divided into three categories, the variable was recoded 
to create two dummy variables with two categories each in order to carry out the linear 
regression. A dummy variable is a way of recoding a categorical variable with more than two 
categories into several dichotomous variables (Field 2005). 
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Data is reported as mean ± standard error of mean (SEM). Statistical significance 
represented p < 0.05. Statistical tests were performed using the Statistical Package for the 
Social Sciences (SPSS) software (version 17.0, SPSS Inc., Chicago, IL, USA). 
 
 
2.1.4 Results 
Gender (F (1.812, 39.874) = 0.623, p = 0.526), age at time of implant (F (1.812, 39.874) = 
0.185, p = 0.811) and duration of pain prior to IDDS implantation (F (1.812, 39.874) = 2.389, 
p = 0.109) did not have a significant effect in the intrathecal opioid dose. The addition of 
adjuvant intrathecal medication did not have a significant effect on dose throughout the 
years, F (1.812, 39.874) = 0.220, p = 0.782. The morphine dose was not influenced by the 
location of pain (F (1.812, 39.874) = 0.227, p = 0.776) or type of pain (F (4.074, 57.032) = 
1.38, p = 0.252). 
 
Although not statistically significant, it was observed that neuropathic pain patients required 
lower doses throughout duration of therapy (Table 2.1.2). At baseline the opioid doses were 
approximately the same between the different types of pain. At two year follow-up, 
differences start to be evident, remaining throughout the duration the study. 
 
 
 
During the study period, 12 patients did not need a replacement of the IDDS. Pump 
replacements were performed at a mean follow-up period of 59 ± 3.72 months (range: 17-
84). None of the patients required more than one IDDS replacement. The patients that 
required a replacement of the IDDS had a higher opioid dose throughout the study period 
(Figure 2.1.2). 
 
The intrathecal opioid dose was not significantly affected by the need of an IDDS 
replacement F (1.812, 39.874) = 2.562, p = 0.095. In accordance with the average duration 
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of therapy until an IDD system replacement surgery was required, a reduction in the opioid 
dose can be observed in Figure 2.1.3 between years 4 and 5. 
 
Significant increases in the intrathecal morphine dose were verified between follow-up at 
one year and all subsequent observations, F (2.075, 62.238) = 13.858, p < 0.001. From year 
three onwards, no significant differences were observed with the following assessments, F 
(3, 90) = 2.516, p = 0.63. 
 
 
 
Multiple linear regressions were used to analyze the relationship between yearly morphine 
doses. The results of the regression analysis indicated that the morphine doses of year two 
together with duration of pain were significant predictors of the intrathecal opioid doses at 
year six (year six dose = -0.509 + [1.296 x (year two dose)] + [0.061 x (duration of pain)]. 
Although the duration of pain initially was found not to have a significant effect in the 
intrathecal opioid dose throughout the duration of the study, it was verified that it improved 
this model, albeit modestly. Gender (p = 0.419), age at time of implant (p = 0.2), topography 
of pain (p = 0.46), type of pain 1 (p = 0.406) and type of pain 2 (p = 0.544) were not 
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significant predictors for the model. This model accounted for 76% of the variability of 
morphine doses at year six based on year two assessment. The residuals follow normal 
distribution (p = 0.809), which indicates that the assumptions for regression were met and 
confirms the validity of the model. 
 
 
 
2.1.5 Discussion 
In this sample, a slow increase in opioid dose was observed. Statistically significant 
increases were observed on a yearly basis from baseline up to year three, but the 
intrathecal opioid dose increase ceased to be significant from the third year onwards 
indicating stability. The average intrathecal dose of 3.51 mg/day at last follow-up (year six) 
was lower than previously reported average doses of 7.42 mg/day at 29.14 months (Kumar, 
Kelly and Pirlot 2001); 9.6 mg/day at year one (Paice, Penn and Shott 1996), and 12.2 
mg/day at year three (Atli et al., 2010). An approximate opioid dose of 4.7 mg/day has been 
reported, although at an average of 3.4 years (Winkelmüller and Winkelmüller 1996). This 
suggests differences in practice between departments administrating this therapy. 
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Nevertheless, previous surveys have reported modest morphine dose escalations in patients 
with chronic non-malignant pain (Paice, Penn and Shott 1996; Winkelmüller and 
Winkelmüller 1996). 
 
There are several factors that may have contributed to the modest dose escalation 
throughout duration of therapy. To some extent, the small increase verified in the intrathecal 
opioid dose may be related with the fact that the majority of the patients (87.1%) were 
receiving intrathecal bupivacaine in addition to the intrathecal morphine. The addition of 
intrathecal bupivacaine has been effective in keeping a low intrathecal morphine dose in the 
treatment of cancer pain as well as preventing the potential side effects of high doses of 
intrathecal morphine (Sjöberg et al., 1994; van Dongen, Crul and De Bock 1993). Drugs that 
have the potential to reduce the addiction liability of opioids or enhance the analgesic 
efficacy of opioids, as well as having analgesic properties on their own, may be useful as 
adjuvant therapies in combination with opioids (Fundytus 2001). This supports the 
suggestion that the use of adjuvant analgesics appears to contribute to an opioid-sparing 
effect. Other factors could also be relevant, such as the continuous care by the same team, 
in the same context, allowing the establishment of a doctor/nurse-patient relationship in a 
safe environment for the patient. 
 
Contrary to what was expected, the opioid dose administered to neuropathic pain patients 
was lower than the dose received by the nociceptive pain patients. In accordance with our 
results, previous literature has reported lower opioid dose administered to neuropathic pain 
patients when compared to the dose administered to patients with nociceptive pain (Kumar, 
Kelly and Pirlot 2001; Winkelmüller and Winkelmüller 1996). The lower dose in patients with 
this pathology may also be related with the administration of adjuvant medication. 
Neuropathic pain has shown to be responsive to intrathecal therapy but opioids alone may 
not always be sufficient to control it (Paice et al., 1997). The reduced sensitivity of 
neuropathic pain to opioids may be the result of a decreased expression of µ opioid 
receptors in dorsal root ganglia neurons as a consequence of nerve injury (Zhang et al., 
1998). 
 
There was no evidence of opioid addiction or abuse in the investigated patients. The 
screening and exclusion of patients with a history of addictive behaviours prior to intrathecal 
morphine trial could have contributed to this outcome. The cerebrospinal fluid has limited 
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capacity to distribute intrathecally administered morphine away from the catheter tip (Flack, 
Anderson and Bernards 2011). Besides having implications to the efficacy of the intrathecal 
therapy, this also means that only very small amounts of the medication would reach the 
supraspinal regions. It is known that the opioid regulation of pain involves µ opioid receptors 
in both spinal and supraspinal regions of the central nervous system (Bohn, Lefkowitz and 
Caron 2002). The amygdala, whose nuclei have no direct association with analgesia, has 
the greatest abundance of opioid receptors in the brain and the receptors in this area are 
likely to be associated with the influences of opioids on emotional behaviour (Snyder 1977). 
It seems plausible that the development of addictive behaviours as a consequence of 
intrathecal morphine therapy is even more remote than with the use of systemic opioid 
therapy because of the much lower dose and region of opioid receptor activity. 
 
It is likely that the reason for the modest opioid escalation observed was due to 
progress/deterioration of the patients’ condition, rather than tolerance. Progression of a 
disease may result in an increase of nociceptive activity, development of sensitisation or 
changes in the pain modulation processes, leading to an increase in pain and consequently 
a requirement of dose escalation. Morphine doses may stabilize for long periods and when 
dose escalation occurs it is usually considered to be due to tolerance, progress of the 
disease (Bennett et al., 2000) or opioid induced hyperalgesia (Angst and Clark 2006; Chu, 
Angst and Clark 2008). In the clinical setting, true pharmacological tolerance to the 
analgesic effects of opioids is an uncommon cause for the need of opioid dose escalation to 
maintain analgesic effects (Portenoy 1994). The need for higher doses to maintain an effect 
as a result of the progression of pathology should not be considered as tolerance; the 
requirement of higher doses should only be perceived as tolerance when the prior 
administration of a drug is the reason for the change in dose (Portenoy 1994; Portenoy and 
Savage 1997). 
 
It is important to note the limitations of this study. Pain ratings were not requested on a 
regular basis to verify if a change or deterioration in pain occurred. The study presented in 
Chapter 3 of this thesis demonstrates a small, non-significant increase in the pain ratings 
between assessments following IDDS implantation. This increase in pain could be due to 
progression of disease or decrease of therapy effectiveness (tolerance), leading to the small 
increases observed in the morphine dose. 
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Oral opioid medication was not collected from the notes. At this centre rescue oral opioid 
medication has been provided to the patients on an individual basis, for occasional flare-ups. 
The average duration of pain prior to IDDS was 12 years. Prior to implantation of IDDS, all 
these patients have tried and failed more conservative treatments, including oral opioid 
medication with little or no benefit or unbearable side effects. The effective rescue 
medication dose is a fraction of the effective intrathecal dose. Hence, systemic medication 
as well as other interventions that might have been undertaken during the study period 
would only be sporadic to cope with flare-ups and would therefore have limited impact in the 
results verified. Providing additional oral medication to patients may improve their 
psychological well being as well as an improvement in effective pain control. There is no 
evidence of a correlation between reduction in pain intensity and the intake of additional oral 
medication (Kumar, Kelly and Pirlot 2001; Winkelmüller and Winkelmüller 1996). 
 
This model assumes particular importance because it can predict 76% of morphine dose 
variability at year six. Since the pump battery life usually ranges between 48 to 60 months 
(de Lissovoy et al., 1997; Kumar, Hunter and Demeria 2002) an informed decision can be 
made taking into account the risks and benefits of continuing intrathecal opioid therapy. The 
possibility of anticipation of the opioid dose could also lead to consideration by the physician 
of alternative bio-psycho-social treatment strategies. Examples of alternatives are the 
addition of adjuvant drugs to the intrathecal mixture and physical or behavioural approaches 
(Flor, Fydrich and Turk 1992; Guzmán et al., 2002). There is no intention to declare that the 
future treatment of a patient should be decided based on a mathematical model. This model 
should be seen as a supplementary tool assisting a physician’s work. 
 
Intrathecal opioid therapy strategies differ across pain management centres. Therefore, the 
applicability of this model to other centres needs to be tested. A large, international, 
multicentre study could have the potential to develop a model applicable to the majority of 
centres where intrathecal drug delivery therapy is administered. 
 
 
2.1.6 Conclusion 
The opioid dose escalation observed was not a limiting factor for this therapy as the 
increase throughout the years was modest. Due to the duration of the study and small dose 
increase verified, it is likely that increased or altered pain contributed more than 
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pharmacological tolerance to the tolerance to the analgesic effects. Concerns about 
development of tolerance do not justify the delay or withholding of intrathecal opioid therapy 
for chronic non-malignant pain. 
 
The evaluation of the intrathecal opioid dose throughout a six year period allowed the 
development of a model. This model accounts for 76% of the variability of the opioid dose at 
year six based on the dose of year two combined with duration of pain prior to initiation of 
intrathecal therapy. This has significant clinical implications. It can assist the physician to 
identify the need of an alternative treatment strategy. Moreover, since many of the pump 
replacements are performed prior to year six, it can assist in the informed decision of the 
benefits and risks of the maintenance of this therapy. 
 
The following section of this thesis focuses on a potential early indicator of the formation of 
intrathecal inflammatory masses as a result of intrathecal opioid therapy. 
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SECTION 2. Yearly opioid dose increase as an early indicator of granuloma formation 
 
This section has been published in Neuromodulation 2010;13(2):109-113 (appendix 9). It 
has been reformatted to fit with the overall PhD thesis. 
 
2.2.1 Abstract 
Objectives 
The objective of this study was to investigate the association between intrathecal drug, flow 
rate, drug concentration and drug dose with the formation of intrathecal inflammatory 
masses. 
 
Methods 
A retrospective longitudinal study of 56 consecutive patients receiving long-term intrathecal 
analgesic administration was undertaken through screening of medical records. Data 
regarding drug flow rate, dose per day and concentration of drugs administered were 
recorded for morphine, diamorphine, bupivacaine, clonidine and baclofen and averages 
computed. 
 
Results 
The average follow-up time post-implant was 91 ± 55 months (range: 9–209). Four of the 56 
patients were diagnosed with intrathecal granuloma indicating a rate of 7%, the equivalent to 
0.009 events per patient year. Twenty-one of the patients had received morphine either 
alone or combined; 22 had received diamorphine either alone or mixed; and 13 crossed over 
from diamorphine to morphine. None of the patients with granuloma crossed over before 
diagnosis. A significant correlation was found between opioid dose (r = 0.275, p < 0.05), 
yearly increase of the opioid dose (r = 0.433, p < 0.05) and granuloma formation. Clonidine 
appeared to have a protective effect for the non-granuloma patients. No association was 
found with flow rate (r = 0.056) or opioid concentration (r = 0.214). 
 
Conclusion 
This is the first detailed study showing an association of diamorphine with granulomas. This 
study supports the previous finding of intrathecal opioid dose being a risk factor for 
intrathecal granulomas and clonidine being protective. In addition, it was found that the 
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yearly increase in opioid dose is a risk factor for the development of granulomas and could 
serve as an indicator for closer surveillance. 
 
 
2.2.2 Introduction 
One of the possible side effects of intrathecal opioid administration is the development of an 
intrathecal inflammatory mass, also known as granuloma, granulomata or granulomatous 
mass (Fig. 2.2.1). Although rare, the magnitude of this complication can be serious with 
potential for neurologic morbidity if not recognized and treated appropriately (Blount et al., 
1996; Cabbell, Taren and Sagher 1998; Miele et al., 2006a). An intrathecal granuloma is a 
soft tissue mass resulting from an inflammatory reaction and usually located at the level of 
the catheter tip. 
 
The formation of a spinal granuloma due to opioid administration using an implanted pump 
delivery system was first observed in the epidural space in 1985 (Rodan et al., 1985) and in 
the intrathecal space in 1991 (North et al., 1991). 
 
Although this lesion develops very slowly, patient re-evaluation and vigilance is essential for 
an early diagnosis (Deer, Raso and Garten 2007). Failure to identify the occurrence of a 
granuloma can lead to a diagnosis of tolerance and an increase in the rate of infusion 
(Anderson et al., 2001; Bejjani, Karim and Tzortzidis 1997). 
 
 
Granuloma detection 
It is of extreme importance to detect a granulomatous mass in its early stages. The increase 
in size of a granuloma occurs with the maintenance of intrathecal drug administration while it 
remains undetected. The appearance of clinical symptoms can be sudden. The clinical 
presentation of these masses is usually marked by an increase in pain while receiving the 
scheduled medication, which previously controlled the painful symptoms, and small 
increases in the intrathecal medication dose only provide temporarily relief (Langsam 
1999a). Typically, this increase is followed by slow progressive signs and indicators of 
neurological deterioration including incontinence, constipation, loss of balance, sensory loss 
and paraparesis with a potential to culminate in functional paraplegia (Deer et al., 2008a; 
North et al., 1991). 
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When attending for a refill at Russells Hall Hospital Pain Management Department, all 
patients are asked if since the last follow-up, the pain was controlled and if new symptoms 
had emerged, such as new pain, altered sensation or weakness of limb. In case of new 
symptomatology, a neurological examination (sensory and motor function) would take place. 
If a clear change was observed, a magnetic resonance imaging (MRI) scan would be 
performed. For this purpose, programmable pumps would be turned off, non-programmable 
pumps emptied, and the imaging would be carried out via a 1.5 Tesla MRI system through 
Short Tau Inversion Recovery (STIR) sequence. In the existence of doubts regarding the 
formation of intrathecal inflammatory masses, a second MRI would be completed with the 
contrast-enhancing agent Gadolinium. 
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Treatment 
Several techniques to manage inflammatory masses have been reported in the literature. 
When detected early, the mass might recede using a conservative approach which consists 
of replacing the medication administered with preservative-free saline (Cabbell, Taren and 
Sagher 1998; Shields et al., 2005; Toombs et al., 2005) or with a different opioid (McMillan, 
Doud and Nugent 2003) thus avoiding surgery. The authors report near complete resolution 
of the granuloma after one or two months. Following confirmation of the mass recession, re-
initiation of intrathecal therapy should be carefully monitored to avoid recurrence of the 
intrathecal inflammatory mass. 
 
When surgery is elected, several alternatives are possible. Repositioning of the catheter at a 
distance of about 2 cm from its prior location can be effective in preventing the growth of the 
mass (Deer et al., 2008a). Surgery to remove the granuloma occurs in the presence of 
significant neurological symptoms (Blount et al., 1996; Cabbell, Taren and Sagher 1998). 
This intervention is often accompanied by the removal of the catheter and occasionally, the 
drug reservoir, along with the mass (Deer, Raso and Garten 2007; North et al., 1991). 
 
Enduring neurological disabilities have been associated with delayed diagnosis and 
treatment (Coffey and Burchiel 2002). The same authors stated that situations where the 
mass filled the spinal canal and surgery was not performed promptly contributed to 
permanent neurological impairment. 
 
Despite the severity of this complication, there are reports in the literature of patients 
requesting the resumption of the intrathecal opioid delivery regardless of the risk of recurrent 
granulomatous masses (Cabbell, Taren and Sagher 1998; McMillan, Doud and Nugent 
2003). 
 
 
Aetiology 
Since the first report of an intrathecal granuloma as consequence of IDDS in 1991 (North et 
al., 1991), several hypotheses for its formation have been depicted. It has been 
hypothesized that the formation of these masses could be the result of an inflammatory 
reaction to the catheter (Anderson et al., 2001; Bejjani, Karim and Tzortzidis 1997), 
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morphine or other preservative used inadvertently, or a reaction to the trauma sustained 
during catheter implantation (Bejjani, Karim and Tzortzidis 1997). 
 
Intrathecal administration maintains a relatively high drug concentration within and around 
the spinal cord, which may contribute to the phenomenon of catheter tip mass formation 
(Coffey and Burchiel 2002). Inflammatory masses have developed more commonly in result 
of IDDS therapy involving opioids such as morphine (North et al., 1991), hydromorphone 
(Fernandez, Madison-Michael and Feler 2003), diamorphine (Mutagi et al., 2007), fentanyl 
(Zacest et al., 2009), sufentanil (Gupta, Martindale and Christo 2010) or tramadol (De 
Andrés et al., 2010a). Less commonly, administration of intrathecal baclofen alone has also 
been related to this complication (Deer, Raso and Garten 2007; Murphy et al., 2006). 
 
The association between opioid concentration and the development of catheter tip 
intrathecal granulomas has only been inferred from case reports and animal studies (Deer et 
al., 2008a). Animal studies revealed an apparent dose or concentration response in relation 
to the development of intrathecal masses in both dogs and sheep (Gradert et al., 2003; 
Yaksh et al., 2002; Yaksh et al., 2003). However, the formation of granulomas in humans is 
less predictable than in sheep and dog models (Deer et al., 2008a). Whether the absolute 
opioid dose, concentration, or both (or neither) influence a patient’s risk for development of a 
granulomatous mass remains unclear (Hassenbusch et al., 2002). The correlation of opioid 
dose with the formation of inflammatory masses in humans has only been demonstrated in a 
small sample size (seven patients) study (McMillan, Doud and Nugent 2003). 
 
The aim of this study was to investigate the association between intrathecal drug, flow rate, 
drug concentration, and drug dose with the development of intrathecal inflammatory 
masses. 
 
 
2.2.3 Methods 
A single centre retrospective longitudinal study of 56 consecutive patients receiving 
continuous intrathecal analgesics by implanted reservoir administration was undertaken 
through assessment of medical records. All participants undertaking IDD at Russells Hall 
Hospital were included in the study. Pump refill notes from date of implant to June 2009 
were screened for flow rate (mL/day), dose (mg/day) and concentration (mg/mL) of drugs 
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administered intrathecally. The drugs delivered were morphine, diamorphine, bupivacaine, 
clonidine, and baclofen. Yearly averages and yearly changes in concentration and dose 
were computed for each patient from the time of implant until last refill between April and 
June 2009. For patients diagnosed with granuloma, only the data until date of diagnosis was 
considered for analysis. Information regarding positioning of the catheter tip was recorded 
from the surgical notes. 
 
 
Data analysis 
The Kolmogorov-Smirnov test was carried out to test normality of numerical data followed by 
the appropriate statistical tests. Dichotomous data was compared using the Mann–Whitney 
U-test. Mann–Whitney U-test is a non-parametric test that investigates differences between 
two independent samples (Field 2005). Associations between variables were investigated 
through Spearman’s correlations. Spearman’s correlations analyses the strength of 
relationship between two non-parametric variables (Field 2005). Means are reported as 
mean ± standard deviation. 
 
Statistical significance represented p < 0.05. Events per patient year were calculated using 
the formula ((number of events ÷ number of patients) ÷ average follow up). Statistical tests 
were performed using the Statistical Package for the Social Sciences (SPSS) software 
(version 12.0, SPSS Inc., Chicago, IL, USA). 
 
 
2.2.4 Results 
The sample comprised 33 women (58.9%) and 23 men (41.1%) with an average age at time 
of implant of 50 ± 10 years (range: 30–72). The mean duration of painful symptoms prior to 
date of implant was 14 ± 9 years (range: 2–36) and the average follow-up time post-implant 
was 91 ± 55 months (range: 9–209). Twenty-one of the patients had received morphine 
either alone or with one or other of bupivacaine, clonidine, and baclofen; 22 of the patients 
had received diamorphine either alone or with one or other of bupivacaine, clonidine, and 
baclofen; and 13 participants crossed over from diamorphine to morphine. None of the 
patients with granuloma crossed over before diagnosis. 
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Four of the 56 patients were diagnosed with intrathecal granuloma. The rate of this 
diagnosis was 7%, the equivalent to 0.009 events per patient year. Besides the patients with 
granulomatous masses, 16% of the remaining patients presented clear changes in their pain 
including new symptoms. Following an MRI scan, no intrathecal inflammatory masses were 
detected in these patients. Drugs administered at the time of granuloma diagnosis included 
morphine mixed with bupivacaine (N = 1), diamorphine alongside clonidine and bupivacaine 
(N = 2) and diamorphine combined with bupivacaine and baclofen (N = 1). 
 
The mean time span until granuloma formation was 39.5 ± 13.5 months (range: 22–52). The 
mean time of treatment for the non-granuloma patients was 90 ± 57 months (range: 9–209). 
In this sample only one patient receiving morphine was diagnosed with granuloma. Until 
diagnosis, the mean intrathecal morphine concentration of this patient was 7.95 mg/mL and 
the mean morphine dose was 3.91 mg/day. The mean intrathecal morphine concentration 
for non-granuloma patients was 5.83 ± 3.01 mg/mL (range: 1.55–12) and the mean 
morphine dose was 2.21 ± 1.20 mg/day (range: 0.52–5.60). Both dose and concentration 
were inferior to the maximum recommended concentration and dose values to minimize not 
only the risk of granuloma formation but also the risk of all other possible side effects (Table 
2.2.1). 
 
At the time of diagnosis three of the patients were receiving diamorphine intrathecally. The 
average diamorphine concentration of these patients was 14.62 ± 5.74 mg/mL (range: 
11.09–21.25) and the dose was 4.72 ± 1.79 mg/day (range: 3.61–6.80). The patients not 
diagnosed with granuloma had a mean diamorphine concentration of 12.23 ± 6.87 mg/mL 
(range: 1.23–30.36) and the average diamorphine dose was 3.78 ± 2.57 mg/day (range: 
0.60–11.23). 
 
The mean clonidine concentration received by the patients diagnosed with granuloma was 
0.01 ± 0.006 mg/mL (range: 0.008–0.017) and the mean clonidine dose was 0.004 ± 0.002 
mg/day (range: 0.003–0.005). For the non-granuloma patients, the mean clonidine 
concentration was 0.029 ± 0.04 mg/mL (range: 0.009–0.17) and the mean concentration 
dose was 0.01 ± 0.016 mg/day (range: 0.003–0.06). 
 
Associations were attempted between the variables and granuloma formation (Table 2.2.1). 
No significant association between flow rate and granuloma was established (r = 0.056). 
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Additionally, the opioid concentration was not significantly associated with granulomatous 
masses (r = 0.214). A significant positive correlation was found between opioid dose and 
granuloma, r = 0.275, p < 0.05. The patients diagnosed with inflammatory masses had a 
significantly higher opioid dose (Mdn = 3.96) compared with those not diagnosed with 
granuloma (opioid dose median = 2.42, U = 40.00, p < 0.05, r = -0.27). 
 
The yearly increase of the opioid dose was computed and a significant correlation was found 
with granuloma formation in this sample, r = 0.433, p < 0.01. The mean opioid dose increase 
per year was significantly higher in patients were a granuloma was identified (Mdn = 0.83) 
than those with no granuloma formation (opioid dose increase per year median = 0.21, U = 
6.00, p < 0.005, r = -0.43) (Fig. 2.2.2). 
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The mean yearly increase of diamorphine dose was also found to be influential in the 
formation of these masses. This variable was significantly correlated with granuloma 
development, r = 0.447, p < 0.05.The mean diamorphine dose increase per year was 
significantly higher in patients diagnosed with granuloma (Mdn = 0.62) than in those where 
no development of masses occurred (diamorphine dose increase per year median = 0.19, U 
= 5.00, p < 0.05, r=-0.44) (Fig. 2.2.3). 
 
 
 
Two out of three patients (66.66%) with the catheter tip positioned at T11 were diagnosed 
with granuloma compared with one out of 33 patients (2.94%) with the catheter tip at T10. 
 
 
2.2.5 Discussion 
The average duration of intrathecal administration in this study was 39.5 ± 13.5 months. 
Contrary to what was expected, an association between flow rate and granulomatous 
masses was not found. It has been recommended that ultra slow flow rates should be 
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avoided and the drug delivered into the dorsal CSF space at L1-L2 or at T7-T10 (Deer et al., 
2008a). Most implanters position the catheter in the thoracic level which has the narrowest 
relative intrathecal space and slow CSF (Yaksh et al., 2002) even though granulomas have 
been known to form at all levels of the intrathecal space (Deer et al., 2008a). 
 
In this sample, intrathecal granuloma formation was identified in patients receiving morphine 
and diamorphine. Diamorphine is considered to have several advantages over morphine. 
Because it is more soluble, diamorphine can be combined with larger quantities of other 
analgesics for intrathecal administration, thus achieving greater analgesic effects (Kleinberg 
et al., 1990). Theoretically the greater solubility might have been considered protective for 
the risk of granuloma; however, this was not verified. The development of granuloma when 
the treatment is carried out with intrathecal diamorphine may be a result of the diamorphine 
breaking down into morphine (Raphael et al., 2004). 
 
Average opioid dosage and yearly increase were associated with the formation of intrathecal 
inflammatory masses. The yearly increase is a presumable risk because a high dose is a 
risk, but could be useful as an early indicator of development of granulomatous masses. 
When higher doses are required, patients should be properly informed of the association 
with granulomas and its risks and the physician should be alert for signs of spinal cord 
compression (Miele et al., 2006b). In a study with canines it was verified that the dogs with 
intrathecal masses had a considerably lower cisternal CSF/plasma morphine ratio than the 
dogs without masses (Yaksh et al., 2003). According to the same author, the lower cisternal 
levels could be due to a misdistribution resulting from the mass at the catheter tip, explaining 
the need for dose escalation. In this study, all patients diagnosed with granuloma had opioid 
doses <10 mg/day which indicates that this side effect may also occur with lower doses. 
 
Concentration of all the drugs administered was also investigated but no significant 
association was found with granulomatous masses in this study group, although high 
concentration of all opioids may increase patient risk of granuloma formation (Coffey and 
Burchiel 2002; Deer et al., 2008a; Yaksh et al., 2002). One of the possible explanations for 
the association between average opioid dose and granuloma formation, although not 
between opioid concentration and granulomatous masses, is that it may be due to the more 
common clinical practice of altering the delivered dose rather than the drug concentration 
when responding to patients’ level of pain. The effect of this dose alteration yet maintenance 
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of drug concentration is to cause a compensatory flow rate change in the commonly used 
programmable pumps. Consequently, this pragmatic clinical sample may have been unable 
to detect an association between granuloma formation and flow rate. 
 
Although significance was not found, clonidine appeared to have a protective effect in this 
sample confirming studies based on animal data (Yaksh et al., 2003). A report has 
suggested that clonidine may not have the same protective effect in humans (Toombs et al., 
2005). Although not eliminating the risks, clonidine may help to reduce the incidence of 
granuloma formation. The patients diagnosed with inflammatory masses presented higher 
values both for concentration and dose for the majority of the intrathecal drugs, except for 
clonidine. 
 
Further studies using human data are warranted as the formation of granulomatous masses 
in humans is less predictable than in animal models (Deer et al., 2008a). In addition, it is 
necessary to confirm if clonidine is significantly associated with the prevention of intrathecal 
inflammatory masses at the catheter tip of intrathecal drug delivery devices. 
 
A limitation of this study is the low number of patients diagnosed with granulomas in this 
group. A larger sample may corroborate these findings and allow determination of a cut-off 
point for yearly opioid change as well as possibly confirming associations with other 
hypothesis such as opioid concentration, flow rate and catheter tip location and design. 
 
 
2.2.6 Conclusion 
This thorough evaluation of medical records has confirmed the association of opioid dose 
with the formation of granulomas. Intrathecal opioid dose is a risk factor but also the yearly 
opioid increase has proven to be influential in the formation of intrathecal inflammatory 
masses. In this group diamorphine has not prevented the occurrence of granulomas. 
Calculating the opioid dose increase per year throughout treatment can indicate a clinical 
change and, therefore, facilitate the early detection of asymptomatic intrathecal inflammatory 
masses, consequently decreasing the possible side effects of this complication for the 
patient. Calculating the yearly opioid change could give clinicians a useful and inexpensive 
method of early recognition of this side effect and, at the same time, gathering data that 
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could be valuable for future studies in this area. Confirming previous preclinical studies, in 
this study, clonidine appeared to have a protective effect. 
 
The following section presents a study conducted with the aim of overcoming the most 
noteworthy limitation of the current section – the small number of patients diagnosed with an 
intrathecal granuloma. A systematic review of intrathecal granulomas case reports was 
performed and the data extracted was compared with a control group. 
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SECTION 3. Systematic review of intrathecal granulomas case reports and 
comparison with a control group 
 
This section is under review by the journal Clinical Neurology and Neurosurgery. It has been 
reformatted to fit with the overall PhD thesis. 
 
2.3.1 Abstract 
Background and aims 
Continuous intrathecal analgesia using opioids and other analgesics has become a 
recognized therapy for the management of severe and otherwise intractable chronic pain. 
Intrathecal granuloma is a potentially serious complication derived from this therapy. The 
cause of catheter tip granulomas remains speculative despite opioid dose and/or 
concentration being hypothesized as being related with this complication. The aim of this 
study was to investigate the existence of an association between formation of catheter tip 
intrathecal inflammatory masses with opioid dose and/or concentration. 
 
Methods 
A systematic review of catheter tip granulomas case reports and comparison with a control 
group was carried out. A Boolean search was conducted in the electronic databases 
MEDLINE and EMBASE using a combination of MESH/Thesaurus terms and free text. The 
patients’ data extracted from the case reports was tested for homogeneity with a control 
group. Subsequent analysis investigating the association of opioid dose, concentration and 
flow rate with the formation of catheter tip granulomas was performed. 
 
Results 
Following screening of abstracts and hand search of reference lists, 32 articles were 
retrieved for review. Seventeen articles resulting in 24 patients with granulomata were 
included in the review. One patient in our department with a history of granuloma formation 
was added to this group. The control group comprised 31 patients with an average follow-up 
of 68.3 ± 9.7 months. The groups were homogeneous considering the variables age, gender 
and duration of pain prior to implant. Morphine dose (r=0.821, p<0.001) and concentration 
(r=0.650, p<0.001) were significantly correlated with the development of catheter tip 
intrathecal masses. 
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Conclusion 
Opioid dose and concentration were significantly associated with the development of 
catheter tip granulomas. A correlation with opioid concentration was confirmed for the first 
time. The relative risk can be decreased by reducing dose and concentration from 15 
mg/day and 20 mg/mL to 10 mg/day and 15 mg/mL respectively. 
 
 
2.3.2 Background 
The study presented in Chapter 2, Section 4 was well received by experts in the field (see 
comments in appendix 9), which included two of the authors of the consensus statement for 
management of intrathecal catheter-tip inflammatory masses (Deer et al., 2008a). Attempts 
at a more robust study aimed at exploring the results of the previous section were made. A 
multicentre study which would involve other UK pain management departments where this 
procedure is performed was considered but set aside due to differences in (not) recording 
intrathecal pump refills data. As an alternative, Medtronic, Inc. (one of the main 
manufacturers of IDDS) was contacted to investigate the possibility of accessing 
unpublished reports for data of intrathecal granulomata formation as previously 
accomplished by Coffey and Burchiel (2002). The process of obtaining the company’s 
approval to use this data would be bureaucratic, complex and consequently long with no 
guarantees of a successful outcome. The solution found for the continuation of the research 
on granuloma formation was to perform a systematic review of the case reports available in 
the literature and use the extracted data for comparison with a control group. 
 
The objective of this study with an augmented group was to further examine the association 
between intrathecal opioid dose and granuloma development and to investigate the possible 
links between flow rate and drug concentration with the formation of intrathecal inflammatory 
masses. 
 
 
2.3.3 Methods 
Experimental design 
A systematic literature review of case reports and subsequent analysis by comparison with a 
control group was performed. This design allows investigation of variables with potential to 
cause formation of granulomas by comparing a group of patients with this condition with a 
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group of patients undertaking the same therapy that did not develop this side effect. 
Because the majority of granuloma patients were derived from the literature, an investigation 
of homogeneity of the groups was carried out prior to analysis. To investigate if the groups 
were suitable for analysis, comparisons for the variables age, gender, duration of pain prior 
to implant and duration of therapy were performed. Moreover, to decrease the influence in 
the analysis of outliers not caused by sampling or data errors but due to the changes in 
practice of intrathecal medication delivery, a truncation method was used. 
 
 
Search strategy 
Information on duration of IDD therapy, dose and concentration of drugs administered at 
time of diagnosis was sought from granulomatous masses case reports using a Boolean 
search conducted in the electronic databases MEDLINE and EMBASE. A combination of 
MESH/Thesaurus terms and free text terms were employed according to the database 
(Figure 2.3.1). The year of publication was restricted to between 1991 (first intrathecal 
granuloma due to IDD reported (North et al., 1991)) and 25th August 2010. There were no 
language restrictions. Hand searches of reference lists of included studies, previous reviews 
and consensus statements were performed. Search sensitivity was checked by ensuring 
that all articles identified via hand search of reference lists were identified through the 
structured bibliographic database searches. 
 
MEDLINE      EMBASE 
1. “intrathecal granuloma*”.af    1. “intrathecal granuloma*”.af 
2. “catheter tip granuloma*”.af   2. “catheter tip granuloma*”.af 
3. “intrathecal mass*”.af    3. “intrathecal mass*”.af 
4. “intrathecal inflammatory mass*”.af  4. “intrathecal inflammatory mass*”.af 
5. “catheter tip inflammatory mass*”.af  5. “catheter tip inflammatory mass*”.af 
6. “intrathecal catheter granuloma*”.af  6. “intrathecal catheter granuloma*”.af 
7. #1 or #2 or #3 or #4 or #5 or #6   7. #1 or #2 or #3 or #4 or #5 or #6 
8. granuloma/      8. granuloma/ 
9. spinal cord compression/    9. spinal cord compression/ 
10. spinal cord injuries/    10. spinal cord injury/ 
11. #8 or #9 or #10     11. #8 or #9 or #10 
12. infusion pumps/     12. infusion pumps/ 
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13. infusion pumps, implantable/   13. drug delivery systems/ 
14. drug delivery systems/    14. “intrathecal drug administration”.af 
15. “intrathecal drug administration”.af  15. “intrathecal administration”.af 
16. “intrathecal administration”.af   16. “it administration”.af 
17. “it administration”.af    17. #12 or #13 or #14 or #15 or #16 
18. #12 or #13 or #14 or #15 or #16 or #17  18. #7 or #11 
19. #7 or #11      19. #17 and #18 
20. #18 and #19     20. #7 or #19 
21. #7 or #20 
 
 
 
Inclusion and exclusion criteria 
Papers were included in the review on the basis that they provided individual information 
related to dose or concentration of intrathecal opioids administered. Articles were excluded if 
any of the following was observed: the articles were reviews or guidance papers that did not 
present original work; morphine dose and/or concentration were presented as group 
averages instead of individual values; no intrathecal opioid medication had been delivered 
until granuloma development; the opioids administered are not currently in use at the 
department from which the control patient group were drawn; infection, tumour or trauma 
could not be ruled out as the cause of the granuloma reported. The author of this thesis 
selected the studies for inclusion in the review. 
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Data extraction 
Data extraction was undertaken by the author of this thesis after the articles considered 
suitable were retrieved. The data extracted from the case reports consisted of gender and 
age of the patient, duration of pain prior to implant, duration of IDD therapy, drugs 
administered, morphine peak concentration (mg/mL) and morphine peak dose administered 
(mg/day). Detailed summaries of the studies selected for inclusion are presented (Table 
2.3.1). The drug information most of the articles reported was peak dose and/or peak 
concentration, thus the reason to extract this information and not use mean doses or 
concentrations delivered throughout the duration of IDD therapy. 
 
 
Control group 
Fifty six patients receiving continuous intrathecal analgesics by implanted reservoir 
administration at Russells Hall Hospital, Dudley, one of the largest UK centres for intrathecal 
drug therapies. A longitudinal retrospective assessment of medical records was performed 
and pump refill notes were screened for dose (mg/day), concentration (mg/mL) and flow rate 
(mL/day) of morphine administered intrathecally. Twenty four patients were receiving 
diamorphine and were excluded from the analysis for purposes of comparison. Although 
diamorphine breaks down to mono-acetyl morphine which in turn breaks down to morphine 
(Raphael et al., 2004), concentrations and doses are different from morphine. One of the 32 
patients receiving morphine had been diagnosed with granuloma formation and was added 
to the group generated from the systematic review of case reports (see Table 2.3.1, RHH). 
 
 
Data analysis 
The Kolmogorov-Smirnov test was performed to test normality of numerical data. 
Homogeneity of the group of patients diagnosed with granuloma and the control group was 
tested for the variables age, gender, years in pain prior to IDDS and duration of therapy. 
Gender differences between the groups were analyzed with Pearson’s Chi-Square test. The 
majority of the numerical data was not normally distributed; therefore differences between 
patients diagnosed with granuloma and those from the control group were investigated 
through Mann-Whitney tests. Age was the only variable normally distributed, however, to 
keep uniformity with the other variables, it was examined with a non-parametric test. 
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Associations between variables were investigated through Spearman’s correlations. 
Statistical significance represented p < 0.05. Means are reported as mean ± SEM. 
 
While verifying the distribution of the data, several outliers were identified for the variables 
dose and concentration. In an effort to reduce the impact of these outliers, increasing the 
power of nonparametric tests, a truncation method was used (Osborne and Overbay 2004). 
This method was employed as the outliers observed were not caused by sampling or data 
errors but were due to the changes in practice of intrathecal medication dose delivery 
through awareness of possible complications related to high intrathecal dose and 
concentration. Using the recommended values derived from an expert panel (Deer et al., 
2008a), the maximum values for morphine dose and concentration subsequent to truncation 
of the data were 15 mg/day and 20 mg/mL respectively. 
 
Statistical tests were performed using the Statistical Package for the Social Sciences 
(SPSS) software (version 17.0, SPSS Inc., Chicago, IL, USA). Post hoc power analyses 
were performed using G*Power 3.1.2 software (Faul et al., 2007). 
 
 
2.3.4 Results 
Systematic literature review 
The search resulted in a total of 771 abstracts after removal of duplicates. Following 
screening of abstracts and hand search of reference lists, 32 articles were retrieved for 
review (Figure 2.3.2). 
 
Articles were excluded after reading the full text when information regarding dose or 
concentration administered was not provided (Bejjani, Karim and Tzortzidis 1997; Langsam 
1999b; Leong, Laing and Saines 2010; Phillips et al., 2007); there were no opioids included 
in the intrathecal medication (Deer, Raso and Garten 2007; Kunkel, Sörensen and Matschke 
2010; Murphy et al., 2006); the opioids were hydromorphone (Fernandez, Madison-Michael, 
and Feler 2003; Peng and Massicotte 2004; Phillips et al., 2007; Ramsey et al., 2008; 
Wadhwa, Shaya and Nanda 2006; Zacest et al., 2009), fentanyl (Zacest et al., 2009), 
tramadol (De Andrés et al., 2010a) or sufentanil (Gupta, Martindale and Christo 2010) which 
are currently not administered in the institution where the control group is followed; or the 
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granuloma could be the result of infection, tumour or trauma (Cabbell, Taren and Sagher 
1998; Lehmberg et al., 2006; Perren et al., 2004; van Dongen, van Ee and Crul 1997). 
 
 
 
Seventeen articles resulting in 24 patients with information regarding dose and/or 
concentration of intrathecally administered morphine were included in the analysis (Table 
2.3.1). In reports where a reoccurrence of a granulomatous mass was observed (Cabbell, 
Taren and Sagher 1998; De Andrés et al., 2010b; Hoederath et al., 2010), only the morphine 
dose and/or concentration until the formation of the first mass were considered. 
 
Eight of the studies reported a rapid increase in the morphine dose prior to diagnosis 
(Anderson et al., 2001; Blount et al., 1996; Cabbell, Taren and Sagher 1998; Hoederath et 
al., 2010; Miele et al., 2006b; North et al., 1991; Phillips et al., 2007; Toombs et al., 2005). 
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The subjects identified in the case reports, in addition to the patient from our department, 
comprised of 13 males (52%) and 12 females (48%) with an average age at the moment of 
diagnosis of 54 ± 1.9 years (range: 38-76). The average duration of treatment until 
intrathecal inflammatory mass formation was 36.6 ± 6.5 months (range: 3-108) and the 
mean peak dose and concentration were respectively 23.19 ± 4.9 mg/day (range: 3.5-120) 
and 37.29 ± 6.37 mg/mL (range: 10-75). Following truncation of data, the mean peak dose 
and concentration were respectively 13.06 ± 0.76 mg/day (range: 3.5-15) and 18.12 ± 1.11 
mg/mL (range: 10-20). 
 
 
Control group (Table 2.3.2) 
The control group consisted of 11 males (35.5%) and 20 females (64.5%). The mean age in 
this group was 50.7 ± 1.9 years (range: 30-72) and the average follow-up period post 
implant was 68.3 ± 9.7 months (range: 9-203). The mean peak opioid dose was 2.89 ± 0.26 
mg/day (range: 0.85-6.88) and the average peak concentration was 6.94 ± 0.64 mg/mL 
(range: 1.70-18). Eleven of these patients had crossed over from diamorphine to morphine 
during their treatment. In addition to the patients who developed a granuloma, 16% of the 
remaining patients presented clear changes in their pain including new symptoms. Following 
a magnetic resonance imaging scan, no masses were detected in these patients. 
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Homogeneity between groups 
Demographic differences between patients diagnosed with granuloma (GG) and the control 
group (CG) were investigated prior to analysis, to confirm if these could be compared (Table 
2.3.3). 
 
 
 
No significant differences were observed for age, gender and duration of pain prior to IDDS 
between granulomata patients and the control group. The number of months with IDDS in 
the CG (Mdn = 49) was significantly longer than the duration of treatment of patients in the 
GG (Mdn = 24.5), U = 203.5, p < 0.05, r = -0.34. This was not considered as an impediment 
for analysis as the risk of developing an inflammatory mass increases with the duration of 
intrathecal therapy. The incidence has been reported as 0.04% after one year, increasing to 
1.15% after six years (Yaksh et al., 2002). 
 
 
Associations with granuloma formation 
Both morphine dose (r = 0.821, p < 0.001) and concentration (r = 0.650, p < 0.001) were 
significantly associated with the development of intrathecal masses. 
 
The morphine concentration was significantly higher in the GG (Mdn = 20.0) than in the CG 
(Mdn = 6.0), U = 13, p < 0.001, r = -0.72 (Fig. 2.3.3). The morphine dose in the GG (Mdn = 
15) was significantly higher than in the CG (Mdn = 2.82), U = 13.5, p < 0.001, r = -0.82 (Fig. 
2.3.4). Post hoc power analyses were performed indicating a power of 81% for dose 
administered and a power of 52% for concentration. 
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The relative risk of developing a granuloma increases with dose and concentration (Table 
2.3.4 and 2.3.5). Although possible, the risk of granulomata is lessened with lower doses 
and concentrations. 
 
 
 
 
 
Flow rate and catheter tip location were not found to be associated with the formation of 
intrathecal inflammatory masses (p > 0.05). 
 
 
2.3.5 Discussion 
Opioid dose and concentration were found to be associated with the development of 
catheter tip granulomas indicating that this link might be more causal than casual. 
 
The mean peak morphine dose of 3 mg/day at an average follow up of 70 months in our 
patient group was lower than previously reported doses of 4.7 mg/day after an average of 
3.4 years (Winkelmüller and Winkelmüller 1996); 7.42 at 29.14 months (Kumar, Kelly and 
Pirlot 2001); 9.6 mg/day at one year (Paice, Penn and Shott 1996); and 21 mg/day at 52 
weeks (Yaksh and Onofrio 1987). However, it is important to state that with the exception of 
the Yaksh and Onofrio (1987) paper which was published before the first case report of an 
intrathecal granuloma, the opioid doses reported are significantly lower, even after 
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truncation of data, than those of the patients with granulomata and therefore significant 
differences would also be observed between these cohorts and the patients diagnosed with 
granuloma. 
 
Opioid dose has previously been suggested to be associated with intrathecal inflammatory 
masses formation (Duarte et al., 2010; McMillan, Doud and Nugent 2003). Concentration 
rather than daily dose has been suggested to be the primary contributing factor in the 
development of these masses (Allen et al., 2006); however, a significant association had not 
yet been established in human data. In this study, significant differences between the groups 
were verified despite the effect size being more elevated for opioid dose. This may be due to 
the fact that it might be more usual to adjust the delivered dose than to alter the drug 
concentration when responding to patients’ level of pain to obtain a compensatory flow rate 
change in the commonly used programmable pumps. This would also explain why in the 
McMillan, Doud and Nugent (2003) and Duarte et al. (2010) studies an association with 
concentration was not established. 
 
The influence of dose and concentration applies only to catheter tip granulomas. When the 
mass is a consequence of an infection or reaction to catheter material then sometimes the 
granuloma can be traced along the length of the catheter (Langsam 1999b). 
 
Flow rate was not found to be significantly associated with the development of catheter tip 
granulomas, possibly due to the flow rate being computed with the peak concentration and 
peak dose values. Throughout the course of treatment the flow rate was likely to change 
when concentration, dose or both were altered. It is advisable to avoid ultra slow flow rates 
and the drugs should be delivered into the dorsal cerebrospinal fluid space at L1-L2 or T7-
T10 to prevent the formation of intrathecal inflammatory masses (Deer et al., 2008a). 
 
An association between catheter tip location and development of inflammatory masses was 
not established in this study. This can be related to the fact that most implanters position the 
catheter tip in the thoracic level (Yaksh et al., 2002), even though these masses have been 
known to form at all levels of the intrathecal space (Deer et al., 2008a). 
 
The identification of this complication in its early stages is imperative and determinant to 
reduce the magnitude of the consequences. Forty per cent of the reports mentioned that a 
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rapid increase in the dose administered was observed prior to granuloma diagnosis. The 
development of a granuloma reduces the efficacy of the intrathecal medication (Bloomfield 
et al., 1995) and the failure to identify the occurrence of a granuloma can lead to a diagnosis 
of tolerance and an increase in the rate of infusion (Anderson et al., 2001; Bejjani, Karim 
and Tzortzidis 1997). Although this lesion develops very slowly, patient re-evaluation and 
vigilance are essential for an early diagnosis (Deer, Raso and Garten 2007). 
 
MRI remains as the gold standard for diagnosing intrathecal inflammatory masses; however, 
routine imaging in all patients with intrathecal pumps is not cost-effective taking into 
consideration the low occurrence of granulomas and the elevated cost of an MRI (Deer 
2004). Pump refills have been suggested as a good opportunity to examine patients’ lower 
extremity motor, sensory and reflex function (Aldrete et al., 1994). The yearly opioid dosage 
change can be used as an early indicator of the formation of granulomas (Duarte et al., 
2010). If new pain symptoms are observed alongside clear changes in intrathecal 
medication requirements, an MRI or as an alternative a computed tomography myelogram 
should follow (Deer et al., 2008a). 
 
Both dose and concentration should be kept as low as possible to reduce the relative risk of 
granulomata. The relative risk can be decreased by reducing dose and concentration from 
the currently recommended maxima of 15 mg/day and 20 mg/mL to 10 mg/day and 
15mg/mL respectively. These doses are still higher than the average reported to achieve an 
optimal pain control (Kumar, Kelly and Pirlot 2001; Paice, Penn and Shott 1996; 
Winkelmüller and Winkelmüller 1996). Patients that require high doses should be adequately 
informed of the risk of granuloma formation and what signs and symptoms might occur 
(Miele et al., 2006b; Penn 2003). When the maximum recommended values for dose and 
concentration do not generate the desired pain relief, Ziconotide should be taken into 
consideration as an alternative intrathecal medication. To date there are no reports 
associating this drug with the occurrence of catheter tip granulomas and its use has been 
recommended in the 2007 polyanalgesic consensus conference algorithm for intrathecal 
drug selection (Deer et al., 2008b). 
 
The findings, though significant, have to be considered against the background of the limits 
of the study. In our department, besides the morphine patient diagnosed with granuloma 
formation, 16% of the remaining patients had presented clear changes in their pain including 
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new symptoms but were not found to have developed an inflammatory mass following MRI 
screening. Despite not all the patients in the control group being screened for granulomata 
using an MRI scan, the rate of this diagnosis has been reported to be the equivalent to 
0.009 events per patient year (Duarte et al., 2010), which means it would have little or no 
statistical impact in the analysis. The analysis is also limited by the exclusion of patients 
diagnosed with inflammatory masses not being administered morphine as the intrathecal 
medication. It was considered that for the purpose of comparison, it would be preferable to 
only include patients undertaking an identical intrathecal therapy. Therefore, it cannot be 
ascertained if the same results would be verified with other opioids not investigated in this 
study. One of the limitations of this study is the fact that the control group is based on a 
single centre cohort. A large multi-centre study is warranted not only to confirm these 
findings but also to investigate other hypotheses as to the aetiology of granulomas, including 
dose and concentration of other intrathecal agents, flow rate, catheter tip design and 
location. An analysis of the dose, concentration and flow rate throughout duration of 
treatment instead of peak values would shed more light on the role of intrathecal medication 
in the formation of granulomas. 
 
 
2.3.6 Conclusion 
This is the first review of case reports performed in a systematic method studying the 
influence of opioid dose and concentration in the development of catheter tip intrathecal 
inflammatory masses. The comparison with a control group allowed for the first time to 
statistically confirm a long-standing inference that concentration plays an important role in 
the formation of granulomas. Additionally, significant differences were observed for dose 
administered corroborating results of previous studies. 
 
The relative risk can be decreased by reducing dose and concentration from the currently 
recommended maxima of 15mg/day and 20 mg/mL to 10mg/day and 15mg/mL respectively. 
 
The following section of this thesis evaluates the prevalence of hypogonadism in a cohort of 
male patients undertaking intrathecal drug delivery for the management of chronic non-
malignant pain. 
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SECTION 4. Hormonal effects as consequence of intrathecal drug delivery 
 
This section was published as two separate abstracts in Regional Anesthesia and Pain 
Medicine; in press. One of these abstracts was selected for oral presentation at the 30th 
Annual European Society of Regional Anaesthesia Congress, 2011. These publications 
have been reformatted to fit with the overall PhD Thesis. 
 
2.4.1 Abstract 
Background and aims 
Opioids are one of the factors that can modulate the functioning of the hypothalamic-
pituitary-gonadal axis at the hypothalamic or pituitary level, with the potential to cause 
hypogonadism. The aim of this study was to investigate the effects of long-term opioid 
intrathecal drug delivery therapy on the hypothalamic-pituitary-gonadal axis of male chronic 
non-malignant pain patients and the possible occurrence of differences between 
hypogonadism diagnostic criteria. 
 
Methods 
Twenty consecutive male patients undertaking long-term IDD therapy for chronic non-
malignant pain had the gonadal axis evaluated by assays of luteinising hormone (LH), 
follicle stimulating hormone (FSH), total testosterone (TT) and sex hormone binding globulin 
(SHBG). Free androgen index (FAI), free testosterone (FT) and bioavailable testosterone 
(BT) were calculated. 
 
Results 
The average age at the time of blood collection was 58 ± 1.47 years (range 47-69), the 
average time from implantation of IDD system to hormone assay was 92 ± 12.8 months 
(range 15-203) with a mean intrathecal opioid dose of 3.22 ± 0.64 mg/day (range 1-9.7). The 
mean LH was 2.69 ± 0.99 IU/L (0.2-19.9), FSH 7.98 ± 1.57 IU/L (0.3-23.9), SHBG 54.7 ± 
6.76 nmol/L (17-123) and TT 7.18 ± 1.19 nmol/L (1.2-18.8). Testosterone levels were 
significantly below the cut-off mark of 12 nmol/L for borderline/low testosterone (t = -4.043, p 
< 0.005, r = 0.68). The mean FAI was 16.89 ± 3.63 (1.9-57.06), the average FT was 109.64 
± 20.68 (14-328) and the average BT was 2.57 ± 0.48 (0.33-7.7). Based on either TT or FT 
being low or borderline/low, 19 (95%) of the investigated patients, were biochemically 
Page | 109 
hypogonadal. Significant differences were observed between diagnosis based on FT and 
FAI, χ2(1) = 10.588, p < 0.01. 
 
Conclusions 
Hypogonadism is common in patients undertaking intrathecal drug delivery. The diagnosis of 
hypogonadism in IDD patients, should take into consideration not only total testosterone but 
also free testosterone or bioavailable testosterone, LH and FSH levels. 
 
 
2.4.2 Introduction 
The hypothalamic-pituitary-gonadal (HPG) axis starts to function with the secretion by the 
hypothalamus of the gonadotropin releasing hormone (GnRH) which stimulates the pituitary 
gland to produce luteinizing hormone (LH) and follicle stimulating hormone (FSH). LH and 
FSH are released into the systemic circulation, stimulating the gonads (testicles and ovaries) 
to produce the sex hormones testosterone (androgen) and estradiol (estrogen) respectively 
(Figure 2.4.1). These sex hormones control the secretion of GnRH, LH and FSH via a 
negative feedback on the hypothalamus and pituitary gland (Katz and Mazer 2009). 
Testosterone or estrogen levels affect sexual and reproductive development as well as 
behaviour and gender characteristics. 
 
Opioids are one of the factors that can modulate the hypothalamic-pituitary-gonadal axis 
functioning at the hypothalamic or pituitary level, with the potential to cause central 
hypogonadism, also known as secondary hypogonadism or hypogonadotropic 
hypogonadism. Animal studies suggest that the opioid control of gonadotropin release 
occurs via the inhibition of the GnRH by β-endorphin (Schulz et al., 1981), most likely at µ-
receptors (Pfeiffer et al., 1983). This inhibition secondarily reduces the release of LH and 
FSH by the pituitary gland and production of testosterone by the gonad, indicating 
hypogonadism. This condition is caused by disorders at the hypothalamic or pituitary level 
leading to decreased testosterone production with loss of libido (Figure 2.4.2). It is 
characterized by low or low-normal FSH levels, low or low-normal LH levels and low 
testosterone levels (Petak et al., 2002). The main site of action of both exogenous and 
endogenous opioids appears to be in the hypothalamus, but further modulating effects may 
occur at the pituitary level and at the end organs (Morley 1981). 
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The influence of exogenous opioids on reproductive capability was inferred based on the 
observation that many heroin addicts were amenorrhoeic or hypogonadal (Genazzani et al., 
1993). This deduction was confirmed by studies which reported low testosterone levels in 
heroin addicts (Mendelson and Mello 1975; Mendelson, Mendelson and Patch 1975) and 
subjects on methadone maintenance programmes (Bliesener et al., 2005; Hallinan et al., 
2008; Mendelson, Mendelson and Patch 1975). 
 
Testosterone circulates in plasma non-specifically bound to albumin, specifically bound to 
the sex hormone binding globulin (SHBG) and only a small percentage of testosterone is 
unbound (Vermeulen, Verdonck and Kaufman 1999). SHBG also binds to estradiol which is 
the predominant female sex hormone. The free and the non-specifically bound testosterone 
represent a small percentage of the hormone available, however, there is good evidence 
that this fraction reflects more accurately the clinical situation than total testosterone in 
plasma (Vermeulen, Verdonck and Kaufman 1999). The unbound or free testosterone is 
able to link to and activate a receptor. SHBG bound to testosterone will inhibit this action. 
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The gold standard test for verification of the androgen status is an assay of free testosterone 
(FT) or bioavailable testosterone (BT) by equilibrium dialysis, however, this technique is not 
practical for routine evaluations since it is time consuming, requires sophisticated 
equipment, the use of freshly puriﬁed radioactive tracers, several hours of dialysis to achieve 
equilibrium and a long counting time for radioactivity (Raverot et al., 2010; Vermeulen 2005). 
This procedure examines the levels of total testosterone, SHBG and albumin, therefore 
allowing a precise analysis of FT and BT values. 
 
An alternative to this method is the calculation of FT and BT through the Vermeulen 
equations (Vermeulen, Verdonck and Kaufman 1999). In the FT equation, Kt is the 
association constant of SHBG for testosterone; N = KaCa + 1 where Ka is the association 
constant of albumin for testosterone, and Ca is the albumin concentration. 
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BT is the sum of FT with the albumin-bound testosterone (AT). The calculated FT has been 
considered as a reliable index of unbound testosterone (Hackett et al., 2008; Rosner et al., 
2007; Vermeulen, Verdonck and Kaufman 1999). 
 
 
 
The free androgen index (FAI) is also often calculated to examine the presence of 
hypogonadism. This index takes into consideration testosterone and SHBG levels. 
 
 
 
In this equation both testosterone and SHBG are expressed as nanomoles per liter (nmol/L) 
(Harman et al., 2001; Vermeulen, Verdonck and Kaufman 1999). The FAI is an index of free 
testosterone, it does not indicate the actual physical concentration of free testosterone 
(Miller et al., 2004). The validity of FAI as a reliable equivalent of free testosterone has been 
questioned with studies considering FAI a poor index of free testosterone (Kapoor, Luttrell 
and Williams 1993; Vermeulen, Verdonck and Kaufman 1999). 
 
The possible effect of intrathecal drug delivery on the endocrine system is one of the least 
noted and investigated IDD side effects (Doleys et al., 1998). Currently, opioid induced 
hypogonadism is under-recognised and undertreated (Reddy et al., 2010). Some patients 
may attribute the signs and symptoms of hypogonadism such as decreased libido, tiredness, 
loss of muscle mass and strength, among others to the chronic pain and its related 
conditions, rather than the intraspinal medication (Doleys et al., 1998; Katz and Mazer 
2009). Moreover, hypogonadism symptoms are often denied by the patient and ignored by 
the physician (Petak et al., 2002). The current limited clinical awareness of the opioid effects 
on the endocrine system, together with the lack of information on their long-term 
consequences, is likely to result in a lack of information provision to the patient when long-
term opioid therapy is being considered (Vuong et al., 2010). 
 
It is important to detect and refer these patients to appropriate care as chronic low levels of 
testosterone can lead to effects on sexual function and fertility (Roberts et al., 2002), as well 
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as to other complications such as muscle atrophy, anaemia, and cognitive impairment 
(Morales and Heaton 2001; Roberts et al., 2002; Zitzmann and Nieschlag 2000). 
 
The aim of this study was to investigate the effects of long-term intrathecal opioid therapy on 
the hypothalamic-pituitary-gonadal axis of male chronic non-malignant pain patients and 
variations in the prevalence of this complication according to the diagnostic criteria 
employed. 
 
 
2.4.3 Review of the literature 
Six studies have been published on the effect of IDD in the endocrine system. The first study 
(Paice, Penn and Ryan 1994) investigated this side effect in six male patients undertaking 
intrathecal opioid delivery for FBSS (n=1), reflex sympathetic dystrophy (n=1), pain due to 
hemangioma of the spinal cord (n=1), visceral pain (n=1), postherpetic neuropathy (n=1) 
and back pain and arachnoiditis (n=1). 
 
The next publication on this topic was by the same first two authors, a letter reporting the 
case of a woman that became amenorrheic following IDD therapy (Paice and Penn 1995). 
 
A cross-sectional study investigated the testosterone levels of 15 consecutive male patients 
(Doleys et al., 1998). The only endocrine marker investigated was testosterone, therefore it 
would not be possible to distinguish between primary or secondary hypogonadism in this 
study. Low back pain was present in 86.7% of the sample, while the other 13.3% were 
diagnosed with cervical radiculopathy. 
 
Abs et al. (2000) studied both male and female patients being administered intrathecal 
opioids and compared the results with a control group with analogous pain syndromes but 
not receiving opioid treatment. This study evaluating the endocrine consequences of 
intrathecal opioids involved the greatest number of participants (n=73). Diagnosis of the 
patients included FBSS (n=47); chronic pancreatitis; complex regional pain syndrome 
(CRPS) I and II; polyneuritis; neurinome; spinal stenosis; phantom limb pain; and scoliosis 
and neck pain. 
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One month following the publication of the Abs et al. (2000) study, a case-control study 
comparing 30 IDD patients with a matched control group of chronic pain patients not taking 
any form of opioid drugs was published (Finch et al., 2000). The patients involved in this 
study presented with FBSS (n=15); spinal pain (n=5); CRPS I (n=6); benign spinal tumor 
(n=1); facial pain (n=1) and chronic pancreatitis or abdominal pain (n=2). 
 
A prospective, short term (12 weeks) study evaluated the hypothalamic-pituitary-gonadal 
axis function in males during the first weeks of intrathecal opioid delivery (Roberts et al., 
2002). The diagnosis were FBSS (n=4); CRPS I (n=3); cervical discogenic pain (n=1); post-
thoracotomy pain syndrome (n=1) and central pain (n=1). The patients were evaluated 
before and after one, four and 12 weeks of intrathecal opioid delivery. 
 
Gonadal axis in males (Table 2.4.1) 
In the Paice, Penn and Ryan (1994) study, the route of opioid delivery was intrathecal in five 
of the six patients included in the study. The remaining patient was being administered 
opioids via epidural route. Four of the six patients were receiving an average additional oral 
opioid therapy of 71.8 ± 112.6 mg/day (0-280). Testosterone levels were significantly below 
the normal levels (t= -3.11, p = 0.026). Prolactin, LH and SHBG were within the normal 
limits. The FSH levels were above normal, although the difference was not statistically 
significant. Only one of the patients was within the normal testosterone level range. 
 
The investigation of the testosterone levels of 15 consecutive male patients by Doleys et al. 
(1998) indicated that the average testosterone level was significantly below the cut-off mark 
for low testosterone (t = -7.80, p < 0.0001). The majority of patients (86.7%) were also taking 
oral opioids in addition to the intrathecal therapy. Criteria for inclusion in this study included 
at least six months of intrathecal morphine administration, however, the duration of IDD 
therapy reported ranged from 14 - 473 days. This inaccuracy did not seem to influence the 
results since the testosterone levels in all the patients were below the cut-off mark for low 
testosterone. 
 
In the Abs et al. (2000) study, after initiation of IDD therapy, 23 out of 24 male participants 
(95.8%) noticed a decrease or even disappearance of libido and potency, whereas prior to 
treatment 25 of 26 males considered their libido as normal. Serum testosterone (p < 0.001) 
and FAI (p < 0.001) levels were significantly lower in the IDD group compared to the control 
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group. The majority of IDD patients (25/86.2%) and one control patient had a testosterone 
level below 9.0 nmol/L. The FAI level was lower than twenty in 18 of the 29 male IDD 
patients (62.1%) and in one control patient. The LH concentration was significantly lower in 
the opioid group (p < 0.001). No differences between the groups were identified for serum 
SHBG and FSH. This study measured bone mineral density (BMD) in 49 of the opioid 
patients which revealed a z-score of -0.19 ± 1.54 (range: -4.17 – 2.4) at the lumbar spine 
and -0.53 ± 1.46 (range: -5.91 – 2.87) at the femoral neck. There was no indication of the 
number of patients with osteoporosis or osteopaenia. No comparison was made with the 
control group because BMD was not measured in that group. 
 
In the Finch et al. (2000) study, IDD male patients showed significantly lower testosterone 
(p=0.0032) and FAI levels (p = 0.0126) when compared with a group of chronic pain patients 
not taking any form of opioid drugs. One male patient was excluded in this study on the 
basis of a history of mumps orchitis prior to IDD therapy. Six male patients reported poor 
libido and four of these were impotent with the onset of symptoms corresponding to 
commencement of IDD therapy. FSH and LH levels, although lower in the IDD group were 
not significantly different when compared with the control group. SHBG and prolactin levels 
were within the normal range for both groups. After cessation of intrathecal opioid delivery in 
two men aged 37 and 64 years old, there was an increase in testosterone levels from 8.3 to 
12 nmol/L and 1.3 to 9.9 nmol/L, respectively. Hypogonadotropic hypogonadism was 
present in all male IDD patients and absent in the control subjects. 
 
The participants in the Roberts et al. (2002) study were administered oral opioids at an 
average of 211 ± 60 mg/day of morphine equivalents prior to IDD. The oral opioid dose 
decreased throughout IDD therapy to a median dose of 23.5 and 7.9 mg/day at four and 12 
weeks assessment, respectively. The majority of the patients were already below the lower 
limit of the reference range of serum testosterone (10-35 nmol/L) prior to the start of 
intrathecal therapy. Nevertheless, significant decreases in testosterone and FSH levels were 
verified after one, four and 12 weeks of intrathecal opioid delivery (p < 0.0001). 
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Gonadal axis in females (Table 2.4.2) 
Paice and Penn (1995) published a letter reporting the case of a woman that became 
amenorrheic after IDD treatment. The patient ceased menstruating within one month 
following pump implantation. Endometrial biopsies, serum estradiol, FSH and LH levels were 
normal indicating that the patient was not menopausal. 
 
In the Abs et al. (2000) study, following commencement of IDD therapy, 22 out of 32 women 
(68.8%) noticed a decrease or disappearance of libido, whereas prior to treatment 32 of 36 
women considered their libido as normal. LH levels were inferior to 2 U/l in nine of 21 
premenopausal women (42.9%) in the IDD group. FSH levels were less than 2 U/l in five of 
the 21 premenopausal women (23.8%). Serum LH, FSH, estradiol and progesterone 
concentrations were lower in the opioid group, although not statistically significant probably 
due to the small number of premenopausal patients in the control group (n=3). Fourteen of 
21 premenopausal women became amenorrheic and seven developed an irregular 
menstrual cycle, with ovulation only in one woman. 
 
The LH (p < 0.001) and FSH (p = 0.012) levels in postmenopausal women were significantly 
lower in the IDD group than in the six postmenopausal control women. No significant 
differences were observed between the groups for estradiol and progesterone 
concentrations. In this study, five female patients were excluded without being accounted 
for. 
 
In the Finch et al. (2000) study, all the premenopausal women reported low libido since 
commencement of therapy. Five of the seven women reported amenorrhea; in two of these 
the amenorrhea predated the intrathecal therapy. Seven of the twelve postmenopausal 
women were on sex hormone replacement therapy which was ceased at least two weeks 
prior to hormone assay. These women reported low libido levels both before and after 
initiation of intrathecal opioid therapy. All estradiol levels were within the normal 
postmenopausal range. FSH (subjects, 24.5 ± 10.8 IU/L; controls 78.5 ± 3.7 IU/L; p = 
0.0037) and LH (subjects, 12.3 ± 7.2 IU/L; controls 35.3 ± 3.6 IU/L; p = 0.0024) levels were 
significantly lower than those observed in the control group. 
Page | 118 
 
Page | 119 
2.4.4 Methods 
Participants 
Twenty consecutive male patients undertaking long-term IDD therapy at Russells Hall 
Hospital for the management of chronic non-malignant pain were included in the study. 
Patients who had received testosterone supplementation within the previous three months 
were not included (Roberts et al., 2002). The pain syndrome the majority of the participants 
(58.8%) experienced was nociceptive, while neuropathic pain was present in 5.8% of the 
patients and 35.3% suffered from mixed nociceptive-neuropathic pain. All the patients were 
receiving intrathecal opioids for the management of their pain. Intrathecal morphine was the 
only medication administered to 50% of the sample. In individual cases, other substances 
were added to the intrathecal medication, such as bupivacaine (50%), clonidine (25%) and 
baclofen (12.5%). 
 
 
Assessment of Sex Hormones 
The gonadal axis was evaluated by measurement of single serum concentrations for the 
indicative markers of endocrine glands functioning, such as LH, FSH, total testosterone (TT) 
and SHBG (Table 2.4.3). The validity of single serum concentrations assessment has been 
demonstrated in patients evaluated for testosterone replacement therapy (Vermeulen and 
Verdonck 1992). SHBG was measured by immunoradiometric assay (Oregon Diagnostica, 
Espoo, Finland) according to the manufacturer’s instructions with intra-assay coefficients of 
variation (CV) of two to 5%. All other assays were performed by automated 
chemiluminescence on the ACS:180 (Chiron Diagnostics, East Walpole, MA, U.S.A.) 
according to the manufacturer’s instructions with within-run CV of less than 5% for LH and 
FSH and less than 10% for testosterone. Calculations of the free androgen index (FAI), free 
testosterone (FT) and bioavailable testosterone (BT) were also carried out (Harman et al., 
2001; Vermeulen, Verdonck and Kaufman 1999). 
 
Normal reference ranges for LH represented a value between 2.2-13.3 IU/L, FSH 1-7 IU/L 
and SHBG 13-71 nmol/L. A TT level of < 8 nmol/L, FT < 180 picomoles per liter (pmol/L), BT 
< 3.8 nmol/L was considered as biochemical hypogonadism and TT levels of 8 – 12 nmol/L, 
FT 180-250 pmol/L, BT 3.8-6.1 nmol/L as borderline/low (Hackett et al., 2008). FAI levels < 
15.3 were considered as hypogonadism (Harman et al., 2001). 
Page | 120 
 
 
During a seven month period (April to October 2010) 20 blood samples were obtained. The 
blood tests were collected between 8am and 11am. All blood assays were carried out by the 
Department of Clinical Biochemistry at Russells Hall Hospital, Dudley. 
 
 
Data analysis 
Results are expressed as mean ± SEM unless specified otherwise. The Kolmogorov-
Smirnov test was performed to test distribution of numerical data, followed by the 
appropriate statistical tests. One-sample T test was performed to investigate differences 
between TT levels of the sample with normal endocrine values. Associations between 
variables were investigated by Spearman’s’ correlation coefficients. Analysis of categorical 
data was carried out through Pearson’s Chi-Square test. Results were considered 
statistically significant at p ≤ 0.05. Statistical tests were performed using the Statistical 
Package for the Social Sciences (SPSS) software (version 17.0, SPSS Inc., Chicago, IL, 
USA). 
 
Page | 121 
2.4.5 Results 
The sample consisted of 20 male IDDS patients with a mean age at the time of blood 
collection of 58 ± 1.47 years (range 47-69). The average time from implantation of the IDD 
system to hormone assay was 92.12 ± 12.81 months (range 15-203) with a mean intrathecal 
opioid dose of 3.22 ± 0.64 mg/day (range 1-9.7). The mean duration of pain prior to 
commencement of IDD was 13.9 ± 2.34 years (range 3-35) (Table 2.4.4). 
 
The mean TT level was 7.18 ± 1.19 nmol/L (1.2-18.8), which was significantly lower than the 
cut-off mark of 12 nmol/L for borderline/low testosterone (t = -4.043, p < 0.005, r = 0.68). 
 
The mean FT levels were significantly lower than the cut-off mark of 180 pmol/L for low FT (t 
= -3.403, p < 0.005, r = 0.61). The mean BT levels were significantly lower than the cut-off 
mark of 3.8 nmol/L for low BT (t = -2.533, p < 0.05, r = 0.50). No significant differences were 
observed between the mean FAI and the cut-off mark of 15.3 for hypogonadism (p = 0.665). 
LH, FSH and SHBG mean levels were within the normal reference range. 
 
 
 
Based on TT, 17 (85%) of the patients were hypogonadal with 12 (60%) at less than 8 
nmol/L and five (25%) between eight and 12 nmol/L (Figure 2.4.3). Based on FT 
calculations, 17 (85%) were hypogonadal with 15 (75%) at less than 180 pmol/L and two 
(10%) patients between 180 and 250 pmol/L. The same outcome was observed for the 
analysis of BT calculations, therefore FT was considered for further statistical comparisons 
as the result would be the same if carried out with either FT or BT. Based on hypogonadism 
defined as FAI < 15.3 in men, 14 (70%) patients were identified. Based on either TT or FT 
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being low or borderline/low, 19 (95%) of the investigated patients, were biochemically 
hypogonadal. In this sample FAI was highly correlated with FT (r = 0.929, p < 0.01) and BT 
(r = 0.929, p < 0.01) and less associated with testosterone (r = 0.701, p < 0.01). FT (r = 
0.866, p < 0.01) and BT (r = 0.866, p < 0.01) were more strongly correlated with 
testosterone. 
 
Significant differences were observed between diagnosis based on FT and FAI, χ2(1) = 
10.588, p < 0.01. No significant differences were observed between diagnosis based on TT 
and FT (p = 0.404) or TT and FAI (p = 0.14). 
 
 
 
2.4.6 Discussion 
The gonadotropin levels of the patients in our sample were either low or low-normal, which 
suggests that testosterone suppression was caused at the hypothalamic-pituitary-gonadal 
axis through an inhibition of pituitary FSH and LH secretion. Direct suppression at a 
testicular level would result in primary hypogonadism, characterized by an increase in FSH 
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and LH levels. Smaller changes observed in FSH are likely to be due to its relatively long 
circulatory half-life (Grossman 1983). In a group of cancer survivors on opioids, 90% 
exhibited hypogonadism and median testosterone levels; LH levels but not FSH levels were 
found to be significantly lower when compared with cancer survivors not on opioid therapy 
(Rajagopal et al., 2004). The important role of endogenous opioids in the control of LH 
secretion has been demonstrated (Genazzani et al., 1993). Suppression of the 
hypothalamic-pituitary-gonadal axis by intrathecal opioids may be caused by a similar 
mechanism to that of endogenous opioids (Finch et al., 2000). Nevertheless, the 
suppression of LH levels may be less accentuated when the opioids are administered orally 
or transdermally rather than intrathecally (Vuong et al., 2010). Direct effects of opioids at the 
testicular level, including decreased secretion of testosterone have also been reported 
(Cicero et al., 1975). 
 
Total testosterone levels were significantly below the cut-off mark of 12 nmol/L for 
borderline/low testosterone even after an average duration of IDD therapy equivalent to 92 ± 
12.8 months (range 15-203). The reduction in testosterone levels is a secondary result of a 
primary suppression of the hypothalamic-pituitary-LH axis caused by opioids (Cicero 1980). 
Low testosterone levels in intraspinal opioid patients after an average duration of treatment 
of 47.7 months have been demonstrated (Paice, Penn and Ryan 1994). 
 
Significant differences were observed in this study when the diagnoses of hypogonadism 
were compared based on calculated FT or BT and FAI. The prevalence of this complication 
based on diagnosis criteria ranged from 70% (14 patients) for FAI, to 85% (17 patients) 
based on TT or FT. When both TT and FT were considered 95% (19 patients) were 
diagnosed as biochemically hypogonadal. The incidence of this side effect although 
variable, is approximate across prior studies. The diagnostic criteria may account for much 
of this variation. The majority of studies investigating the effects of intrathecal opioids in the 
endocrine system have considered mainly TT, LH and FSH levels. To our knowledge, this is 
the first study with IDD patients that also used Vermeulens’ calculated free testosterone as a 
diagnostic tool. In studies where FAI was calculated, 25 of 29 intrathecal opioid patients 
(86.2%) had a testosterone level lower than 9.0 nmol/L but only 18 of the patients (62.1%) 
had a FAI lower than 20 (Abs et al., 2000). Another study reported that all the patients 
(n=10) had testosterone below the normal range of 10 to 35 nmol/L, however, the average 
FAI was 29.1 ± 11.0 (Finch et al., 2000). The prevalence of hypogonadism in male patients 
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undertaking oral opioids has been reported to range from 83% to 90% (Daniell 2002; Fraser 
et al., 2009; Rajagopal et al., 2003). These results indicate a high prevalence of opioid 
induced hypogonadism, regardless of the administration route. Even at clinically very low 
intrathecal opioid doses (1.5 ± 0.7 mg/day (range 0.35-2.3)) hypogonadism was present in 
five out of seven patients (Alam et al., 2008). 
 
It is important to note the limitations of this study. A small number of patients was included 
without a control group and the gonadal status was not evaluated prior to commencement of 
IDD therapy. Women were not included in this study. Low libido and amenorrhea have been 
reported in female IDDS patients (Abs et al., 2000; Finch et al., 2000; Paice and Penn 
1995), although the prevalence has been reported to be lower in women (Fraser et al., 
2009). 
 
The development of hypogonadism is multifactorial and in this specific population there are 
many other possible confounding factors. Psychological aspects such as depression, 
passive coping strategies and catastrophising are some of the factors hypothesized to 
influence the sexual function in chronic pain patients (Monga et al., 1998). However, chronic 
pain did not seem to be the cause of gonadal function reduction which was observed in 
patients undertaking intrathecal morphine therapy (Finch et al., 2000). Of the possible 
chronic illnesses identified in a longitudinal study with 890 male participants, only cancer 
(9%) was associated with a greater decrease in testosterone levels than the decrease that 
occurred with aging alone (Harman et al., 2001). 
 
The hypothalamic-pituitary-gonadal axis should be routinely monitored in IDD patients and 
adequate treatment provided. Hypogonadism is a risk factor associated with several 
conditions. Low total testosterone, FT and SHBG are independent risk factors for later 
development of type 2 diabetes (Feldman et al., 1994; Haffner et al., 1996). Low 
testosterone levels may be associated with increased cardiovascular risk (Hackett 2009). 
 
Opioid induced hypogonadism may be reversible. Clinically significant improvements in 
hypogonadal symptoms, sexual function and mood were observed in men with opioid 
induced androgen deficiency being treated with transdermal testosterone patches (Daniell, 
Lentz and Mazer 2006). Improvements in aspects of sexual activity and decrease in ratings 
of mood aspects such as depression, anger and fatigue were detected in previously 
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untreated hypogonadal men following testosterone injections (Burris et al., 1992). Recovery 
of serum testosterone levels following cessation of IDD therapy or significant improvements 
in libido following hormonal replacement therapy have been reported (Abs et al., 2000; Finch 
et al., 2000). After the opioid is stopped, testosterone levels generally recover within one 
month (Cicero et al., 1975; Mendelson and Mello 1975; Wang, Chan and Yeung 1978). 
 
The increase of testosterone levels and consequently libido may have added importance to 
chronic pain patients. The results of animal studies have suggested that reduced libido may 
be linked with a lower pain threshold (Forman et al., 1989; Pednekar and Mulgaonker 1995). 
In humans, it has been observed that men with opioid-induced androgen deficiency required 
lower oral opioid doses during hormonal replacement therapy, suggesting that 
hypogonadism patients may have a lower pain threshold (Daniell 2002). 
 
 
2.4.7 Conclusion 
Hypogonadism is common in patients undertaking IDD therapy for the management of 
chronic non-malignant pain. The hypothalamic-pituitary-gonadal axis should be routinely 
monitored in patients undertaking intrathecal opioid administration from the start of therapy. 
This assessment should include evaluation of total testosterone, free testosterone or 
bioavailable testosterone, LH and FSH. 
 
This section allowed confirmation that hypogonadism is a prevalent side effect of intrathecal 
drug delivery. Hypogonadism is a risk factor for decreased bone mineral density. The 
following section of this thesis evaluates the prevalence of low bone mass density in the 
hypogonadal patients identified in the current section. 
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SECTION 5. Osteopaenia and osteoporosis as a secondary side effect of intrathecal 
drug delivery 
 
2.5.1 Abstract 
Background and aims 
Hypogonadism is common in patients undertaking intrathecal opioid therapy and a known 
risk factor for decreased bone mineral density (BMD). There is limited information available 
about BMD levels in intrathecal opioid patients. The aim of this study was to investigate 
BMD levels and the presence of osteopaenia and osteoporosis in the hypogonadal patients 
identified in the previous section of this thesis. 
 
Methods 
The patients diagnosed with hypogonadism based on free testosterone (FT) in the previous 
section were included in this study. BMD was evaluated via dual energy X-ray 
absorptiometry (DEXA) scans of the femur and lumbar spine or left forearm. Osteopaenia 
was defined as a T-score between -1.0 and -2.5 SD, and osteoporosis as a T-score at or 
below -2.5 SD. 
 
Results 
The average age was 59.1 ± 1.99 years (range 47 - 69) and the average duration of 
intrathecal drug delivery therapy was 99.8 ± 15.96 months (range 22 - 203) with a mean 
intrathecal opioid dose of 3.70 ± 0.90 mg/day (range 1 - 9.7). The mean duration of pain 
prior to IDD was 15.2 ± 2.89 years (range 4 - 35). Individual T-scores below -1.0 SD in at 
least one site were identified in 10 (71.4%) of the participants. Osteopaenia defined as a T-
score between -1.0 and -2.5 SD was diagnosed in eight (57.1%) of the patients at femoral, 
neck (50%) or hip (28.6%), forearm (14.3%) or lumbar (14.3%) sites. Osteoporosis defined 
as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects at the femur 
site. 
 
Conclusions 
These findings show that hypogonadal intrathecal opioid patients have increased risk of 
developing low bone mass density. The assessment of BMD in hypogonadal intrathecal 
opioid delivery patients should be performed and adequate treatment provided to avoid the 
consequences of osteopaenia or osteoporosis. 
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2.5.2 Introduction 
Osteoporosis has been defined by a consensus statement as a disease characterized by 
low bone mineral density which indicates an increased fragility of the bone and consequent 
increase of the risk of fracture (Consensus Development Conference 1991). Osteopaenia 
should not be mistaken with osteoporosis. Osteopaenia is an asymptomatic risk factor for 
osteoporosis characterized by a decrease in the bone mineral density whether in the 
presence or absence of osteoporosis (Kanis 1990). The prevalence of osteoporotic fractures 
is high with an estimated 9.0 million osteoporotic fractures occurring in the year 2000 of 
which 1.6 million were at the hip, 1.7 million at the forearm and 1.4 million were clinical 
vertebral fractures (Johnell and Kanis 2006). According to the same study, the greatest 
incidence of these fractures was in Europe (34.8%). 
 
A DEXA scan is a reliable and commonly used technique to assess BMD (Cummings, Bates 
and Black 2002). This scan consists of two low dose X-ray beams with distinct energy 
peaks. The X-ray beams are absorbed by bone and soft tissue allowing the calculation of 
bone mineral content. The amount of mineral in the specific site scanned, divided by the 
area of bone measured, can derive a value for BMD (Kanis 2002). The presence of 
osteopaenia or osteoporosis can be established by the measurement of BMD (Figure 2.5.1). 
A comparison of an individual BMD measurement with the mean BMD value of a young 
healthy adults’ reference range provides a T-score. A Z-score is an age-matched score and 
compares an individual BMD with the mean for that age. The standard against which BMD 
reduction should be measured is a normal range derived from young healthy adults (Nordin 
1987). The current recommendation of the World Health Organization and International 
Osteoporosis Foundation is to use the National Health and Nutrition Examination Survey 
reference database for women aged 20-29 years as reference range (Kanis and Glüer 
2000). 
 
The BMD concentration is normal if not more than one standard deviation (SD) below the 
young adult mean; a value that lies between one and 2.5 SD below the mean indicates low 
bone mass or osteopaenia (individuals who would benefit from prevention of bone loss); a 
score of 2.5 SD or more below the young adult mean value suggests osteoporosis; a value 
of 2.5 SD or more below the young adult mean alongside one or more fragility fractures is 
indicative of severe or established osteoporosis (Kanis et al., 1994; Kanis and Glüer 2000). 
The proportion of patients with osteoporosis increases exponentially with age, because 
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although BMD is normally distributed at all ages, it decreases progressively with age (Kanis 
et al., 1994) (Figure 2.5.2). 
 
 
Diagnostic cut-off values for men are less well defined than for women (Kanis 2002), 
however a similar cut-off value for hip BMD that is used in women can be used for the 
diagnosis of osteoporosis in men (Kanis and Glüer 2000). 
 
The risk of fracture is multifactorial and several independent risk factors, including 
hypogonadism, contribute to an increase in this risk above that reflected by BMD alone 
(Kanis 2002). Sex steroids are important for the maintenance of bone mass and may protect 
men against osteoporosis (Riggs, Khosla and Melton 2002; Vanderschueren et al., 2004). 
Hypogonadism, as demonstrated in the previous section of this thesis is common in patients 
undertaking intrathecal opioid therapy. To our knowledge, the assessment of BMD in 
patients undertaking intrathecal drug delivery is limited to the Abs et al. (2000) study. The 
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authors suggested a tendency towards decreased BMD in these patients. However, the 
prevalence of osteopaenia or osteoporosis was not reported. 
 
 
 
The aim of this study was to investigate the presence of osteopaenia and osteoporosis in a 
sample of hypogonadal patients undertaking intrathecal opioid delivery for the management 
of chronic non-malignant pain. 
 
 
2.5.3 Methods 
The 17 male patients diagnosed as hypogonadal through calculated free testosterone (FT) 
or bioavailable testosterone (BT) on the previous section of this thesis were considered for 
inclusion in this study. Three patients were excluded. One patient was excluded on the basis 
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that the primary indication for IDD use was spinal osteoporosis; one patient had the 
intrathecal opioid therapy discontinued and one patient passed away. 
 
 
Assessment of Bone Mineral Density 
Bone mineral density was measured via DEXA scans of the femur (neck and hip) and 
lumbar spine or left forearm using the Lunar Prodigy DEXA (GE Lunar Corp., Madison, WI, 
USA). Lumbar spine scan was not carried out in patients who had previous spinal surgery. 
In those cases, assessment was performed at the left forearm site. Results are presented as 
BMD (g/cm2), T-scores and Z-scores (Table 2.5.1). Osteopaenia was defined as a T-score 
between -1.0 and -2.5 SD, and osteoporosis as a T-score at or below -2.5 SD. 
Measurements of height, weight and body mass index (BMI) were also performed. BMI was 
calculated using the following metric formula: 
 
 
 
The BMI scores were categorised according to the World Health Organisation key cut-off 
points as < 18.5 (underweight), ≥ 18.5 and ≤ 24.9 (normal weight), ≥ 25 and ≤ 29.9 
(overweight), and ≥ 30 (obese) (World Health Organization 2000). Bone densitometry DEXA 
scans were carried out by the Department of Radiology, at Corbett Hospital, Dudley. 
 
 
Data analysis 
Results are reported as mean ± SEM unless specified otherwise. The Kolmogorov-Smirnov 
test was performed to test distribution of numerical data, followed by the appropriate 
statistical tests. Comparisons between groups were carried out with the Mann-Whitney test. 
Results were considered statistically significant at p ≤ 0.05. Statistical tests were performed 
using the Statistical Package for the Social Sciences (SPSS) software (version 17.0, SPSS 
Inc., Chicago, IL, USA). 
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2.5.4 Results 
The average age of this sample was 59.1 ± 1.99 years (47-69). The average duration of IDD 
therapy was 99.8 ± 15.96 months (22-203) with a mean intrathecal opioid dose of 3.70 ± 
0.90 mg/day (1-9.7). The mean duration of pain prior to IDD was 15.2 ± 2.89 years (range 4-
35). The mean BMI score was 28.83 ± 1.86 kg/m2 (20.1 - 45.4). According to the BMI score, 
the majority of the patients (64.3%) were either overweight or obese and none of the 
patients were underweight. 
 
Table 2.5.2 shows the results of the BMD assessment. Individual T-scores below -1.0 SD in 
at least one site were identified in 10 (71.4%) of the participants. Osteopaenia defined as a 
T-score between -1.0 and -2.5 SD was diagnosed in eight (57.1%) of the patients at femoral, 
either neck (50%) or hip (28.6%), forearm (14.3%) or lumbar (14.3%) sites. Osteoporosis 
defined as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects. One 
of the patients presented osteoporosis levels both at the hip and femoral neck site; another 
patient, besides osteoporosis levels at the hip and femoral neck sites, also presented a 
score below - 2.5 at the forearm site. The other osteoporotic patient presented osteoporosis 
levels at the hip site and osteopaenia levels at the femoral neck and forearm sites. Two 
patients had osteopaenia levels both at hip and femoral neck locations. One patient 
presented osteopaenia levels at both femoral (neck and hip) and forearm sites; and one 
patient presented osteopaenia levels at both femoral (neck and hip) and lumbar sites. 
 
No statistical differences were observed between the patients within normal reference range 
values and those with osteopaenia or osteoporosis for age (p = 0.760) or BMI (p = 0.374). 
 
Several known risk factors for osteoporosis were present in this sample. All of the patients 
were hypogonadal. Half of the participants reported low levels of calcium intake, 43% were 
active smokers and 36% prior smokers. In addition, three of the patients reported high 
propensity to fall, indicating two to three falls in the last six to 12 months and one patient 
reported a recent rib fracture. 
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2.5.5 Discussion 
Osteopaenia was present in 57.1% of the participants, while osteoporosis was detected in 
21.4% of the subjects. One patient presented osteoporosis levels at the femur sites and 
forearm; another osteoporotic patient presented scores below -2.5 at both femur sites; and 
the other patient with osteoporosis also had osteopaenia levels in the forearm and femoral 
neck. There is limited available literature investigating the effects of opioids on BMD. This 
effect is likely to be secondary to opioid induced hypogonadism and not a direct effect of 
opioids. Hypogonadism is an important risk factor for development of osteoporosis in both 
sexes, but opioids have not been considered a risk factor and smoking and alcohol intake 
were considered weak risk factors (Kanis 2002). Tendency in intrathecal opioid patients 
towards decreased BMD has been noted previously (Abs et al., 2000), although the 
incidence of osteopaenia or osteoporosis was not reported. An association between oral 
opioid administration and reduced BMD was established (Kinjo et al., 2005) but this study 
failed to investigate the presence of hypogonadism in the investigated sample. In a cross-
sectional study, osteopaenia was present in 50% of the male patients undertaking oral 
opioids (Fraser et al., 2009) although it is not clear if the six patients with osteopaenia were 
hypogonadal. 
 
An association between oral opioid medication and an increase in fracture risk has been 
reported (Vestergaard, Rejnmark and Mosekilde 2006), however bone mineral density 
assessment was not performed. The authors suggested that this increase in fracture risk 
was possibly related to the risk of falls due to the central nervous system side effect of 
dizziness caused by oral opioids. Opioid induced dizziness is less likely to occur in IDD 
patients since only a fraction of the opioid delivered via intrathecal route reaches the brain. 
Low bone mass is an important component of the risk of fracture as well as non-skeletal 
factors such as propensity to fall (Center et al., 2000; Kanis 2002). Many fragility fractures 
occur in the absence of osteoporosis, although in the presence of this disease, the risk of 
fracture is higher (Kanis et al., 1994). Osteoporotic fractures are a significant cause of 
morbidity and mortality especially in the developed countries (Johnell and Kanis 2006), and 
are associated with increased mortality, particularly in men (Center et al., 1999). 
 
The assumption that hypogonadism is a risk factor for decreased BMD is not always 
confirmed. No association between age-related hypogonadism (based on total testosterone) 
and decreased BMD was found in elderly men (Amin et al., 2000). In contrast, free 
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testosterone (calculated according to the Vermeulen equation (Vermeulen, Verdonck and 
Kaufman 1999)) was demonstrated to be an independent predictor of BMD and fractures in 
elderly men (Mellström et al., 2006) and a positive predictor of cortical bone size in young 
men at the age of peak bone mass (Lorentzon et al., 2005). These contradictory findings 
may have occurred because free testosterone is more important physiologically than 
testosterone. Sex hormone binding globulin levels, which generally are genetically 
determined, seem to play an important role in bone mass density, hence the reason for free 
testosterone to be a stronger predictor than total testosterone alone. Recently it has been 
demonstrated that SHBG levels in healthy adult men at the age of peak bone mass were 
positively associated with cortical bone size independently of sex-steroid levels 
(Vanbillemont et al., 2010). However, in middle aged and elderly men, SHBG elevation was 
significantly associated with the occurrence of osteoporotic fractures (Hoppé et al., 2010; 
Legrand et al., 2001; Lormeau et al., 2004). Although not yet confirmed, it has been 
suggested that the effect of SHBG on BMD may change with age and/or testosterone 
sufficiency or deficiency (Khosla 2006). 
 
The limitations of this study need to be acknowledged. A small number of participants were 
included without a control group and bone mineral density assessment was not performed 
prior to commencement of intrathecal opioid therapy. Female patients were not included in 
the study. A large meta-analysis, which included approximately 39,000 men and women has 
concluded that the age-specific risk of hip fracture is similar in both men and women with the 
same BMD and age (Johnell et al., 2005). Despite these limitations, the high prevalence of 
decreased BMD suggests that the IDD population may have an increased risk for 
osteoporotic fractures. 
 
It is important to provide adequate treatment to patients with low bone mass density. The 
presence of either osteopaenia or osteoporosis suggests that intervention is appropriate to 
avoid their consequences (Kanis 1990). BMD can be normalized and maintained within the 
normal range in men with either primary or secondary hypogonadism by continuous, long-
term hormonal replacement therapy (Behre et al., 1997; Katznelson et al., 1996; Leifke et 
al., 1998). The full effect of testosterone replacement therapy on BMD has been reported to 
take up to 24 months (Snyder et al., 2000). 
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2.5.6 Conclusion 
This study suggests an association between hypogonadism and low bone mass density in 
patients undertaking intrathecal opioid delivery for the management of chronic non-
malignant pain. Early detection of hypogonadism followed by appropriate treatment may be 
paramount to reduce the risk of osteoporosis development and prevention of fractures in this 
population. Furthermore, surveillance of BMD levels in hypogonadal intrathecal opioid 
delivery patients should be performed. 
 
The following chapters of this thesis focus on the long-term effectiveness and cost 
effectiveness of IDD. After an analysis of some of the possible pharmacological 
complications it is essential to verify if this therapy is cost effective and if long-term benefits 
are discernible despite the possible complications. 
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Chapter 3 
 
 
Long-term effectiveness of intrathecal drug delivery 
 
 
A 13 year follow-up cohort study of intrathecal drug delivery therapy 
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This chapter has been accepted for publication by the Journal of Neurosurgical 
Anesthesiology; in press. Aspects of this work have been selected for oral presentation at 
the 30th Annual European Society of Regional Anaesthesia Congress, 2011. It has been 
reformatted to fit with the overall PhD thesis. 
 
3.1 Abstract 
Background 
Chronic pain of non-malignant origin requires effective long-term treatments, since for many 
patients, pain management will be necessary throughout the rest of their lives. Intrathecal 
drug delivery systems have become a recognised therapy for the management of severe 
and otherwise intractable chronic pain and their long-term outcome is particularly important. 
However, it is still not clear if this treatment can be effective for periods up to 10 years or 
longer given the paucity of long-term follow-ups. 
 
Methods 
Twenty patients participated in a longitudinal study with an average follow-up of 13.5 years 
(range: 10.4-17.9), equivalent to 271 patient years following IDD system implantation. 
Investigation was carried out through a questionnaire prior to IDD and after an average of 
four and 13 years of IDD therapy and assessment of pharmacological data and 
complications/side effects. 
 
Results 
Significant differences were identified between the three time points for the following 
sensory and psychosocial variables: pain intensity, pain relief, coping, self-efficacy, 
depression, quality of life, housework, mobility, sleep and social life (all p < 0.001). 
Beneficial changes were still visible following 13.5 years of IDDS therapy when compared 
with assessment prior to IDDS for all the variables mentioned (p < 0.005). No significant 
differences were detected between assessments at averages of four and 13.5 years. 
 
Conclusion 
This study, with one of the longest follow-up time spans reported in the IDDS literature, 
shows that IDDS has the potential to be a life-long solution in appropriately selected chronic 
non-malignant pain patients. 
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3.2 Introduction 
The current non-cancer intrathecal drug delivery literature is limited by the absence of 
randomised controlled trials (RCTs). Recent systematic reviews were unable to find RCTs 
evaluating the effectiveness of long-term IDDS for the management of chronic non-
malignant pain (Hayek et al., 2011; Noble et al., 2010; Patel et al., 2009). In appropriately 
selected patients, based on Level II-3 or Level III evidence, the recommendation for 
intrathecal infusion systems for long-term relief in chronic non-malignant pain is currently 
1C/strong, which indicates that benefits clearly outweigh the risk and burdens (Patel et al., 
2009). Although case series studies may be more prone to criticism than RCTs, they 
currently provide the best available evidence for this intervention (Noble et al., 2010). 
 
IDDS therapy may have the potential to be a life-long pain management solution for chronic 
non-cancer patients. A favorable outcome has been reported at a three year follow-up (Atli 
et al., 2010). However, it remains to be seen whether this treatment can be effective at 
periods up to 10 years or even several decades (Hassenbusch et al., 1995). Long-term 
effects of IDDS remain unclear, given the paucity of data from follow-ups longer than one 
year (Noble et al., 2010; Turner, Sears and Loeser 2007). It has been considered that before 
firm conclusions regarding this therapy can be made, it may be necessary to examine the 
outcome of this therapy for five to 10 years (Wallace and Yaksh 2000). The aim of this study 
was to investigate through a prospective approach the long-term effectiveness of IDDS 
treatment. 
 
 
3.3 Methods 
A longitudinal study with an average follow-up of 13.5 years (range: 10.4-17.9), the 
equivalent to 271 patient years following IDDS implantation was performed. Assessment 
was retrospective regarding the patients condition prior to IDDS and prospective in the 
subsequent follow-ups at an average of four years and at an average of 13 years following 
IDDS implantation. 
 
 
Participants 
A cohort of 36 consecutive patients previously described was revisited (Raphael et al., 
2002). Sixteen of the patients who completed the questionnaire in the previous study (44%) 
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were lost to follow-up. The majority (62.5%) due to death not directly related to a known 
pharmacological effect of the opioid. There is an awareness of the co-morbidities and 
pathologies that the patients suffered and developed. Recently, it has been reported that 
chronic pain patients have an increased 10 year mortality, either because of the high 
intensity of the pain and/or the associated disability irrespective of the cause of chronic pain 
(Torrance et al., 2010). The mortality rate following IDDS implantation was reported to be 
3.89% within one year and superior to the 1.36% mortality rate after spinal cord stimulation 
(SCS) implantation over the same interval (Coffey et al., 2010). The main cause of mortality 
for IDDS patients was respiratory depression due to opioid or central nervous system 
depressant drugs as a primary or contributing factor. Nevertheless, from the nine index 
cases reported by Coffey et al. (2010), seven patients received an initial intrathecal opioid 
dose that exceeded the 0.2 - 1 mg/day dose mentioned on the drug manufacturer label; two 
of the patients had a history of prescription drug abuse or overuse, and the two patients with 
an initial intrathecal opioid dose within the suggested range were obese, which may 
contribute to decreased respiratory reserve (Coffey et al., 2010). 
 
Two patients (12.5%) did not wish to participate in the study, however, these should not be 
considered as failures as IDDS therapy has not been discontinued. The remaining four 
patients (25%) continued their treatment at a different center. As this treatment cannot be 
accounted for, these patients could be regarded as treatment failures. The rate of 
discontinuation of intrathecal opioid therapy due to unsatisfactory pain relief or adverse side 
effects is lower (17%) when compared with the discontinuation rates of oral opioid (45%) or 
transdermal opioid therapy (25%) (Chapman et al., 2010). 
 
Twenty patients receiving continuous intrathecal opioid analgesics by implanted reservoir 
administration for chronic non-malignant pain at Russells Hall Hospital Pain Management 
Department, Dudley were included in the study. The sample consisted of 10 women (50%) 
and 10 men (50%) with an average age at time of last assessment of 60 ± 1.98 years 
(range: 43-79). The average duration of pain prior to IDDS implant was 9.63 ± 1.39 years 
(range: 2-26). The mean follow-up period following pump implantation was 13.5 ± 0.66 years 
(range: 10.4-17.9). The pain syndrome was nociceptive in 40% of the patients and mixed 
nociceptive-neuropathic in the remaining 60%. The topography of pain for the majority of the 
patients (85%) was the low back, mostly following failed back surgery (60%). Other 
Page | 141 
topographies included the abdomen, spine and leg. Radiating pain from the low back to the 
legs was present in 65% of the participants. 
 
A research protocol (appendix 1), patient information sheet (appendix 2) and patient consent 
form (appendix 3) were developed to submit an application for University sponsorship 
(appendix 4) and Research Ethics Committee (REC) approval (appendix 5) prior to the 
commencement of recruitment. Ethical approval was granted by Birmingham, East, North 
and Solihull Research Ethics Committee (REC reference: 08/H1206/184, appendix 5) and 
informed consent was obtained from all participants. 
 
Patients who participated in the previous assessment were approached when attending for 
follow-up (pump refill) at the hospital. The study was explained at this time and patients 
received an information form, questionnaire and patient consent form. The questionnaires 
were given to the patients to complete at their convenience. Decision whether to participate 
or not in the study was communicated by the next follow-up (between one and three 
months). Questions/concerns the patients had regarding participation were fully addressed. 
The questionnaires were returned when the patient attended for the next pump refill. All 
participants enrolled in the study read and signed a written informed consent form outlining 
the relative advantages and disadvantages to participation in the study as well as the study 
objectives. Participation was voluntary and remuneration was not offered as the results were 
dependent upon the participants’ opinion and remuneration could bias their answers. All 
patients were entitled to withdraw from the study at any time without prejudice to future care. 
 
 
Sensory and psychosocial measures 
A questionnaire (appendix 10) was completed at three different time points: baseline, 
averages of four years and 13 years of IDDS therapy. The baseline data was collected 
retrospectively following an average of four years (range: 0.5-9) of IDDS treatment. For the 
other time points, the data was collected prospectively at an average of four years and at an 
average of 13 years following IDDS implantation. Although patient recall presents a potential 
source for bias and concern, there are reports in the literature on the accuracy of pain recall 
(Morley 1993; Salovey et al., 1993) and research that found fair to moderate agreement for 
recalled versus initial reports after a mean interval of 9.4 years (Dawson et al., 2002). 
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The questionnaire comprised of sensory, psychological and sociological dimensions and 
requested comments on satisfaction about treatment. The questionnaire followed the scale 
design of the Brief Pain Inventory (BPI) pain interference items (Cleeland and Ryan 1994). 
The patients were approached to participate in the study by a non-clinical researcher not 
involved in the treatment process and the questionnaire was given to the patients to 
complete at their convenience. The questionnaires were returned when the patient attended 
for the subsequent pump refill. 
 
Pain intensity was measured through an eleven point NRS (where zero represents no pain 
and 10 represents worst possible pain) (Dworkin et al., 2005). Clinical changes were 
calculated from the NRS scores measured prior and after four years of IDDS therapy; and 
prior and after 13 years of treatment by the following method: ((NRS baseline – NRS 
endpoint) / NRS baseline) x 100 (Farrar et al., 2001). Clinically important changes were 
classified in accordance with a consensus statement that established a 10 - 20% decrease 
as minimally important, ≥ 30% as moderately important and ≥ 50% as a substantial change 
(Dworkin et al., 2008). 
 
Psychological aspects of pain were addressed by measurement of coping skills, 
dependency, depression and quality of life. Eleven point scales with zero representing no 
interference with coping ability, no dependency, no depression or no implication in quality of 
life due to pain and 10 representing maximum imaginable interference with coping ability, 
dependency, depression or quality of life due to pain. Sociological dimensions of pain were 
addressed by measurement of housework, mobility, sleep and social life. The same method 
was employed with zero representing no interference in activity due to pain and 10 
representing the utmost interference possible in activity due to pain. 
 
Five-point verbal rating scales were used to assess satisfaction about treatment (very 
unsatisfied, fairly unsatisfied, adequate, fairly satisfied or very satisfied) and perception of 
worthiness (not at all worthwhile, not very worthwhile, adequate, quite worthwhile or very 
worthwhile) (Gracely and Dubner 1987). 
 
The questionnaire has not been validated for the measurement of psychosocial variables. 
For the purpose of comparison with the previous assessments the questionnaire needed to 
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remain the same, hence the motive why validated questionnaires were not used to assess 
the psychosocial dimensions studied. 
 
 
Pharmacological data and complications 
The patients’ case notes were screened from date of implant to November 2010. Intrathecal 
drugs administered and intrathecal opioid dose (mg/day) were recorded. Yearly opioid dose 
averages were computed for each patient from the time of implant until last refill between 
June and November 2010. The intrathecal opioids administered included morphine and 
diamorphine. All patients received either morphine or diamorphine since the beginning of 
therapy. Due to concerns regarding the stability of diamorphine in the intrathecal pump, 
which could result in corrosion of the mechanism and eventual malfunction, patients were 
scheduled to have diamorphine converted to morphine (Simpson 2004). At the time the 
study was carried out, 80% per cent of the patients had already had the diamorphine 
medication converted to morphine. In individual cases, other substances were added to the 
intrathecal medication, such as bupivacaine (95%), clonidine (75%) and baclofen (30%). 
 
The intrathecal pumps used throughout duration of therapy were programmable (Medtronic 
SynchroMed) for 60% (12) of the patients and fixed rate (Medtronic Isomed or Codman) for 
15% (three) of the participants. Four (20%) of the patients had the pump changed from 
programmable to fixed rate and one (5%) from fixed rate to programmable when undertaking 
a pump replacement. 
 
Complications related with IDDS therapy identified from the case notes were recorded and 
categorized. Since initial assessment for IDDS therapy, all the patients included in the study 
attended this centre for pain management related therapies. Throughout the duration of 
treatment, when attending for a pump refill, the patients were asked if the pain was under 
control or if new symptomatology had emerged. Between follow-ups, a helpline managed by 
pain management nurses would be available for urgent situations. Information regarding 
complications, side effects or new symptoms would be recorded in the patients’ case notes. 
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Data analysis 
Means are reported as mean ± SEM. The Kolmogorov-Smirnov test was performed to test 
normality of numerical data. The majority of the numerical data was not normally distributed 
and attempts to transform the data were unsuccessful. Sensitivity analyses were performed 
to compare the results for the variables studied with parametric, non-parametric and 
bootstrap tests and no differences were observed. 
 
The results presented evaluate differences between the three periods using repeated 
measures ANOVA. To further investigate differences between the three time points, a 
Bonferroni correction was applied in order not to inflate Type I error probability and 
significance represented p < 0.016. A Bonferroni correction consists in dividing the 
significance level (0.05) by the number of tests conducted (Field 2005). Post-hoc tests were 
performed using bootstrapped paired-samples t test based on 10,000 samples (Thompson 
and Barber 2000). The bootstrap technique creates samples based on the variance of the 
existing dataset to allow analysis with more robust parametric tests. 
 
Differences between four years and 13 years follow-up involving categorical variables were 
investigated using Fishers’ exact test. Differences between four years and 13 years follow-
up involving categorical grouping variables were investigated using bootstrapped 
independent-samples t test based on 10,000 samples. Statistical significance represented p 
< 0.05 except when otherwise mentioned. Statistical tests were performed using the 
Predictive Analytics Software (PASW) (version 18.0, SPSS Inc., Chicago, IL, USA). 
 
 
3.4 Results 
Response to treatment 
IDDS therapy was considered to be very worthwhile by 90% of the patients at the last 
assessment. The perception of worthiness by the patients was not significantly different 
when compared with the four-year follow-up (p = 0.368). All of the investigated patients 
indicated that they would recommend IDD as a pain management treatment. Significant 
differences were observed between the assessments for the variables included in the Table 
3.1. Other variables presented non-significant differences between assessments, including 
ability to work (p = 0.113), sex life (p = 0.070), capacity to drive (p = 0.132) and ocurrence of 
nightmares (p = 0.337). 
Page | 145 
To further investigate these results, analyses comparing the different time points (pre-
treatment with four years post-treatment; pre-treatment with 13 years post treatment, and 
four years post-treatment with 13 years post-treatment) were carried out with significance 
representing p < 0.016 following a Bonferroni correction. 
 
Beneficial changes were observed for sensory (pain intensity, pain relief), psychological 
(coping, dependence, depression, quality of life) and social aspects (housework, mobility, 
sleep, social life) when comparing the assessments at four years and 13 years with 
evaluation prior to treatment (Table 3.2). No statistically significant differences were 
observed for the variables studied between the prospective assessments at an average of 
four years and 13 years of IDDS therapy. 
 
The average clinical change calculated from the NRS scores after four years of IDDS 
therapy was 43.40 ± 5.46% with 25% of the patients obtaining between ≥ 10% and < 30% 
decrease, whereas 30% of the participants achieved between ≥ 30% and < 50% decrease 
and 40% of the subjects attained ≥ 50% decrease. Thirteen years following treatment the 
average clinical change relative to NRS scores prior to treatment was 37.91 ± 5.44% 
including 20% of the participants with ≥ 10% and < 30% decrease, 20% obtaining ≥ 30% 
and < 50% decrease and 55% achieving ≥ 50% decrease. No statistically significant 
differences were observed between the clinical change after four years and the clinical 
change subsequent to 13 years of IDDS treatment (p = 0.460). Patient gender did not seem 
to contribute to clinical change obtained either at four years (p = 0.225) or 13 years of 
therapy, (p = 0.693). 
 
Following an average of 13 years of IDDS therapy, 90% of the patients continued to be very 
satisfied with the treatment. No significant differences were observed for satisfaction 
between the prospective assessments (p = 0.822). No differences in the variables studied 
were observed between patients with nociceptive pain and those with mixed nociceptive-
neuropathic pain (p > 0.05). 
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Pharmacological data 
The mean opioid dose throughout duration of treatment was 3.93 ± 0.56 mg/day (range: 
1.21 – 10.78) and ranged from 0.55 ± 0.06 mg/day (range: 0.2 – 1) at baseline, to 4.81 ± 
0.78 mg/day (range: 1.23 – 12.02) at year 13 (Figure 3.1). An opioid dose greater than 10 
mg/day was administered to only one patient. 
 
The dose administered at baseline was not associated with the average dose at year one. 
From year one onwards, every yearly mean intrathecal opioid dose was significantly 
correlated with the following year. The weakest correlation verified occurred between year 
one and year two, r = 0.648, p < 0.05. Following that year, all correlations were significant at 
p < 0.01. From year three onwards the intrathecal opioid dose did not increase significantly 
when compared with the subsequent year (p > 0.05). This indicates some opioid dose 
stability following year three of therapy. 
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No evidence of opioid addiction or abuse was observed in the investigated patients. No 
significant associations were identified between the percentage of clinical change and the 
intrathecal opioid dose (p > 0.05). No differences were observed when analyzing intrathecal 
opioid dose differences taking into consideration patients’ gender (p > 0.05) or type of pain 
(p > 0.05). 
 
 
Complications/side effects 
Complications were assessed retrospectively from the patients’ notes (Table 3.3). These 
included acute pharmacological side effects such as respiratory depression, 
nausea/vomiting, drowsiness, and a case of drug overdose secondary to catheter fracture. 
In all these situations, the side effects resolved either with time or medication. No intrathecal 
devices in this sample were discontinued due to the occurrence of pharmacological side 
effects. The most frequent complications were related with the equipment, either pump or 
catheter with a rate of events per patient year equivalent to 0.0592. Fracture or blockage of 
the catheter or pump failure was responsible for 53.32% of the complications identified. 
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Throughout the study period an average of 2.05 ± 0.18 pump replacements (range: 1-3) 
were performed at a mean follow-up period of 4.95 ± 0.39 years (range: 3-9) for the first 
replacement, 9.86 ± 0.67 years (range: 7-16) for the second replacement and 14.43 ± 0.89 
years (range: 11-17) for a third replacement. 
 
Although no intrathecal inflammatory masses were diagnosed in this sample, 25% of the 
patients presented clear changes in their pain, including new symptoms. Current 
recommendations suggest that if new pain symptoms are observed alongside clear changes 
in intrathecal medication requirements, a MRI or as an alternative a computed tomography 
myelogram should follow (Deer et al., 2008a). Following investigation through MRI scan, no 
intrathecal granulomas were detected. 
 
 
3.5 Discussion 
The clinical change suggested at least minimally important changes for 95% of the 
participants at both follow-ups. The absence of statistically significant differences regarding 
pain intensity reduction between pain syndromes is in agreement with previous studies 
(Winkelmüller and Winkelmüller 1996). Intrathecal opioids were effective in reducing pain 
intensity even after an average of 13 years following initiation of therapy. It is known that 
there is a reduction in pain relief with the passage of time (Kumar, Kelly and Pirlot 2001). 
Although a small increase in pain intensity was observed at the 13 year follow-up, when 
compared with assessment at four years, this was not statistically or clinically significant, 
suggesting stability of this therapy, which is one of the important findings of this study. Even 
after 13 years, the patients’ pain intensity was significantly lower when compared with the 
assessment prior to IDDS therapy. 
 
Improvements in the psychosocial variables studied were observed between assessments 
at baseline and four years. Moreover, these improvements were maintained at the last 
follow-up since statistically significant differences were not observed for these variables 
between the four year follow-up and the last follow-up. A cure for pain in patients 
undertaking IDDS is unlikely, therefore, one of the most important outcomes for these 
patients is improvement in quality of life. Quality of life significantly improved after IDDS and 
did not change significantly when the four year follow-up and last follow-up were compared 
despite the long treatment duration in this sample. Significant improvements in activity 
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levels, depression and quality of life following implantation of IDDS are consistent with 
previous reports (Kumar, Kelly and Pirlot 2001; Paice, Penn and Shott 1996; Thimineur, 
Kravitz and Vodapally 2004; Winkelmüller and Winkelmüller 1996). 
 
The rate of complications was equivalent to 0.111 events per patient year. The 
pharmacological side effects observed are consistent with available literature (Chaney 1995; 
Kumar, Kelly and Pirlot 2001; Ruan 2007; Winkelmüller and Winkelmüller 1996). Acute side 
effects such as nausea, vomiting, dizziness or itching are more common after 
commencement of the therapy and usually resolve with standard medical management 
during the initial three months (Anderson and Burchiel 1999). Decreased libido was reported 
by one male patient, although this side effect was probably underreported in this study. The 
possible effect of IDDS on the endocrine system is one of the least noted and investigated 
IDDS side effects (Doleys et al., 1998). This occurs, mainly because the signs and 
symptoms of hypogonadism such as decreased libido, tiredness, loss of muscle mass and 
strength, among others may be attributed to the chronic pain and its related conditions (Katz 
and Mazer 2009). An investigation of the endocrine consequences of long-term IDDS 
reported that the large majority of men and women involved in the study developed 
hypogonadotropic hypogonadism (Abs et al., 2000). None of the patients included in this 
study was diagnosed with intrathecal granulomas. However, the number of events per 
patient year at this centre has been reported to be 0.009 (Duarte et al., 2010). 
 
Despite the side effects and complications identified, the majority of patients (90%) revealed 
satisfaction with the treatment and considered IDDS to be worthwhile. Similar results were 
obtained by Winkelmüller and Winkelmüller (1996) where 92% of the patients included in the 
study were satisfied with the therapy. 
 
In this sample, a slow increase in opioid dose was needed to maintain adequate pain 
control. Statistically significant increases were observed on a yearly basis from baseline up 
to year three, but the intrathecal opioid dose increase ceased to be significant from the third 
year onwards. Adjuvant intrathecal medication was added to 95% of the patients, which in 
conjunction with responsible follow-up treatment may have contributed to the low dose of 
intrathecal opioids administered. The addition of intrathecal bupivacaine has been effective 
in keeping a low intrathecal morphine dose in the treatment of cancer pain, as well as 
preventing the potential side effects of high doses of intrathecal morphine (Sjöberg et al., 
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1994; van Dongen, Crul and De Bock 1993). The average intrathecal dose throughout the 
duration of therapy of 3.93 mg/day was lower than previous reports. The highest average 
intrathecal opioid dose of 4.81 mg/day was observed at year 13. The opioid doses in this 
centre were lower than previously reported average doses of 7.42 mg/day at 29.14 months 
(Kumar, Kelly and Pirlot 2001); 9.6 mg/day at year one (Paice, Penn and Shott 1996), and 
12.2 mg/day at year three (Atli et al., 2010). An approximate opioid dose of 4.7 mg/day has 
been reported, although at an average of 3.4 years (Winkelmüller and Winkelmüller 1996). 
Morphine doses may stabilize for long periods and when dose escalation occurs is usually 
due to tolerance, progress of the disease (Bennett et al., 2000) or opioid induced 
hyperalgesia (Angst and Clark 2006; Chu, Angst and Clark 2008). A failure to identify the 
occurrence of a granuloma can also lead to a possible diagnosis of tolerance (Bejjani, Karim 
and Tzortzidis 1997). 
 
No significant differences or correlations were observed for the level of opioid dose and type 
of pain, pain intensity or percentage of clinical change. This is in conformity with previous 
studies (Kumar, Kelly and Pirlot 2001; Winkelmüller and Winkelmüller 1996). 
 
An average of two pump replacements was verified in this sample. An important addition to 
the selection of intrathecal pump devices available would be the development of a 
rechargeable programmable pump. This could have the potential to reduce the number of 
replacement surgeries, thus increasing cost-effectiveness and reducing interference with the 
treatment plan. 
 
It is important to note the limitations of this study. The sample size was relatively small and a 
control group was not included. For a last option treatment for severe pain it is challenging to 
find a comparative group, especially for a long-term study. Oral opioid medication was not 
collected from the notes. At RHH Pain Management Department rescue oral opioid 
medication has been provided to the patients on an individual basis for occasional flare-ups. 
The average duration of pain prior to IDDS was 9.63 years. Prior to implantation of IDDS all 
of these patients have tried and failed more conservative treatments, including oral opioid 
medication, with little or no benefit or unbearable side effects. The effective rescue 
medication dose is a fraction of the effective intrathecal dose. Hence, systemic medication, 
as well as other interventions that might have been undertaken during the study period, 
would have been sporadically provided to cope with flare-ups and would, therefore, have 
Page | 152 
limited impact in the results verified. Providing additional oral medication to patients may 
improve their psychological well being as well as an improvement in effective pain control; 
however there is no evidence of a correlation between reduction in pain intensity and the 
intake of additional oral medication (Kumar, Kelly and Pirlot 2001; Winkelmüller and 
Winkelmüller 1996). 
 
 
3.6 Conclusion 
Improvements were observed in sensory, sociological and psychological outcomes. These 
multidimensional benefits remained stable after 13.5 years of IDDS therapy, substantiating 
the effectiveness of IDDS therapy. In appropriately selected chronic non-malignant pain 
patients, IDDS has the potential to be a life-long solution and should be considered, as the 
advantages of IDDS clearly outweigh the disadvantages. Patients being considered for an 
IDDS should be informed of the potential side effects and complications derived from this 
therapy. When other pain management treatment options have been considered and failed, 
the age of the patient should not be an obstacle to IDDS as the rate of complications, side 
effects and the increase of opioid dose may not be substantial when compared with the 
possible benefits of this therapy. Long-term benefits from this treatment are not necessarily 
related to exaggerated intrathecal opioid doses. To our knowledge, this study represents 
one of the longest follow-up time spans reported in the IDDS literature. 
 
The following chapter of this thesis evaluates the cost effectiveness of intrathecal drug 
delivery systems based on real patient data and investigates the existence of a period with 
potential impact in QALY analysis. 
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Chapter 4 
 
 
Cost effectiveness of intrathecal drug delivery 
 
 
Influence of a latent period in the cost effectiveness of intrathecal drug delivery systems 
for chronic non-malignant pain 
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This chapter has been published in the British Journal of Neurosurgery 2011;25(3):401-406 
(appendix 11). Aspects of this work have been published as two separate abstracts in the 
journals Pain Practice (Appendix 12) and Regional Anesthesia & Pain Medicine (Appendix 
13). It has been reformatted to fit with the overall PhD thesis. 
 
4.1 Abstract 
Background 
Previous studies have considered IDDS to be a cost effective pain management therapy for 
chronic non-malignant pain. The period of time between being placed on a waiting list for 
IDDS and the implant (latent period) has not been taken into consideration for cost 
effectiveness analysis. The aim of this study was to investigate the influence of a latent 
(waiting) period when assessing cost effectiveness of IDDS. 
 
Design 
A retrospective longitudinal analysis of all pain related costs for a period of not less than four 
years was undertaken by assessment of medical records. The total cost of patient care for 
two years before latent period, the latent period itself and two years after the implant of an 
IDDS was computed, according to the NHS tariff. An EQ-5D questionnaire was completed 
by all participants before and after IDDS implant. Total costs were converted to cost per day 
for comparison with latent period. 
 
Results 
The sample consisted of five males and seven females with a mean age at the time of 
implant of 54 ± 10.59 years. The average duration of the latent period was 263 ± 176 days. 
The cost of conventional treatments during the pre-implant phase, excluding the latent 
period, was significantly higher (M=£5,005.86, SE=£918.56) compared with the costs of the 
same phase including the latent period (M=£4,086.35, SE=£959.09, t(11) = 2.23, p = 0.05, r 
= 0.56). The cost per day changed significantly over the different periods (χ2(2) = 24.00, p< 
0.05). 
 
Conclusion 
The variability and significantly inferior costs of the latent period may influence cost 
effectiveness evaluations and consequently decision making if not considered. Further 
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studies analysing the influence of a latent period on the cost effectiveness of other 
treatments are warranted. 
 
 
4.2 Introduction 
There are several forms of economic evaluation and it is important to define each of the 
possible methods. All the types of economic evaluations include a measurement of costs in 
monetary units. The differences occur in the measurement of the effects of a treatment, how 
this is reported and if the costs of an intervention are compared with an alternative (Table 
4.1). A full economic evaluation compares two or more health interventions and considers 
both costs and effects; partial economic evaluations consider either costs and/or effects but 
do not involve a comparison with an alternative intervention or do not relate costs with 
effects (Drummond et al., 2005). 
 
In cost minimisation analysis there is a comparison of two or more alternatives where the 
effect of the interventions is assumed to be equal; therefore the least costly is the more 
efficient. This differs from cost effectiveness analysis since this method does not assume the 
intervention effects to be equal. Consequences of different interventions are measured using 
a single outcome such as cost per pain-free day. Cost utility analysis is similar to cost 
effectiveness analysis except that the outcome is measured in utility measures such as 
quality adjusted life years. Cost utility analysis is the approach required by the National 
Institute for Health and Clinical Excellence (NICE) to determine the relative cost 
effectiveness of health interventions (Phillips 2009a). In cost benefit analysis, the total 
expected costs are weighed against the total expected benefits of an intervention, including 
return to work. Since all the costs and consequences or benefits are expressed in monetary 
units, this implies the estimation of monetary values associated to direct health benefits, 
such as pain relief, and indirect benefits, such as productivity gains. 
 
Cost analysis or cost comparison, albeit considered partial economic evaluations, also 
compares an intervention with an alternative but does not take into account the effects. This 
type of economic evaluation is similar to cost minimisation analysis where the effects are not 
measured, but assumed to be the same. Cost description consists of an examination of the 
costs of a single intervention. Cost outcome description considers both costs and 
consequences but no comparison is made with an alternative intervention. 
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The cost effectiveness of a treatment is an important factor in decision making in the United 
Kingdom. The UK National Institute for Health and Clinical Excellence considers as 
acceptable cost effectiveness a range of £20,000-£30,000 per Quality Adjusted Life Year 
(QALY) (National Institute for Health and Clinical Excellence 2008). 
 
Excluding the management of critical/emergency situations, most health care treatments 
involve an uneven waiting time for the patient between decision and procedure. During this 
stage, which was named as the ‘latent’ period, health care interventions may be absent as 
the patient is awaiting a determined treatment. The latent period was identified while working 
on the cost effectiveness of IDDS treatment for the management of chronic non-malignant 
pain. It was noticed that after a patient had undergone all the possible conventional 
treatments short of IDDS for pain management and the decision to use IDDS had been 
taken, changes were evident. At the point of being told that an IDDS was going to be 
implanted, both the attitude of the patient and the treating clinician changed. The patient was 
on a holding phase, a latent period. 
 
There are limited patient based studies investigating the cost effectiveness of IDDS 
compared with more conventional therapies (Anderson, Burchiel and Cooke 2003; Kumar, 
Hunter and Demeria 2002). These studies limited the time horizon of the assessment of cost 
and outcome to that of the study. An alternative to this method is to use a computer-
generated cohort of patients based on best and worst case scenarios (de Lissovoy et al., 
1997; Hassenbusch et al., 1997). These studies extrapolate the cost and outcome findings 
to the lifetime of the patient. All these studies have considered IDDS to be cost effective. 
 
None of the mentioned studies took into consideration the above-mentioned latent period. 
The objective of this study was to evaluate whether the latent period has a significant 
influence on QALY calculations and therefore the cost effectiveness analyses of IDDS. 
 
 
4.3 Review of the literature 
A hand search of reference lists of relevant articles and systematic reviews was carried out. 
Studies where an economic evaluation of IDD for the management of chronic non-malignant 
pain was completed were included in the review (Table 4.2). The effects and cost outcomes 
of the included studies are presented in Table 4.3. 
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Studies were excluded if both cancer pain patients and non-cancer pain patients were 
investigated without costs being differentiated between these conditions (Bedder, Burchiel 
and Larson 1991); the article was a review and not an economic assessment (Nguyen and 
Hassenbusch 2004); the article was a review article including a computer-generated model 
but for cancer pain patients (Hassenbusch et al., 1997); the article was a review including 
the results of two unpublished economic evaluations but did not provide enough detail 
(Mueller-Schwefe, Hassenbusch and Reig 1999). The economic evaluations reported in the 
Mueller-Schwefe, Hassenbusch and Reig (1999) review were not included in Table 4.2 or 
4.3 because of lack of detail provided. Nevertheless, a synthesis of the analysis is presented 
below. 
 
 
Mueller-Schwefe, Hassenbusch and Reig (1999) 
This review of IDD cost effectiveness included two different cost analyses. A cost analysis 
comparing the costs of intrathecal pumps with oral morphine therapy was performed. The 
report comprised 12 IDD patients followed over a period between 10 to 14 years. The daily 
cost of intrathecal morphine therapy including the costs of surgery, the implantable system, 
morphine, refill kit and treatment was significantly less than the costs of oral morphine 
therapy. However, the costs of oral therapy were based on estimations. 
 
The other cost analysis presented within this review compared intrathecal morphine and 
clonidine with an equivalent dose of sustained-release oral morphine. The analysis was 
based on estimates for both therapies and concluded that after one year of therapy, the cost 
of IDD was approximately one third that of oral medication therapy. 
 
 
de Lissovoy et al. (1997) 
A computer-generated model deriving cost calculations based on expected resource use 
and published diagnostic and therapeutic protocols was developed. A large (n = 1000) 
simulated cohort was projected throughout the estimated time span of the pump battery life 
(36 to 60 months). This model focused on chronic pain as a result of failed back surgery 
syndrome. 
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A model can only be as good as the information used to create it. Taking into consideration 
that the authors created a model for the duration of a pump battery life between 36 to 60 
months, it is important to verify the follow-up period of the studies used to obtain 
effectiveness and complications information. The rates of adverse events were based on 
three studies with the following average follow-up periods: one month (Hassenbusch et al. 
1990), 14.6 ± 0.57 months (range 8 – 94 months) (Paice, Penn and Shott 1996) and 27.8 
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months (range 5 – 47) (Krames and Lanning 1993). It was also noticed that one of the 
studies (Hassenbusch et al., 1990) was examining epidural and not intrathecal 
administration. 
 
The effectiveness of IDD was assessed through the percentage of patients reporting good or 
excellent pain relief in two different studies. In one of the studies, 81% reported good to 
excellent pain relief (Krames and Lanning 1993), while in the other study only 65% of the 
patients reported the same amount of pain relief (Auld, Maki-Jokela and Murdoch 1985). 
The intraspinal route of delivery was epidural and not intrathecal in the Auld, Maki-Jokela 
and Murdoch (1985) study. Incremental cost ratios were calculated regarding a base case 
(average pain relief of the two studies), best case (Krames and Lanning 1993) and worst 
case (Auld, Maki-Jokela and Murdoch 1985). 
 
Although it was stated that the model was focused on chronic intractable pain attributed to 
failed back surgery syndrome, none of the studies used to structure the model were 
exclusively exploring this condition. 
 
Charges for alternative pain management therapies were defined for a 60-month period 
based on a representative pattern of care. The authors acknowledged the non-existence of 
published reports describing the history of patients with intractable pain or their health 
expenditures over time. 
 
According to the developed model, in the base case scenario, the cumulative cost of IDD 
may be less than alternative pain management after 22 months; in the best case after 11 
months; and in the worst case scenario alternative therapy would always be less expensive 
than IDD. 
 
 
Kumar, Hunter and Demeria (2002) 
A comparison of IDD with more conventional therapies was carried out using real patients 
with actual cost data; in contrast with the de Lissovoy et al. (1997) study which used a 
computer-generated model. The study sample consisted of 88 patients with chronic low 
back pain as a result of failed back surgery syndrome who did not obtain adequate pain 
relief during a SCS trial. The patients were randomly assigned into either an IDD trial group 
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or conventional pain therapies group. The groups were initially equally distributed and 
matched for age, gender and number of operations undertaken prior to initiation of the study. 
The randomisation process is not clearly described by the authors. From the patients 
assigned to the IDD trial group, 21 patients were excluded from the study and did not 
proceed to IDD implantation due to poor response (pain relief < 50%), undesirable side 
effects or unwillingness to accept the procedure. 
 
The authors used the Oswestry Disability Index (Fairbank and Pynsent 2000) and the VAS 
(Jensen, Karoly and Braver 1986) to measure effects of the therapies. The patients in the 
IDD group reported a five- year average improvement of 27% in disability, compared to the 
12% reported by the conventional pain therapies group. The average five-year pain relief 
score as measured by the VAS was 61 ± 5.2%. No pain relief scores were presented for the 
patients in the conventional pain therapies group. In the abstract and methods it is stated 
that the impact of IDD on quality of life would be analysed prior to implantation and for each 
year subsequent to beginning of therapy. However, the authors did not relate the costs with 
the effects. 
 
There are also some statements that may lead the reader to question if the five-year costs 
are actual costs or estimations. An example is the following statement: “costs of 
pharmacotherapy for each patient were calculated according to the Saskatchewan Health 
Formulary, allowing a predetermined government-approved pharmacist mark-up schedule 
and a flat rate for dispensing according to pharmaceutical standards. From this we 
calculated a monthly and subsequently yearly cost, which was then extrapolated to a five-
year period” (Kumar, Hunter and Demeria 2002). Pump replacement costs can also be 
questioned. It seems that all patients only required one inpatient day stay for replacement 
when the authors justification for the 6.24 days average as inpatient for implantation was: 
“the length of hospitalisation in this province is longer because of its socialised pattern of 
medicine, sparse population, obliging the patient to travel up to 1,000 miles for this type of 
treatment, and lack of supportive infrastructure” (Kumar, Hunter and Demeria 2002). 
 
The authors also mention that based on their experience with IDD patients, an escalation of 
the intrathecal medication dose would result in an increase in maintenance costs of $120 
per year. However, in table 5 of the manuscript (Figure 4.1), years two, three, and four of 
IDD therapy are all reported to have a cost of $1,055 indicating a plateau and not an 
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increase of $120 per year. The non inclusion of trial costs is another limitation of this study 
as well as the lack of rationale for placing all the complications in the costs of year one or 
the pump replacements in the costs of year five, even though the authors reported 
replacements at year four both in best and worst case scenarios. 
 
 
Anderson, Burchiel and Cooke (2003) 
This study proposed to compare in a randomised, prospective manner, the safety and cost 
of continuous epidural infusion with intrathecal injection when employed during trial for IDD 
patient selection. Moreover, the authors tried to identify the prognostic value of intrathecal 
and epidural trial defined in terms of the proportion of patients in each group who had at 
least 50% pain relief following six months of IDD therapy. From the initial 86 consecutive 
patients, only 37 patients were enrolled in the study. Eighteen patients were excluded 
because details of psychological evaluation were not available at the time of screening; the 
surgical team planned to conduct the trial with opioids other than morphine (n = 4); the 
patient decided to pursue treatment options other than IDD (n = 4); the planned 
management of infusion system would be performed at a remote clinic (n = 2); the patient 
declined randomisation (n = 18); or coverage was refused by the insurer (n = 3). 
 
For the trial to be considered successful, at least 50% pain relief was required on two 
consecutive ratings using a 0-10 numerical analogue scale. Six patients had failed 
intrathecal injection trial and four patients failed epidural infusion trial, resulting in 27 patients 
that proceeded to IDD implantation. Three of these patients did not provide complete study 
data during the six months of study period. 
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Follow-up data was collected at three and six months after implantation of IDD and patients 
were asked to rate the extent of pain relief, present pain and perceived benefit on a scale of 
zero (worst) to five (best). Patients were asked to record the systemic medication use at 
each follow-up, quantify health care use and to rate the severity of common opioid related 
side effects on a scale of zero (none) to three (severe). There were no significant differences 
in outcome following implantation between the trial groups. 
 
The economic evaluation of this study consisted of a comparison of the costs of intrathecal 
injection with epidural infusion. The costs of the trial with epidural infusion were significantly 
higher than that required for the intrathecal injection trial with no difference observed in the 
outcome at the six month follow-up. 
 
 
4.4 Methods 
Subjects 
Twelve consecutive patients who filled the EQ-5D before and one year after having an IDDS 
fitted for chronic non-malignant pain relief at RHH. All patients were selected from the same 
pain management department. Informed consent was obtained from the patients to examine 
their hospital records and GP notes throughout the identified study period. 
 
 
Data collection 
Information previous to decision for IDDS surgery, latent period (which varied in length from 
patient to patient) and after IDDS implant was assembled, allowing for a study period of at 
least four years. GP notes were screened and taken into consideration to be included in the 
analysis; however, due to difficulties in identifying which treatments/medications prescribed 
were related to the pain pathology, these costs were excluded. 
 
After identifying the implant date for each patient, the date they were informed of suitability 
for IDDS implant and placed on the waiting list (taken to be the same date and in most 
cases recorded as such) was verified. A two year period prior to the date they were informed 
of the implant was then established as well as a period of two years after the date of the 
implant. The period of time between being placed on the waiting list and the date of the 
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actual implant was identified as the latent period. Cost effectiveness of IDDS was assessed 
using the period before implant both including and excluding the latent period. 
Within each period of study, for each patient, all operative and injection treatments, 
investigations, drugs and consultations related to pain management were identified. Drugs 
were costed in agreement with the British National Formulary (BNF) 57 (Joint Formulary 
Committee 2009). Treatments and appointments were checked against the RHH Finance 
Department records for accuracy and then costed according to the NHS tariff using Health 
Resource Group (HRG) codes for the year 2009. All prices were adjusted to their value in 
the year 2009 and estimated using British Pounds Sterling. 
 
The total costs for each identified period were calculated. As the latent period varied from 
patient to patient, the costs were converted to an average daily cost for the purpose of 
comparison of the latent period with the pre and post IDDS implant periods. 
 
 
EQ-5D and QALY 
Each patient had filled in an EQ-5D questionnaire prior to the IDDS being implanted. The 
patients then repeated this exercise with a second EQ-5D questionnaire one year after the 
IDDS was fitted. This allowed for a comparison to be made regarding the patient’s perceived 
health state before and after the implantation of the IDDS. 
 
The EQ-5D questionnaire is a validated measure of the outcome of health care and is 
applicable to a wide range of health conditions (Rabin and de Charro 2001). It is designed to 
complement condition specific measures and allows the collection of data for comparative 
purposes. It provides both a compact, descriptive profile and a single index value which may 
be used in the calculation of clinical and economic health care. The EQ-5D allows a self-
description of health related quality of life to be recorded (Rabin and de Charro 2001). 
 
The QALY is an outcome measure that takes into account, both the quantity and quality of 
the extra life provided by a healthcare intervention. It is the numerical, arithmetic product of 
the life expectancy and also the quality of life for the remaining years. The quantity is fairly 
easy to calculate but the quality, which is much more difficult to assess, can be measured by 
quality of life questionnaires such as the EQ-5D. The cost per QALY allows for different 
treatments to be compared and measured in a common unit. 
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Data analysis 
The Kolmogorov-Smirnov test was performed to test normality of numerical data. EQ-5D 
data was compared using Wilcoxon’s Signed Rank Test. The analysis of cost data should be 
carried out with either parametric (if the data is normally distributed) or bootstrapping 
methods (Thompson and Barber 2000). The mean costs of treatment pre-implant (including 
latent period) and pre-implant (excluding latent period) were compared by using Student’s t 
test and standard confidence intervals. As the data was not normally distributed, these 
results were analysed with a non-parametric bootstrap method (Thompson and Barber 
2000). All confidence intervals were estimated at the 95% level with bias corrected and 
accelerated. 
 
In order to allow comparison of pre-implant and post implant with the latent period, all values 
were converted to a cost per day and initially compared using Friedman’s ANOVA. A 
Bonferroni correction was used with p ≤ 0.016 considered as significant for comparisons 
between the three different periods and Student’s t test with non-parametric bootstrap 
carried out. Statistical significance represented p ≤ 0.05 except when otherwise mentioned. 
Statistical tests were performed using the Predictive Analytics Software (PASW) (version 
18.0, SPSS Inc., Chicago, IL, USA). 
 
 
4.5 Results 
The sample was comprised of seven females (58.3%) and five males (41.7%) with a mean 
age at time of implant of 54 ± 10.59 years (range 41-71). The average duration of painful 
symptoms prior to implant was 14 ± 6.6 years (range 4-23). The mean duration of the latent 
period was 263 ± 176 days (range 3-489). 
 
The mean EQ-5D value prior to IDDS was 0.3341 ± 0.1763 (range 0.1-0.7) and following 
implant was 0.6458 ± 0.1389 (range 0.4-0.8). EQ-5D levels were significantly higher 
subsequent to IDDS implant (Mdn = 0.675) than before implant (Mdn = 0.300), z=-2.907, p < 
0.005, r = -0.59 (Figure 4.2). 
 
The mean cost per year of conventional treatments prior to the latent period (pre-implant 1) 
with 95% confidence intervals was £5,005.86 (£3,384.04-£6,924.88); the mean cost per year 
of conventional treatments including the latent period (pre-implant 2) was £4,086.35 
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(£2,331.51-£6,282.71); for the initial two years, the mean cost per year of IDDS, was 
£13,134.85 (£10,778.82-£15,726.56). 
 
Table 4.4 shows that IDDS treatment, including implant, costs £8,128.99 more than 
conventional treatments but results in an extra 0.3117 QALYs, the equivalent to 114 days of 
perfect health. 
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The extra cost to gain one additional QALY, or in other words, the incremental cost per 
QALY for IDDS versus conventional treatments, not including the latent period, is 
£26,079.54. 
Using the same process including the latent period, it is possible to observe that the average 
cost per QALY of conventional management of pain decreases, and as a result the 
difference and the incremental cost per QALY of IDDS versus more conservative treatments 
increases (Table 4.5). 
 
 
 
On average, the cost of conventional treatments during the pre-implant phase excluding the 
latent period (pre-implant 1) was significantly higher (M = £5,005.86, SE = £918.56) 
compared with the costs of the same phase including the latent period (pre-implant 2) (M = 
£4,086.35, SE = £959.09, t (11) = 2.23, p = 0.05, r = 0.56). 
 
The mean cost per day of conventional treatments (pre-implant 1) with 95% confidence 
intervals was £13.71 (£9.36-£18.77), for the plateau period was £1 (£0.42-£1.69) and for the 
post-implant was £35.99 (£29.26-£43.69). 
 
The cost per day changed significantly over the different periods (χ2(2) = 24.00, p < 0.05) 
(Figure 4.3). 
 
Student’s t tests with non-parametric bootstrap were used to follow up this finding. A 
Bonferroni correction was applied, so all effects are reported at a 0.0167 level of significance 
(Table 4.6). 
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The cost per day changed significantly from pre-implant to latent period, from pre-implant to 
post-implant and from latent period to post implant. 
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4.6 Discussion 
The cost effectiveness of IDDS was attested even when the latent period (where costs are 
significantly lessened) was not taken into consideration. However, if the duration of the 
latent period had been longer for some patients, the cost effectiveness range of £20,000-
£30,000 per QALY considered by NICE as acceptable would have been surpassed. 
 
Cost effectiveness was confirmed at a two year follow-up, including all the resultant costs of 
surgery and intrathecal pump. IDDS has shown to have inferior cumulative costs compared 
to conventional pain treatments for failed back syndrome during a five-year period (Kumar, 
Hunter and Demeria 2002). Following the high initial cost of equipment required for IDDS 
treatment, conservative treatments became more expensive during the follow-up period 
(Kumar, Hunter and Demeria 2002). 
 
Although in this study the average cost per QALY was superior for IDDS treatment it did 
result in an extra 114 days of perfect health. The significant differences verified in the EQ-5D 
values demonstrate that the patients receiving IDDS perceive an improvement in their health 
state when compared to the period where more conventional treatments were administered. 
One of the most significant comparisons was that of the QALY cost with the latent period 
included for each patient against the QALY cost with the latent period removed, showing the 
effect of the latent period on any subsequent QALY calculations. QALYs provide an 
indication of the benefits gained from medical procedures, in terms of quality of life, 
however, suffers from a lack of sensitivity when comparing the efficacy of two similar drugs 
and in the treatment of less severe health problems (Phillips 2009b). 
 
Long-term psychosocial benefits have been reported in the literature (Raphael et al., 2002; 
Winkelmüller and Winkelmüller 1996). Change in work status however, may not change. 
Retired individuals or patients who have been off work for more than three years prior to 
IDDS are unlikely to return to work regardless of pain relief (Anderson and Burchiel 1999; 
Kumar, Kelly and Pirlot 2001; Paice, Penn and Shott 1996). 
 
The inclusion of GP costs would only increase the value of the costs prior to implant. After 
IDDS implantation all pain related treatments would be acknowledged in the hospital 
records, whose costs were all taken into account. Including GP costs in the analysis would 
increase the cost effectiveness of IDDS. The majority of medication used for pain 
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management purposes is relatively inexpensive. There are however some exceptions. 
Considering these exceptions, in the event that even half of the sample was undertaking 
expensive analgesic medication, this would have a significant impact on the costs pre-
treatment, therefore further increasing the cost-effectiveness of IDDS. 
 
The confirmation of statistically significant differences between the costs prior to 
implantation including and excluding the latent period, and the changes between pre-
implant, latent and post-implant further corroborates the importance of taking this time span 
into consideration for cost-analysis purposes. One of the main reasons for extended latent 
periods is concerned with difficulties securing funding in the NHS. This situation can differ 
between Primary Care Trusts and thus pain clinic centres, according to budgetary 
restrictions. 
 
The patient, following a successful intrathecal catheter trial, knows whether an effective pain 
relief mechanism has been found for them. This may be, and often is, the culmination of 
years of unsuccessful treatment, which at last has led to an effective pain relief. The patient 
now knows that effective pain relief is possible. They also know that it is just a matter of time 
before it is made available to them, their place being assured on a waiting list. The ability to 
cope with pain when the prospect is for a limited time only, instead of being the normal and 
unending situation, increases in the patient dramatically. The clinician has now to a certain 
extent ‘solved’ that particular patient’s problem by finding an effective method of pain relief 
and management for them. They can now move on to other problems, leaving the patient in 
a ‘holding phase’ or ‘latent period’ during which time the next most effective pain relief is 
provided, often in a higher dose and as a stop gap until the IDDS is implanted. When cost 
effectiveness is calculated, this latent period must be identified for each patient and dealt 
with if it is not to unduly influence the costs and resultant QALY calculations. In a recent 
randomised controlled trial (RCT) analysing the placebo effect where one of the arms 
consisted of patients on the waiting list, it was noticed that these showed improvement at 
three week follow-up (Kaptchuk et al., 2008). 
 
This study was based on hospital records where all procedures taking place during the study 
period were documented, contrary to the de Lissovoy et al. (1997) hypothetical computer-
generated cohorts of patients. This study also concluded that despite the initial cost of 
equipment, IDDS has long-term benefits. Computer-generated models are useful tools for 
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policy and decision making, however, these are only as good as the information inserted to 
generate the model. 
 
A limitation of this study was the small single centre sample size and not being a RCT. In 
recent systematic reviews, no IDDS randomized trials met the authors’ inclusion criteria, 
meaning there were no RCTs with IDDS or the quality of the available RCTs was poor 
(Hayek et al., 2011; Noble et al., 2010; Patel et al. 2009). One of the difficulties in performing 
RCTs with this therapy concerns the moral and ethical considerations that what a patient is 
submitted to is acceptable. 
 
These results merit further investigation as they cannot be generalised since the period of 
time the patient can be held in a latent stage can be variable across different centres’ 
nevertheless they should be taken into consideration if even slightly different per patient. 
Leaving a patient waiting for treatment does not confer any economic advantage, but can 
influence a cost-effectiveness analysis. 
 
The use of the EQ-5D at some point in the latent period would allow verification of how 
patients perceive their health state during this waiting time. 
 
 
4.7 Conclusion 
This study allowed a comparison between two moments, prior to and following IDDS 
implant, of suitable candidates for IDDS who went through an analogous progression until 
IDDS treatment. 
 
IDDS offers an economically feasible alternative solution for chronic non-malignant pain 
patients whose current treatment is inappropriate or ineffective. Assessments of the cost 
effectiveness of a health care treatment should take into consideration the existence of a 
latent period since this may influence not only cost efficacy evaluations but also decisions to 
go through with a treatment. The latent period can influence cost effectiveness analysis as 
analyses not considering this holding phase will make a treatment appear to be less cost 
effective. Since the latent stage would be included in a pre-therapy period and its costs per 
day are relatively low, this would overall decrease the pre-therapy total costs and the longer 
the duration the higher impact it would have. Further studies need to be carried out to 
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confirm whether differences between pre-implant and the latent period occur, particularly in 
other health care procedures where there is an asymmetrical waiting time between decision 
and treatment. 
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This evaluation of intrathecal drug delivery for the management of chronic non-malignant 
pain is limited by the sample being derived from a single centre and the number of 
participants included in each of the studies. This process was invaluable to further the 
researcher’s knowledge and skills. An understanding of research methods, ethics in 
research, assessment of scientific articles and statistical approaches was acquired during 
the course of this PhD. Despite the findings and clinical implications of this thesis, the 
understanding gained during this process allows the researcher to acknowledge that this 
study could be have enhanced by the addition of more national or international centres 
providing this therapy. Besides the additional patients, this factor would allow some of the 
results to be more relevant to other pain management centres administrating intrathecal 
drug delivery for chronic non-malignant pain. The findings and clinical implications of this 
study, and recommendations for future research are further developed in this chapter. 
 
 
5.1. Findings and clinical implications 
The possibility of prediction of the opioid dose at year six. 
The development of a model accounting for 76% of the variability of the opioid dose at year 
six based on the dose of year two combined with duration of pain prior to initiation of 
intrathecal therapy was developed. This has significant clinical implications. This model has 
the potential to assist the physician in the identification of a need for an alternative treatment 
strategy (Figure 5.1). Moreover, since many of the pump replacements are performed prior 
to year six, it can assist in the informed decision of the benefits and risks of the maintenance 
of this therapy prior to replacement surgery. 
 
A novel tool to identify asymptomatic intrathecal granulomas. 
Through calculation of the opioid dose increase per year throughout the duration of 
treatment, a clinical change may be detected. The formation of intrathecal inflammatory 
masses is one of the most hazardous adverse events of IDD because this can form a space-
occupying lesion within the spinal canal causing spinal cord compression and neurological 
deficit. If asymptomatic and not recognised by the physician, the patient can perceive a 
decrease in pain relief which can be diagnosed as tolerance, leading to increases in opioid 
dose. The calculation of the yearly opioid change is a potentially useful and inexpensive 
method of early detection of clinical change and possibly identification of asymptomatic 
intrathecal granulomas. 
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An association between intrathecal granulomas and opioid concentration was established 
for the first time in humans. 
This thesis presents the first systematic review of case reports describing the development 
of catheter tip intrathecal inflammatory masses. The comparison of the extracted data with a 
control group meant that it was possible, for the first time, to statistically confirm the 
association between concentration and the formation of granulomas in humans. This 
association had been inferred but never confirmed in human studies. Opioid dose and 
concentration are both associated with the formation of intrathecal inflammatory masses. 
The relative risk of occurrence of these masses can potentially be halved through a 
reduction of the opioid dose and concentration from the currently recommended maxima of 
15mg/day and 20 mg/mL to 10mg/day and 15mg/mL respectively. 
 
Prevalence of hypogonadism based on free testosterone assessment. 
It was verified that hypogonadism is common in patients undertaking IDD therapy for the 
management of chronic non-malignant pain. The hypothalamic-pituitary-gonadal axis should 
be routinely monitored in patients undertaking intrathecal opioid administration from the start 
of therapy. This is the first study with IDD patients that also used Vermeulens’ calculated 
free testosterone as a diagnostic tool. The calculation of free testosterone seemed to be a 
more reliable measure than the free androgen index. Assessment of the hypothalamic-
pituitary-gonadal axis should include evaluation of total testosterone, free testosterone or 
bioavailable testosterone, LH and FSH. Moreover, the early detection of hypogonadism, 
followed by appropriate treatment, may be paramount to reduce the risk of developing other 
complications such as muscle atrophy, anaemia, cognitive impairment, type two diabetes 
and cardiovascular risk. 
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An association between hypogonadism and low bone mass density as a result of IDD 
delivery was reported for the first time. 
An association between hypogonadism and low bone mass density in patients undertaking 
intrathecal opioid delivery for the management of chronic non-malignant pain was observed. 
This is the first study reporting the incidence of low bone mass density in hypogonadal IDD 
patients. Surveillance of BMD levels in hypogonadal intrathecal opioid delivery patients 
should be performed followed by appropriate treatment to reduce the risk of osteoporosis 
development and prevention of fractures in this population. 
 
A study with the longest follow-up time span reported in the IDDS literature investigating the 
outcomes of this treatment was carried out. 
The currently available literature investigating the long-term outcomes of IDD has a 
maximum average follow-up time of four years. This study represents the longest follow-up 
time span reported in the IDDS literature with an average follow-up of 13.5 years (range 
10.4-17.9). This study is particularly pertinent as it is very common for chronic non-malignant 
pain patients to require pain management treatment for the remainder of their lives. This 
study demonstrates that IDD has the potential to be a life-long solution for the management 
of chronic non-malignant pain and that potential benefits can remain stable even during 
long-term administration. 
 
A new important concept with influence on cost effectiveness analysis was identified. 
The cost-effectiveness of IDDS for the management of chronic non-malignant pain based on 
real patients’ data was confirmed. Moreover, this study allowed the identification of a latent 
stage, which may affect the cost effectiveness analyses when patient information is 
collected prior and post administration of a therapy. The variability and significantly inferior 
costs of the latent period may influence cost effectiveness evaluations, and consequently 
decision making, if not considered. 
 
 
5.2 Future research 
Prediction of opioid dose escalation 
Since intrathecal opioid therapy strategies differ across pain management centres, the 
morphine dose model developed needs to be tested to confirm its applicability to other 
centres. A large, international, multicentre study could have the potential to develop a model 
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applicable to the majority of centres where intrathecal drug delivery therapy is administered. 
Besides observation of opioid dose increase, the assembly of periodical pain ratings 
alongside additional oral medication could provide valuable information to the discussion of 
tolerance in humans undertaking long-term opioid therapy. 
 
Intrathecal granulomas 
A larger, multi centre data set has the potential to provide additional information regarding 
the formation of intrathecal inflammatory masses. A study with this design would facilitate 
investigation of other hypotheses as to the aetiology of granulomas, including dose and 
concentration of other intrathecal agents, flow rate, catheter tip design and location. It could 
also provide clarification of the potential preventive role of clonidine. When collecting the 
data regarding the dose, concentration and flow rate, mean values should be sought. This 
information would be more representative of the treatment period than peak values of dose, 
concentration and flow rate. 
 
Hormonal effects 
It would be of interest to investigate the impact of decreased sex hormones on pain levels. It 
has previously been suggested that reduced libido may be linked with a lower pain 
threshold. The confirmation of this link would mean that besides opioid induced 
hyperalgesia, pharmacological tolerance or deterioration of a patient’s condition, the 
hypothalamic-pituitary-gonadal axis could also play a role in the escalation of the opioid 
dose. Investigation of this axis should also be carried out in female IDD patients. 
 
Bone mineral density 
Longitudinal studies investigating the predictive value of hypogonadism for fracture risk in 
patients undertaking intrathecal drug delivery are required. The assessment of bone mineral 
density alongside evaluation of the hypothalamic-pituitary-gonadal axis prior to start of 
intrathecal opioid therapy and further assessments throughout therapy could indicate if low 
BMD can be a direct consequence of opioid delivery or a consequence of hypogonadism. 
Investigation of BMD should also be carried out in female IDD patients. 
 
Long-term effectiveness of IDDS 
A longitudinal study with prospective collection of data prior to implantation of IDDS could 
provide confirmation of the long-term effectiveness of intrathecal drug delivery. A 
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randomised controlled trial of IDDS has been carried out for cancer pain (Smith et al., 2002). 
This study reported improvement in pain scores, reduced toxicity scores and improved 
survival for those patients undertaking IDD. An adequately powered randomised controlled 
trial for chronic non-malignant patients would be of substantial value to the IDD therapy and 
literature. 
 
Cost effectiveness 
Studies analysing the cost effectiveness of health related treatments where a waiting period 
is frequent are warranted to confirm the presence of a latent stage. Investigation of patients’ 
perception and quality of life during this period would also be of value. 
 
 
5.3 Conclusions 
In appropriately selected patients IDDS may have the potential to be a life-long solution for 
the management of chronic non-malignant pain. The advantages of this therapy clearly 
outweigh the disadvantages. The multidimensional benefits remained stable even following 
13.5 years of IDDS therapy, substantiating the effectiveness of IDDS therapy. 
 
Patients being considered for an IDDS should always be informed of the potential side 
effects and complications derived from this therapy. When other pain management 
treatment options have been considered and failed, age of the patient should not be an 
obstacle to IDDS as the rate of complications, side effects and the increase of opioid dose 
may not be substantial when compared with the possible benefits of this therapy. 
 
The long-term benefits from this treatment are not necessarily related with exaggerated 
intrathecal opioid doses. The intrathecal opioid dose increase observed throughout the 
years was modest. Therapy strategies differ across treatment centres and can explain much 
of the variation in intrathecal opioid dose administered and escalation. Nevertheless, 
concerns about development of tolerance do not seem to justify the delay or withholding of 
intrathecal opioid therapy for chronic non-malignant pain. 
 
It is extremely important to monitor dose escalation as it may be indicative of the formation 
of intrathecal inflammatory masses. Both dose and concentration of opioids contribute to the 
formation of granulomas. The calculation of the opioid dose increase per year throughout 
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treatment can indicate a clinical change and, therefore, facilitate the early detection of 
asymptomatic intrathecal inflammatory masses, consequently decreasing the possible side 
effects of this complication for the patient. The association between opioid concentration and 
formation of granulomas was confirmed for the first time in humans. 
 
Hypogonadism is common in patients undertaking IDD therapy for the management of 
chronic non-malignant pain. For assessment of this complication, calculated free 
testosterone or bioavailable testosterone are more reliable than calculation of the free 
androgen index. Hypogonadism is also a risk factor for the decrease in bone mass density. 
A high prevalence of low bone mass density in hypogonadal patients undertaking intrathecal 
opioid delivery for the management of chronic non-malignant pain was observed. 
 
Despite the high initial cost, which is frequently a reason for not providing this treatment, it 
was confirmed that IDDS is a cost effective therapy for the management of chronic non-
malignant pain. IDDS offers an economically feasible alternative solution for chronic non-
malignant pain patients whose current treatment is inappropriate or ineffective. 
 
This thorough study of intrathecal drug delivery presents a wide evaluation of this therapy 
with its scope encompassing the long-term effectiveness, cost effectiveness and 
assessment of several adverse events of this treatment. This study demonstrates the long-
term effectiveness and cost effectiveness of IDDS. Adequate and thoughtful follow-ups have 
the potential to prevent the development of the majority of complications derived from this 
therapy. 
 
Intrathecal drug delivery for the management of chronic pain of non-malignant origin 
represents a treatment where numerous pre-conceived ideas still exist. These pre-
conceptions subsist not only in the general population but also in medical staff and funding 
providers. Consequently, intrathecal drug delivery also represents a challenging area of 
study that merits further exploration and is one that can benefit from new knowledge. 
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